De novo mutations in canine evolution and disease by Chew, Tracy
  
 
De novo mutations in canine 
evolution and disease 
 
Tracy Chew 
BAnVetBioSci (Hons 1) 
 
Faculty of Science 
University of Sydney 
Australia 
 
A thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy 
2019 
 
 
 
 
  
i 
Acknowledgements 
I would first like to thank my wonderful supervisors Prof. Claire Wade and Dr. Bianca 
Waud. I must also include Dr. Cali Willet, who was in the Wade laboratory when I 
started honours with Claire as an undergraduate. I am ever so grateful for your 
inspirational passion and knowledge in the fields of bioinformatics and animal genetics 
research. All three of you have taught me many valuable skills and provided me with 
opportunities to gain professional experience throughout my undergraduate and 
postgraduate candidatures. I am especially grateful for the confidence you had in me. I 
achieved many goals that were unimaginable to me with your ongoing support and 
encouragement.  
I received a lot of intellectual, moral and emotional support from many postgraduate 
students within veterinary science. These people include past and present postgraduate 
students in the Wade laboratory, Jessica Gurr, Brandon Velie, Bobbie Cansdale, 
Mitchell O’Brien, Georgie Samaha and Diane van Rooy. I would also like to mention 
other veterinary science postgraduate students, Carol Lee, Annie Pan, Sally Mortlock, 
Theresa Li and Pamela Soh. I am so grateful to have gone through our PhD journeys 
together. Your bright minds, upbeat personalities and love for animals have made my 
journey so much more fun and memorable. I can’t wait to see and hear about all your 
successes in the future. The people mentioned here are reflections of the broader 
veterinary science community here at the University of Sydney, which I am privileged to 
be a part of.  
To our internal and external collaborators, including the University of Sydney Veterinary 
Teaching Hospital, Prof. Hannes Lohi and Maria Kaukonen, it would not have been 
possible to carry out the work in this thesis without your help and generosity in helping 
me collect and obtain samples. This of course includes all animals and their owners for 
providing these samples. I also can’t forget to thank the University staff at the Sydney 
Informatics Hub and the ICT department, who work tirelessly to provide and service the 
facilities used to produce the work included in this thesis. 
  
ii 
I would not have been able to pursue this degree without the financial support that I 
received as the recipient of the Australian Postgraduate Award and the Neil and Allie 
Lesue Scholarship. I only hope that I have honoured Neil and Allie Lesue and this 
country by contributing to excellent research within animal science.  
Finally, I would like to thank my closest friends, biological family, whisky family and my 
partner Nick. Your emotional support and belief in me have kept me pursuing my goals. 
Thank you for all the laughter, board game nights and shenanigans, you have helped 
me keep my sanity. I really appreciate all of you for listening to me ramble on about 
genomics, especially if you didn’t know what I was talking about. I hope I’ve taught you 
something about science.   
I dedicate this thesis to my furry children Evie and the late Oreo, who passed away in 
2014. Your love for life drew me to learn about your species.  
  
  
iii 
Declaration 
I declare that this thesis is my own work and has not been submitted in any form for 
another degree or diploma at any university of institution of tertiary education. 
Information derived from the published or unpublished work of others has been 
acknowledged in the text and reference lists that are provided within each chapter. The 
work contained in Chapter 5 – The Genetics of Severe Haemophilia A in the Australian 
Kelpie was initially analysed as part of the Honours component of my undergraduate 
degree. I have since completely reanalysed the data for this work using larger study 
cohorts, more advanced methodologies and I have completely rewritten the manuscript 
before including this work into this thesis.  
 
Tracy Chew 
7st January 2019 
  
  
iv 
Table of Contents 
Chapter 1. Literature Review 2 
1.1. Introduction 2 
1.2. Causes of de novo mutations 3 
1.3. Somatic and germline mutations 9 
1.4. De novo mutation detection methods 10 
1.4.1. Traditional de novo germline mutation rate detection methods 11 
1.4.2. High throughput sequencing technologies for detecting de novo 
germline mutations 13 
1.4.3. Microarray based technologies for detecting de novo CNVs 19 
1.4.4. Detection of somatic mutations 20 
1.5. The effects of de novo mutations 21 
1.5.1. New mutations and the evolution of canine phenotypes 22 
1.5.2. De novo mutations and disease 23 
1.6. Rates and distribution patterns of new mutations within and across species
 25 
1.7. Aims of this thesis 27 
1.8. References 27 
Chapter 2. A performance comparison of popular single nucleotide variant 
detection methodologies applied to low coverage whole genome sequencing data
 42 
2.1. Abstract 42 
2.2. Introduction 43 
2.3. Methods 47 
2.3.1. Samples 47 
2.3.2. Genotyping array data and the truth dataset 47 
  
v 
2.3.3. Next-generation sequencing 47 
2.3.4. Variant Calling and Hard Filtering Criteria 48 
2.3.5. Refinement of the truth dataset 50 
2.3.6. Comparison metrics 51 
2.4. Results 52 
2.4.1. Truth and whole genome sequencing variant dataset 52 
2.4.2. Comparison of genotype concordance rates of the 10 variant calling 
pipelines to truth dataset 52 
2.4.3. Comparison of genotype concordance rates between raw pipelines 
and corresponding pipelines that include hard filters 55 
2.4.4. Total concordance and discordance and standard deviation of 
genotypes called by each of the pipelines to the truth dataset 55 
2.4.5. Homozygous verse heterozygous concordance 58 
2.5. Discussion 67 
2.6. References 70 
Chapter 3. Direct estimate of the de novo mutation rate in the domestic dog 75 
3.1. Abstract 75 
3.2. Introduction 75 
3.3. Materials and Methods 78 
3.3.1. Samples 78 
3.3.2. Whole genome sequencing 79 
3.3.3. Variant calling and genotyping 80 
3.3.4. Direct estimate of the per base mutation rate in dogs 81 
3.3.5. Characterising de novo mutations 81 
3.4. Results 82 
3.4.1. Whole genome sequencing 82 
3.4.2. Variant calling and per base mutation rate estimates 82 
  
vi 
3.4.3. Characteristics of observed de novo mutations 84 
3.5. Discussion 86 
3.6. References 91 
Chapter 4. The Genetics of Progressive Retinal Atrophy in the Hungarian Puli 97 
4.1. Synopsis - Exclusion of known progressive retinal atrophy genes for 
blindness in the Hungarian Puli 97 
4.1.1. Supplementary materials for section 4.1 100 
4.2. Synopsis - A Coding Variant in the Gene Bardet-Biedl Syndrome 4 (BBS4) Is 
Associated with a Novel Form of Canine Progressive Retinal Atrophy 110 
Chapter 5. The Genetics of Severe Haemophilia A in the Australian Kelpie 120 
5.1. Abstract 120 
5.2. Introduction 120 
5.3. Methods 123 
5.3.1. Animals 123 
5.3.2. Genotyping array and whole genome sequencing data 124 
5.3.3. Screening for putative variants in known bleeding disorder loci 125 
5.3.4. Screening the FVIII gene 125 
5.3.5. Analysis of a putative inversion mutation at intron 22 of FVIII 126 
5.4. Results 127 
5.4.1. FVIII assessment in the affected family 127 
5.4.2. Detection of variants in bleeding disorder loci 128 
5.4.3. Screening the FVIII gene for novel and known mutations 131 
5.5. Discussion 132 
5.6. References 135 
  
vii 
 
Chapter 6. General Discussion and Conclusions 140 
6.1. Conclusions from chapter 2 140 
6.2. Conclusions from chapter 3 143 
6.3. Conclusions from chapter 4 145 
6.4. Conclusion to chapter 5 147 
6.5. Final remarks 148 
6.6. References 149 
Appendices 155 
Appendix I: Supplementary material for chapter 2 155 
Appendix II: Supplementary material for chapter 3 170 
Appendix III: Supplementary material for chapter 4 196 
Appendix IV: Supplementary material for chapter 5 212 
 
  
viii 
List of Figures 
Chapter 1 
Figure 1.1. The eukaryotic cell cycle that embodies the growth and division of 
cells. 4 
Figure 1.2. DNA replication that occurs during the S phase of the cell cycle. 6 
Figure 1.3. Somatic and germline mutations. 10 
Figure 1.4. Representation of NGS data that has been aligned to a reference 
genome. 16 
Figure 1.5. A parent-offspring trio pedigree and a representation of a germline 
de novo mutation. 17 
 
Chapter 2 
Figure 2.1. Representation of the ten variant calling pipelines used in this 
study. 49 
Figure 2.2. Percent concordance of all genotypes (homozygous and 
heterozygous) called by 10 different pipelines using five different variant 
callers with and without hard filtering (FreeBayes, GATK HC, GATK UG, 
SAMtools and VarScan) compared against genotypes obtained using the 
CanineHD BeadChip array. 54 
Figure 2.3 Percentage concordance of homozygous genotypes called by raw 
and filtered pipelines using five different variant callers (FreeBayes, GATK 
HC, GATK UG, SAMtools and VarScan) compared against genotypes 
obtained using the CanineHD BeadChip array. 59 
Figure 2.4. Percentage concordance of heterozygous genotypes called by 
raw and filtered pipelines using five different variant callers (FreeBayes, 
GATK HC, GATK UG, SAMtools and VarScan) compared against genotypes 
obtained using the CanineHD BeadChip array. 60 
 
  
  
ix 
Chapter 3 
Figure 3.1. Parent-offspring trio configurations. 78 
Figure 3.2. Percentage of transition and transversion mutations observed in 
four parent-offspring trios. 84 
 
Chapter 4 
 Chapter 4.1 
Figure 1. Location of 53 candidate genes and 364 SNP markers that are 
concordant with autosomal recessive inheritance on the CanFam 3.1 
autosomes. 98 
Figure S1. Pedigree of Hungarian Puli dogs segregating progressive retinal 
atrophy. 104 
 Chapter 4.2 
Figure 1. Positions of SNP array markers that segregate with the PRA 
phenotype and candidate genes identified. 113 
Figure 2. BBS4 protein sequence alignment of affected dogs containing the 
c.58A > T SNP and of the wild-type protein 114 
Figure 3. Segregation of the BBS4 SNP (c.58A > T, p.Lys20*) in the 
Hungarian Puli family. 115 
Figure 4. Sanger sequencing of a PCR fragment containing the c.58A > T 
SNP at position chr30: 36,063,748 on CanFam 3.1 in exon 3 of BBS4. 116 
 
Chapter 5 
Figure 5.1 Pedigree of the Australian Kelpie family segregating haemophilia 
A. 128 
 
 
  
x 
List of Tables 
Chapter 1 
Table 1.1. Methods for estimating de novo mutation rates in the pre-high 
throughput sequencing era and the potential associated biases. 12 
 
Chapter 2 
Table 2.1. Variant callers and recommended hard filtering criteria used in this 
study. 50 
Table 2.2. P-values from paired, two-tailed t tests on average genotype 
concordance rates of 10 different pipelines using five different variant callers 
with and without hard filtering (FreeBayes, GATK HC, GATK UG, SAMtools 
and VarScan) compared against genotypes obtained using the CanineHD 
BeadChip array. 53 
Table 2.3. Total numbers and standard deviation of concordant genotypes 
called by 10 different pipelines using five variant callers with and without hard 
filtering (FreeBayes, GATK HC, GATK UG, SAMtools and VarScan) 
compared against genotypes obtained using the CanineHD BeadChip array. 56 
Table 2.4. Total number and standard deviation discordant genotypes called 
by 10 different pipelines using five variant callers with and without hard 
filtering (FreeBayes, GATK HC, GATK UG, SAMtools and VarScan) 
compared against genotypes obtained using the CanineHD BeadChip array. 57 
Table 2.5. Total numbers of concordant homozygous genotypes called by raw 
and filtered pipelines using five variant callers (FreeBayes, GATK HC, GATK 
UG, SAMtools and VarScan) compared against genotypes obtained using the 
CanineHD BeadChip array. 62 
Table 2.6. Total numbers of concordant heterozygous genotypes called by 
raw and filtered pipelines using five different variant callers (FreeBayes, 
GATK HC, GATK UG, SAMtools and VarScan) compared against genotypes 
obtained using the CanineHD BeadChip array. 63 
Table 2.7. Total numbers of discordant homozygous genotypes called by raw 
and filtered pipelines using five variant callers (FreeBayes, GATK HC, GATK 65 
  
xi 
UG, SAMtools and VarScan) compared against genotypes obtained using the 
CanineHD BeadChip array. 
Table 2.8. Total numbers of discordant heterozygous genotypes called by raw 
and filtered pipelines using five different variant callers (FreeBayes, GATK 
HC, GATK UG, SAMtools and VarScan) compared against genotypes 
obtained using the CanineHD BeadChip array. 66 
 
Chapter 3 
Table 3.1. Per base mutation, transition and transversion rate estimates for 
the domestic dog in five unique parent-offspring trios. 83 
Table 3.2. Per base mutation rate estimates (x 10-8) within coding, CpG 
islands, intergenic, intronic, conserved, 3’ UTR and 5’ UTR features in dogs 
using five unique parent-offspring samples. 85 
Table 3.3. P-values obtained from paired, two tailed t-tests performed 
between seven genomic features to determine if the per base mutation rate 
was significantly different between each feature in the dog. 86 
Table 3.4. De novo mutation rate estimates for dogs, humans, mice, 
chimpanzees and birds. 87 
 
Chapter 4 
Chapter 4.1 
Table S1. A list of the 53 PRA candidate genes screened. 105 
Table S2. PCR primer sequences.  107 
Table S3. Putative variants identified from screening 53 candidate genes in 
parent-proband and an affected half sibling case. 108 
  
  
  
xii 
Chapter 4.2 
Table 1. Number of SNP and indel variants detected after applying standard 
hard filtering criteria 11. 114 
Table 2. Semen analysis report of affected Hungarian Puli.  116 
 
Chapter 5 
Table 5.1. Variants detected in 14 bleeding tendency candidate genes using 
whole genome sequencing data of one case and 11 control Australian 
Kelpies.   129 
 
  
  
xiii 
List of Manuscripts and Conference proceedings 
This thesis contains published manuscripts, manuscripts which are currently in 
submission for publication and research that was presented at a range of Faculty, 
national and international conferences, as listed below. 
2013 Poster: Developing a genetic test for Haemophilia A in Australian Kelpies. 
Genetics Society of AustralAsia Conference, Sydney, Australia, 14th-17th 
July. 
 Oral presentation: Whole Genome Sequences and Detection of De Novo 
Mutations in Parent to Offspring Trios of The Domestic Dog. Faculty of 
Veterinary Science Annual Postgraduate Conference, Camden, Australia, 
6th-7th November. 
2014 Poster: Detection of De Novo Mutations in Parent To Offspring Trios in 
Whole Genome Sequences of the Domestic Dog. Genetics Society of 
AustralAsia Conference, Sydney, Australia, 6th-9th July. 
 Oral presentation & poster: De Novo Mutations in Dogs. Faculty of 
Veterinary Science Annual Postgraduate Conference, Sydney, Australia, 5th-
6th November. 
2015 Poster: An Evolutionarily New, Deleterious Mutation Causes Bardet Biedl 
Syndrome in the Hungarian Puli. Lorne Genome Conference, Lorne, 
Australia, 15th-17th February. 
 Oral presentation: An Evolutionarily Recent, Deleterious Mutation Causes 
Bardet Biedl Syndrome in the Hungarian Puli. The 8th International 
Conference on Advances in Canine and Feline Genomics and Inherited 
Diseases. Cambridge, England. 22nd-26th June. 
  
xiv 
 Oral presentation: Discovery of a Deleterious Mutation in the Hungarian Puli 
That Causes Disease Similar to Bardet Biedl Syndrome in Humans. Boden 
Conference, Adelaide, Australia, 8th-10th July.  
 Oral presentation: Bardet Biedl Syndrome in Hungarian Puli. Faculty of 
Veterinary Science Annual Postgraduate Conference, Camden, 28th-29th 
October. 
2016 Oral presentation & poster: Understanding How Canine Disease and 
Evolution Transpires Through the Analysis of De Novo Mutations. Faculty of 
Veterinary Science Annual Postgraduate Conference, Sydney, Australia, 9-
10th November. 
2017 Published manuscript: Chew, T., B. Haase, C.E. Willet, and C.M. Wade, 
2017 Exclusion of known progressive retinal atrophy genes for blindness in 
the Hungarian Puli. Anim. Genet. DOI: 10/1111/age.12553 
 
Published manuscript: Chew, T., B. Haase, R. Bathgate, C. E. Willet, M. K. 
Kaukonen et al., 2017 A Coding Variant in the Gene Bardet-Biedl Syndrome 
4 (BBS4) Is Associated with a Novel Form of Canine Progressive Retinal 
Atrophy. G3 (Bethesda). 4: g3.117.043109. 
2018 In submission: Chew, T., B. Haase, C.M. Wade, 2018 Direct estimate of the 
de novo mutation rate in the domestic dog.  
In submission: Chew , T., C. E. Willet, B. Haase, C. M. Wade, 2018 A 
performance comparison of popular single nucleotide variant detection 
methodologies applied to low coverage whole genome sequencing data. 
 
  
  
xv 
Authorship Attribution Statement 
Chapter 4.1 of this thesis is published as Chew, T., B. Haase, C.E. Willet, and C.M. 
Wade, 2017 Exclusion of known progressive retinal atrophy genes for blindness in the 
Hungarian Puli. Anim. Genet. DOI: 10/1111/age.12553. 
I co-designed this study with Prof. Claire Wade and performed the experiments under 
her supervision. I performed the analysis, wrote the manuscript and developed the 
arguments that were included in the draft manuscript. Critical revisions were made by 
myself, Dr. Bianca Haase, Dr. Cali Willet and Prof. Claire Wade.  
Chapter 4.2 of this thesis is published as Chew, T., B. Haase, R. Bathgate, C. E. Willet, 
M. K. Kaukonen et al., 2017 A Coding Variant in the Gene Bardet-Biedl Syndrome 4 
(BBS4) Is Associated with a Novel Form of Canine Progressive Retinal Atrophy. G3 
(Bethesda). 4: g3.117.043109.  
I co-designed this study with Prof. Claire Wade and Assoc. Prof. Roslyn Bathgate. The 
bioinformatics and sequencing analysis was carried out by myself under the supervision 
of Prof. Claire Wade. The fertility analysis was jointly performed by myself and Prof. 
Roslyn Bathgate. I developed the ideas and arguments for the manuscript and wrote the 
drafts. Critical revisions to the manuscript were made by Prof. Claire Wade, Dr. Bianca 
Haase, Assoc. Prof. Roslyn Bathgate, Dr. Cali E. Willet and Prof. Hannes Lohi.    
  
xvi 
Abbreviations 
ANKC Australian National Kennel Council  
bp Base pair 
BWA Burrows-Wheeler Aligner 
oC Degrees Celsius 
cDNA Complementary DNA 
CDS Coding exonic sequence 
CHISQ Chi-squared  
CpG 5’ – Cytosine – phosphate – Guanine – 3’ 
CNV Copy number variant 
dbSNP Database of single nucleotide polymorphisms 
BBS Bardet-Biedl Sydnrome 
BED Browser extendable format 
DNA Deoxyribonucleic acid  
DSBs Double stranded breaks 
EDTA Ethylenediaminetetraacetic acid 
EXO Exonulease 
FTA Flinders Technology Associates  
GATK Genome Analysis Tool-Kit 
Gb Gigabase 
GC Guanine-cytosine  
GWAS Genome wide association study 
G1 phase Gap 1 phase 
G2 phase  Gap 2 phase 
HapMap Haplotype Map 
IBD Identity by descent  
ID Identifier 
Indel Insertion-deletion  
Kb Kilobase 
Labrador Labrador Retriever  
  
xvii 
LD Linkage disequilibrium  
M phase Mitotic phase 
Mb Megabase 
NCBI National Centre for Biotechnology Information 
NGS Next generation sequencing 
OMIA Online Mendelian Inheritance in Animals 
OMIM Online Mendelian Inheritance in Man  
PacBio Pacific Biosciences 
PCR Polymerase chain reaction 
Pol Polymerase 
PRA Progressive retinal atrophy 
RP Retinitis pigmentosa  
S phase Synthesis phase 
SAM Sequence Alignment Map  
Sec seconds 
SIFT Sorting Intolerant From Tolerant  
SMRT Single molecule real time 
SNP Single nucleotide polymorphism 
SNV Single nucleotide variation  
Ti Transition 
Tv Transversion  
U Enzyme unit  
UCSC University of California, Santa Cruz  
USCF University of Sydney, Canis Familiaris  
UTR Untranslated region  
UV Ultraviolet 
VEP Variant Effect Predictor  
WGS Whole genome sequencing  
X Fold of sequence coverage 
yr year 
µL Microlitres   
  
1 
Abstract 
The domestic dog is an evolutionarily unique animal and has a special niche within 
genomics research. Since their domestication from the grey wolf, dogs have become 
one of the most phenotypically diverse living land animals. Man’s desire to create 
individuals with specialised morphological and behavioural traits has led to the 
development of over 400 recognised breeds. Dogs share a significant number of 
inherited disease phenotypes with humans and are regarded as valuable animal models 
for understanding evolution and disease. New mutations are the ultimate source of new 
phenotypic diversity and evolutionary change. They can also cause rare spontaneous 
genetic disorders and collectively, they make a significant contribution to disease 
burden in managed populations. To comprehensively understand the mechanisms of 
evolution and disease, discovering the rates of occurrence, type, and patterns of 
distribution of de novo mutations across the genome is essential. Until recently, the 
characteristics of de novo mutations could be inferred only using indirect or biased 
methods. With recent technological advancements, it is now possible to directly observe 
de novo mutations that occur in a single generation directly through parent-offspring 
sequencing studies. Whole genome sequencing provides the opportunity for genomic 
variants associated with rare diseases caused by spontaneous mutations to be 
identified directly. We are on the brink of the capacity to utilize these technologies more 
fully in the field of personal medicine. In this thesis, de novo germline mutations 
affecting the evolution and occurrence of disease in the dog are identified and 
characterised. The inspiration for this work stemmed from the extraordinary phenotypic 
diversity in the species and its close relationship to people.  
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Chapter 1. Literature Review 
1.1. Introduction 
All genetic variation that drives evolution or contributes to disease once arose from a 
new DNA mutation. Characterising the rate of mutation and types of mutations that 
occur helps us to understand the mechanisms of evolutionary processes and disease. 
The identification of de novo variants and the methods for doing so have several 
practical applications. Patients with rare diseases could potentially achieve a rapid 
genetic diagnosis. Currently in Australia, an estimated 7% of rare disease patients do 
not receive a diagnosis at all and 30% received a delayed diagnosis of five years or 
more (Molster et al. 2016; Zurynski et al. 2017). Incorrect or delayed diagnosis can also 
lead to the administration of inappropriate and potentially harmful treatments, as well as 
incur additional emotional and financial burdens to affected families (Zurynski et al. 
2017). Delays in obtaining genetic diagnoses for rare diseases in animals has strong 
potential for negative economic and ecological impacts, especially for species with a 
short optimal breeding age and short lifespans. Rapid genetic diagnoses are required 
for the quick development of accurate genetic tests. Mutation rates also have an 
application in research. With ancestral DNA sequence, the mutation rate can be used 
as a molecular clock to estimate the timing of species divergence. This was previously 
heavily debated in dog domestication research (Axelsson et al. 2013; Wang, Zhai, et al. 
2013; Callaway 2013; Freedman et al. 2014). Mutation rates are also commonly used 
as a prior probability to obtain more accurate calling of de novo variants in many variant 
calling algorithms (Francioli et al. 2017).  
With the recent advancements and increased accessibility in obtaining next generation 
sequencing (NGS) data, direct observation of new mutations is now possible through 
parent-offspring sequencing. Sequencing of whole genomes using NGS technologies is 
superior to traditional methods of de novo variant characterisation. Before NGS existed, 
new mutation events could only be indirectly inferred or observed in small proportions of 
large vertebrate genomes. We begin the first chapter of this thesis with a review of the 
current understanding of how de novo mutations are formed, their impacts on fitness, 
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methods of their detection and what is currently known about de novo mutation activity 
in animal species. Our purpose is to elucidate how de novo mutations impact evolution 
and diversity within a single species. As our interest is in mutations that persist in a 
species, this work primarily concentrates on germline mutations.  
1.2. Causes of de novo mutations 
Many new mutations are caused by the imperfect process of the division and 
proliferation of cells. The process of growth and differentiation of cells, commonly 
referred to as the cell cycle, involves four coordinated phases in eukaryotes: the gap 1 
(G1); synthesis (S); gap 2 (G2); and the mitotic (M) phase (Figure 1.1). G1, S and G2 are 
collectively known as interphase and occur 95% for the duration of the cell cycle. In the 
G1 phase, the cell is metabolically active. Cytosolic contents and organelles grow and 
replicate. In the S phase, DNA replication occurs. In G2, the cell checks for errors in 
DNA replication that may have occurred in the previous phase and attempts to repair 
errors that are detected. The cell will continue to grow and synthesize proteins that are 
required in the next mitotic phase. The mitotic phase, consisting of four sub-phases 
(prophase, metaphase, anaphase and telophase), followed by cytokinesis, is where the 
cell proceeds to divide to form two daughter cells (Cooper 2000). The process 
described here describes the growth and replication of somatic cells. The growth and 
replication of germline cells is slightly different, as daughter cells are required to contain 
half the number of chromosomes (n) as somatic cells (2n). Gametes will undergo the 
prophase, metaphase, anaphase, telophase and cell division rounds twice (meiosis I 
and meiosis II), to produce four daughter cells. Importantly, parental chromosomes 
within gametes undergo homologous recombination during the first prophase.  
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Figure 1.1. The eukaryotic cell cycle that embodies the growth and division of 
cells.  
The cell cycle starts at the G1 phase. DNA replication occurs in the S phase. The S 
phase is followed by more cellular growth. In the next G2 phase, the cell checks for 
errors in that could have occurred during DNA replication. The cell then proceeds to 
divide in the M phase and two daughter cells are created following cytokinesis at the 
end of the cell cycle. Author’s own artwork.   
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Mutations arise from errors that occur during DNA replication during the S phase of the 
cell cycle (Figure 1.2). In eukaryotes, the predominant DNA polymerases ε and δ 
replicate the leading and lagging DNA strand respectively and with high fidelity (Korona 
et al. 2011). The reported error rates for the replication process range between one 
mistake per 104 base-pairs (bp) to one per 105 bp in vitro. However the rate at which 
mutations which are permanently incorporated into daughter cells is much lower 
because most of the errors that occur are recognised and corrected by proofreading 
exonucleases present within DNA polymerases ε and δ (Kunkel 2009; Korona et al. 
2011; Acuna-Hidalgo et al. 2016). Other accessory proteins such as the single strand 
binding protein also enhance the accuracy of DNA replication by DNA polymerases 
(Yang 2000). Errors which are missed by proofreading subunits can be corrected during 
the mismatch repair pathway. Mismatch repair pathway proteins (including MLH1, 
MLH3, MSH2, MSH3, MSH6, PMS1 and PMS2 in humans) excise the DNA containing 
the incorrectly incorporated nucleotide that is recognised by the proteins’ ability to 
distinguish the newly synthesized daughter strand from the parental strand (Preston et 
al. 2010; Seshagiri 2013). Mismatch repair proteins are highly conserved across 
prokaryotes and eukaryotes (Yang 2000). DNA polymerase and DNA ligase then 
replace and seal in the correct nucleotides to the newly replicated strand. Cells that 
contain mutations that are not repaired will undergo DNA damage induced apoptosis if 
the mutation is lethal, or will be sustained in the daughter cell and its subsequent 
descendant cells (Preston et al. 2010).  
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Figure 1.2. DNA replication that occurs during the S phase of the cell cycle.  
DNA polymerases (Pol) ε and δ replicate the leading and lagging strand respectively 
with an error rate of one per 104 to 105 nucleotides in eukaryotes. Both polymerases 
contain proofreading exonucleases (EXO) which ensure that an identical nucleotide to 
the leading or lagging template strand is incorporated into the newly synthesized 
strand. Errors which bypass the proofreading subunit can be correct in the mismatch 
repair pathway (this can also occur on the replication of the lagging DNA strand but is 
not represented in the figure). Author’s own artwork.  
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Errors in DNA replication have the potential to generate different types of mutations. 
The relative frequencies of their occurrences and the relative ease of their repair 
influences the observable error rate for each type of mutation. The incorrect 
incorporation of a single nucleotide base leads to nucleotide substitutions. Among 
these, transitions (purine-purine involving A and G nucleotides; or pyrimidine-pyrimidine 
involving C and T nucleotides) occur the more frequently than transversions (purine-
pyrimidine, or vice versa) in all species studied to date (Gojobori et al. 1982; Hershberg 
and Petrov 2010; Smeds et al. 2016). Each of the four nucleotides can obtain 
spontaneous, reversible rearrangements of their molecular bonds. Such 
rearrangements create a new form of the original nucleotide (termed a tautomer). 
Transition and transversion mutations can arise through tautomeric shifts. A tautomeric 
nucleotide sometimes pairs with a different nucleotide than the standard nucleotide that 
the originating nucleotide bonds with. For instance, the standard A (amino) form pairs 
with T, but its non-standard imino form A’ pairs with the C nucleotide. If this error is not 
corrected during DNA replication, a transition mutation in the newly synthesized DNA 
strand results (Griffiths et al. 2000). 
In the newly synthesized strand, changes are observed at C or G nucleotides more 
frequently than alterations at A and T bases, especially within the hyper-mutable, 
methylated cytosine base regions in CpG dinucleotide islands (Cooper and Youssoufian 
1988). The reasons for the increased mutability are not yet clear, but it is postulated that 
the ease or difficulty of separation of the paired nucleotides contributes to easier repair. 
C and G nucleotides have a strong three hydrogen bond connection, making 
dissociation and repair more difficult in GC rich regions (Ségurel et al. 2014). A and T 
nucleotides are more easily separated with only two hydrogen bonds connecting these 
nucleotides, allowing easier repair in AT rich regions. Other causes of single nucleotide 
or multinucleotide substitutions include incomplete repair of the newly replicated DNA 
strand (Acuna-Hidalgo et al. 2016).  
DNA polymerases can add or fail to incorporate occasional nucleotides due to 
misalignments to the template strand, causing small insertion-deletion (indel) errors. 
Larger indels involving double stranded breaks (DSBs) in DNA and larger chromosomal 
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segments of >1,000 bp in size are often termed structural variants (Scherer et al. 2007) 
and are most often caused by homologous recombination, non-allelic homologous 
recombination and replication-based mechanisms (Gu et al. 2008; Yang et al. 2013). 
Depending on the type of mutation, structural variants can be further classified as a 
copy number variant (CNV), inversion, translocation or segmental duplication. DSBs 
can be repaired by either the homologous recombination or non-homologous end 
joining pathways (Lieber 2010).  
Genetic context is a major determinant of frequency of mutation. Regions of low 
complexity such as minisatellite and microsatellite regions have higher mutation rates 
than complex regions of unique DNA (Baer et al. 2007). Homopolymer regions are 
similarly hyper-mutable as they are prone to replication slippage. Replication slippage 
occurs when there is a misalignment in the template and newly synthesized DNA, 
causing expansion or contraction of the homopolymer. In eukaryotes, single nucleotide 
changes occur more frequently in DNA that is in close proximity to indel mutations or 
recombination sites (Lercher and Hurst 2002; Tian et al. 2008; Duret and Arndt 2008). 
At the M phase of the cell cycle, aneuploidies can occur when chromosomes do not 
correctly segregate into their respective daughter cells (Figure 1.1). The accuracy of 
chromosomal segregation is dependent on the structural integrity of spindle 
microtubules and their ability to adequately attach onto the chromosome through a 
structure called the kinetochore (Compton 2011). Aneuploidies often have severe 
effects on cell survival and apoptosis of the affected daughter cells is usually initiated. 
Occasionally some cells survive and go on to have profound phenotypic effects. 
Aneuploidies are frequently recognised in cancerous cells and other diseases which will 
be reviewed later in this chapter.   
Spontaneous DNA mutations caused by factors independent of the cell cycle, especially 
those involving DSBs, can be caused by mutagens of endogenous (retrotransposons, 
oxygen-free radicals, by products of metabolism) or exogenous (viruses, UV radiation, 
DNA-reactive chemicals commonly found in tobacco products) sources. The main 
mechanisms to repair these DNA lesions are through the base excision repair and 
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nucleotide excision repair systems (Lindahl 1999). If spontaneously caused DNA 
mutations are not repaired before the next round of DNA replication, they become 
permanently fixed into newly created daughter cells.  
1.3. Somatic and germline mutations 
The timing of occurrence, type and location of the cell containing a de novo mutation 
influences the possible effect that the mutation has on the individual or the population. 
Germline mutations occur in the gametes of an individual’s parents and are therefore 
heritable and exposed to evolutionary processes. Somatic mutations occur in all other 
cells of the body and are accumulated post-fertilization throughout an individual’s life ( 
Figure 1.3). Somatic mutations are self-limiting as they are not heritable, but can have 
profound effects on an individual if the mutation occurs early in development (e.g. 
postzygotically), or if it induces oncogenesis (Li et al. 2014). More proliferative cell types 
such as those in the intestinal epithelial tissue are expected to harbour more new 
mutations than cells that are less proliferative, such as cells of the heart tissue 
(Shendure and Akey 2015). Researchers have observed that the somatic mutation rate 
is almost twice as high as that of the germline mutation rate for humans and mice 
(Milholland et al. 2017). The differential mutation rate highlights the importance of 
preserving the genome in the germ cells and that DNA repair in the soma is much less 
efficient.  
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Figure 1.3. Somatic and germline mutations.  
Somatic mutations are not heritable, unlike germline mutations which can be transmitted 
to some or all progeny. Somatic mutations can only occur in somatic tissue. Proliferation 
of a cell containing a somatic mutation leads to a population of cells containing the 
mutation that occurred in the original cell. Germline mutations occur in cells that are 
destined to become a sex cell (i.e. sperm or egg). Gametes containing a specific 
germline mutation that are fertilized result in progeny with the mutation present in all 
cells of their body. Author’s own artwork. 
 
1.4. De novo mutation detection methods 
As new mutations are relatively rare especially in eukaryotes, accurately identifying and 
characterising de novo events in the whole genome has remained a challenging task 
(Kondrashov and Kondrashov 2010). Our ability to detect de novo mutations is limited 
by our ability to observe the DNA sequences for whole genomes, especially in 
eukaryotic genomes with chromosomes that are megabases in total size. With the 
achievement of several technological advancements in DNA sequencing, estimates 
have become more accurate over time and error profiles of different types of mutations 
has been observed at a much higher resolution than previously possible. 
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1.4.1. Traditional de novo germline mutation rate detection methods 
The first few estimates of de novo germline mutation rates were made before DNA 
sequencing was even possible. Large chromosomal abnormalities, in particular 
aneuploidies, were easily detectable under the microscope in the early days of 
cytogenetic research. The path to detecting single nucleotide variation (SNV), small 
indels and sub-microscopic de novo variants such as CNVs required the development 
of more sophisticated methodologies and technologies. We will regard as traditional de 
novo mutation detection methods as those methods that were developed before high 
throughput sequencing technologies existed (current methods are later outlined in 
section 1.4.2).  
The first methods for estimating mutation rates were based on observations of 
spontaneously occurring phenotypes that were caused by de novo mutations in 
functional coding DNA, such as Mendelian diseases in people or lethal mutations in 
laboratory animals (Danforth 1923; Haldane 1935; Keightley et al. 1998; Kondrashov 
2002). Rates of incidence of the new phenotypes in the population were used to 
indirectly infer a mutation rate for that species.  
Once the first DNA sequencing and amplification methods were developed, researchers 
could directly observe de novo mutations, i.e. Maxam-Gilbert and Sanger sequencing in 
the 1970s (Maxam and Gilbert 1977; Sanger et al. 1977). These sequencing and DNA 
amplification methods allowed scientists to obtain DNA sequences that were thousands 
of nucleotides in length, enabling the scientists to directly interrogate small genomes 
(e.g. some viruses), or small regions of larger genomes from other organisms (e.g. 
humans, dogs, mice).  
A description of methods that have historically been used to estimate de novo mutation 
rates and their limitations are summarised in Table 1.1. Some major limitations are 
common to all traditional techniques. For example, given the extreme rarity of de novo 
mutation events in eukaryotes and lack of feasibility to interrogate multiple individual 
genomes (in humans, the current agreed estimates of the per nucleotide mutation rate 
is 1-3 x 10-8 per generation, which is equivalent to 30 – 90 nucleotides in the three 
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gigabase (Gb) human genome) (Conrad et al. 2011; Kong et al. 2012; Campbell and 
Eichler 2013), traditional methods could not provide a high resolution, accurate 
estimation and an investigation into the characteristics of new mutations in large 
eukaryotic genomes. In particular, it was not possible to observe or measure the rates: 
for each mutation type (single nucleotides, indels, CNVs, aneuploidies); across a variety 
of species of interest; in different genomic contexts; and in different physiological and 
environmental conditions, including in natural contexts. 
Table 1.1. Methods for estimating de novo mutation rates in the pre-high 
throughput sequencing era and the potential associated biases 
Measurement and methods 
taken to estimate rates 
Potential biases and 
limitations 
References 
Incidence rates of spontaneously 
occurring phenotypes present in 
natural populations (e.g. 
spontaneous Mendelian diseases 
in people). With the Mendelian 
inheritance pattern, incidence, 
fitness effect, causal locus and its 
sequence length, an estimated 
mutation rate can be calculated. 
This relies on an assumption that 
variant is under a mutation-
selection balance.  
Not all mutations cause a 
phenotypic change leading to 
underestimates of the 
mutation rate. Deleterious 
mutations associated with 
disease may be present in 
mutational hotspots. 
(Danforth 
1923; 
Haldane 
1935; Deng 
and Lynch 
1996; 
Kondrashov 
1998, 2002; 
Nachman 
2004) 
Using inbred populations to 
systematically measure 
spontaneously occurring 
phenotypes (e.g. mutations 
causing with lethal 
consequences) 
Requires inbred lines with 
short generation times, up to a 
thousand generations are 
often required to make an 
observation. Therefore this 
method is not feasible in many 
large animals. As many 
generations may be required 
to obtain an observation of a 
new phenotype, this can be 
extremely laborious. Inbred 
lines may not represent true 
natural populations. 
 
(Muller 
1928; 
Keightley 
1994) 
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Using inbred populations to 
directly identify de novo 
mutations that occur in a few loci 
by DNA sequencing or 
polymerase chain reaction 
Only possible for sites with 
unusually high mutation rates 
(e.g. mitochondria, 
microsatellites), otherwise 
sequencing would become too 
expensive as large sample 
sizes would be necessary to 
make an observation. 
(May et al. 
1996; 
Denver et al. 
2000) 
Identifying polymorphisms at 
neutral sites (e.g. synonymous 
mutations, DNA sequencing of 
orthologous sequences between 
species). Site must be neutrally 
evolving so that it is proportional 
to the mutation rate. Timing of 
species divergence must be 
known.  
Difficult to ascertain whether a 
site is truly neutral. 
(Sueoka 
1961; 
Kimura 
1968; 
Kondrashov 
and Crow 
1993; Drake 
et al. 1998; 
Nachman 
and Crowell 
2000) 
Applying artificial mutagens such 
as ethyl methanesulfonate (EMS) 
to introduce spontaneous 
mutations. EMS-induced 
mutations have been used to 
study the phenotypic effects and 
rate of true spontaneous 
mutations. 
Not ethical or feasible in 
animals with longer generation 
times. Does not provide a true 
representation of naturally 
spontaneous mutations. 
(Mukai 1970; 
Keightley et 
al. 1998) 
1.4.2. High throughput sequencing technologies for detecting de novo germline 
mutations 
Direct observation of de novo germline mutations in whole genomes would enable the 
accurate estimation of the de novo mutation rate and characterisation of their genome 
wide distribution for each mutation type. With multiple individual whole genomes from 
related individuals, many questions about de novo mutations can be answered. Before 
sequencing genomes from individuals of a family became a possibility, sequencing 
technologies had to become more affordable and higher in throughput and resources 
that complement these technologies had to be developed.   
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One of the most important resources in modern genomics research is the reference 
genome. The reference genome is a representation of a species’ DNA, where 
nucleotides are organised linearly by physical position along the lengths of each 
chromosome. Researchers studying a variety of experimental questions can then use 
the reference genome to develop tools or describe DNA of interest in subsequent re-
sequencing projects (e.g. physical positions of de novo mutations) in a consistent and 
reproducible manner. Annotations to the reference genome, including the physical 
position of various features such as genes, regulatory DNA and genomic context would 
enable a deeper understanding of how and why de novo mutations are formed. The first 
draft genome made available was the human genome in 2001 and was developed from 
a pool of four unique individuals (Lander et al. 2001; Venter et al. 2001). Sequencing 
was carried out using Sanger based technologies and the project had an estimated cost 
of up to $1 billion US dollars (USD). For the first time, researchers were able to 
characterise different features of the human genome, including its length, the number of 
genes and their organisation, GC content and relative rate of recombination across the 
genome (Lynch et al. 2016). 
To enable utilization of the reference genome in subsequent re-sequencing projects, it 
was evident that major technological advancements had to be made to reduce the cost 
of whole genome sequencing to under $1,000 USD per individual. Reducing the cost of 
providing whole genome re-sequencing would make population-level studies, 
personalised medicine and research in other species possible (Schloss 2008; Reuter et 
al. 2015). The National Human Genome Research Institute initiated a $70 million USD 
scheme to make high throughput, NGS possible in the subsequent 10 years. The 
resources provided through this scheme resulted in the development of a variety of high 
throughput sequencing platforms (Reuter et al. 2015; Ambardar et al. 2016).  
Since the human genome was sequenced, the genomes of other multicellular model 
organisms were sequenced in rapid succession including the mouse, rat, chimpanzee 
and the dog (Waterston et al. 2002; Gibbs et al. 2004; Mikkelsen et al. 2005; Lindblad-
Toh et al. 2005). NGS platforms developed accelerated genomics research and today 
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there are 35,197 publicly available reference genomes, including 1,331 animal genomes 
(http://www.ncbi.nlm.nih.gov).   
Popular NGS platforms are based on Sanger sequencing technology and involve four 
main wet laboratory steps, each with slight variations in chemistry depending on the 
sequencing platform  (e.g. from 454, Illumina, Ion Torrent companies, developed 
between 2004-2010) (Ambardar et al. 2016; Mardis 2017). The four steps include 
nucleic acid isolation, library preparation, template amplification and sequencing by 
fluorescence detection (Ambardar et al. 2016). Creating DNA libraries involves random 
fragmentation of the DNA strand to create shorter DNA templates and the attachment of 
“adaptors” to template ends. The adaptors create stable priming sites for the ends of 
diverse DNA sequences and are key to enable PCR amplification and sequencing on 
the NGS platform (Timmerman 2015; Ambardar et al. 2016). Clusters of clonally PCR 
amplified DNA templates enhances the detectable fluorescent signal that is produced 
from the extension of one nucleotide during sequencing, as technologies are not yet 
sensitive enough to detect fluorescence using only one DNA molecule. Sequencing is 
carried out from either end of the DNA fragment, resulting in the production of single 
sequences (often termed ‘reads’), or from both ends of the DNA fragment, resulting in 
paired-end reads on either side of a DNA fragment (the middle un-sequenced portion is 
commonly termed the ‘insert sequence’) ( 
Figure 1.4). Significantly, paired-end reads are on opposite strands facing the centre of 
the insert sequence, and library construction can filter DNA fragments so that paired 
reads are separated by a limited distance on the DNA which designates the “read-
length”. Depending on the sequencing platform, reads can vary in length (e.g. 36-300 
bp, single or paired-end reads are available for Illumina platforms, 200-400 bp single 
reads for Ion Torrent platforms).  
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Figure 1.4. Representation of NGS data that has been aligned to a reference 
genome.  
NGS data typically consists of short paired-end reads that are sequenced on opposite 
strands of the original DNA template. Paired-end reads typically contain a non-
sequenced insert sequence. Coverage indicates the number of reads that have 
aligned to a locus in the reference genome. Variant callers detect loci with reads 
containing variation from the reference allele.  Author’s own artwork.  
 
 
When individual genomes are sequenced using NGS technologies, the short reads 
generated must be processed using bioinformatics tools in order to achieve biologically 
relevant observations. First, reads must be arranged into their natural biological order. 
This is done by computationally aligning or ‘mapping’ reads to the reference genome ( 
Figure 1.4). Commonly used mapping algorithms place reads into the most likely 
physical position in the reference genome, by comparing similarity between the read 
and all portions of the reference. Nucleotides in the optimally aligned sequences that 
differ relative to the reference genome can next be identified using variant calling 
programs.  
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To characterise germline de novo variants in eukaryotic species, studies most recently 
employ NGS in parent-offspring trio genomes or transcriptomes (Michaelson et al. 2012; 
Sayyab et al. 2016; Francioli et al. 2017). A “trio” consists of two parents and a progeny 
(often a disease “proband”). When a high-quality variant is detected at specific locus in 
the offspring that is not present in either parent, a deviation from Mendelian law 
suggests the presence of a de novo mutation (Goldmann et al. 2016; Wong et al. 2016) 
(Figure 1.5). De novo variant detection using this technique has been employed in 
humans, mice, chimpanzees and birds to date (Venn et al. 2014; Uchimura et al. 2015; 
Smeds et al. 2016).  
 
 
Figure 1.5. A parent-offspring trio pedigree and a representation of a germline 
de novo mutation.  
One paternal chromosome (the father is represented on the pedigree as a square) 
shown in blue and one maternal chromosome (the mother is represented on the 
pedigree as a circle) shown in red is inherited by the offspring (represented on the 
pedigree as a triangle). The paternal chromosome in the offspring contains variation 
(shown in yellow) that deviates Mendelian inheritance laws, suggesting that this is a 
de novo mutation. Author’s own artwork.   
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Although NGS technologies have advanced genomic research drastically, sequencing, 
mapping and variant calling remain error prone and are limited to variant types that can 
be called accurately using common workflows. The sheer size and complexity of whole 
vertebrate genomes (~3 gigabases in humans, 48% of which are composed of repetitive 
sequences) means that such limitations are common (Mardis 2017). Each NGS platform 
is associated with its own specific propensity to particular error rates and profiles 
(Ambardar et al. 2016; Goodwin et al. 2016). For example, platforms that use PCR 
amplification are subject to PCR errors and the difficulty in re-sequencing GC rich DNA 
(Reuter et al. 2015). Read alignment to the reference genome is based on read 
nucleotide identity to the reference genome causing mapping bias towards reference 
alleles and underrepresentation of alternative alleles, especially in highly polymorphic 
regions such as in human leukocyte antigen and other immunity genes (Degner et al. 
2009; Brandt et al. 2015). The process of alignment and variant calling assumes that 
the reference genome is a true representative of the studied species. Most reference 
genomes are “incomplete” with many containing gaps, un-localised contigs that have 
not been placed on their residing chromosome and technical artefacts (The Genome 
Reference Consortium, https://www.ncbi.nlm.nih.gov/grc/). Also, as the reference 
genome is developed from one or a relatively small number of unique individuals, any 
‘novel’ DNA that is present in the subject individual but not the reference sequence may 
be missed due to the described mapping bias (Rosenfeld et al. 2012).  
To alleviate issues associated with short read NGS platforms such as sequencing errors 
and alignment artefacts, genomes must be sequenced to a high level of redundancy 
(coverage of ~30X) to achieve the high specificity that is required to characterise de 
novo mutations (Francioli et al. 2017). Coverage of >30X can achieve relatively high 
sensitivity and accuracy of calling SNVs (Cheng et al. 2014). Because higher coverage 
is associated with higher sequencing costs, some laboratories opt for exome NGS to 
detect de novo variants, especially those associated with disease (Poultney et al. 2013; 
Francioli et al. 2017). Variant types other than SNVs, in particular longer indels and 
CNVs less than 100,000 bp, are more difficult to detect and genotype to a comparable 
degree of accuracy as genotyping SNVs using short read NGS. As a consequence, the 
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characteristics and rates of large de novo indels and CNVs have not been 
comprehensively studied in species other than humans (Ghoneim et al. 2014).  
Depending upon insert sizes, paired-end sequencing on short read NGS platforms can 
improve the level at which indels and SNVs can be resolved. Long read sequencing 
platforms, which were commercially available from 2010-2014, have been designed to 
outperform short read NGS in accurately calling larger variants such as indels and 
CNVs. Long read platforms include the Oxford nanopore (minION) and single molecule 
real time (SMRT) sequencing by Pacific Biosciences (PacBio). The two dominating 
platforms produce 2,000 and 40,000 bp length reads respectively (Ambardar et al. 
2016). Both platforms are PCR-free, with the advantage of less bias when sequencing 
GC rich content and all long read platforms enable improved mappability of reads due 
the increase in alignment confidence associated with read length (Reuter et al. 2015). 
With these benefits, long read platforms have been shown to identify 85% of novel 
indels and CNVs of ~500 bp that were not detected by other methods (Chaisson et al. 
2014). Despite these benefits, long read platforms are associated with higher 
sequencing error rates (11 - 38.2%, predominantly composed of indel and homopolymer 
errors) than short read NGS platforms (0.11 – 0.28%) (Minoche et al. 2011). To benefit 
from both long and short read platforms, researchers have suggested combining both 
technologies in a single experiment (Weirather et al. 2017). However, as long read NGS 
are more expensive per base and are lower throughput than short read technologies, 
costs still limit their wide-scale use (Reuter et al. 2015; Ambardar et al. 2016). 
1.4.3. Microarray based technologies for detecting de novo CNVs 
Microarray based technologies have been successfully used to detect CNVs larger than 
100,000 bp in length, especially those arising from de novo events (Carter 2007; Egan 
et al. 2007; Sebat et al. 2007; Lupski 2007; Itsara et al. 2010; Alvarez and Akey 2012; 
Elizabeth Locke et al. 2015). There are many types of microarray based technologies 
(for a review of each see (Carter 2007)) but each works using the same principle. 
Microarrays are developed to target multiple, evenly spread sites or markers across the 
lengths of reference chromosomes. Regions where individuals differ in DNA copy 
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number to the reference can be identified by the relative intensity of signal that is 
emitted from hybridized probes in the region of the variant. Because the technology 
relies on linkage disequilibrium for targets to represent surrounding loci, higher density 
microarrays such as those available for human and mice are able to provide a higher 
resolution of the genome. Reliability of these markers diminishes for CNVs less than 
100,000 bp and for these variants NGS platforms are still preferred despite their 
limitations (Willet et al. 2013; Campbell and Eichler 2013; Poultney et al. 2013). 
Additionally, CNVs detected by microarrays cannot be physically placed without 
additional sequence interrogation such as through NGS.  
1.4.4. Detection of somatic mutations 
The de novo mutation detection methods that have been discussed so far relate to 
germline mutations and not somatic mutations, which are more difficult to identify. 
Somatic mutations are unique to a single cell and its descendant cells, unlike germline 
mutations which can be represented by all cells and tissue types in the body. Due to the 
relative rarity of each somatic mutation existing in an individual, obtaining high 
quantities of DNA to represent these mutations sufficiently is the biggest challenge in 
detecting somatic mutations. Many of the developed protocols used to identify somatic 
variants increase template number, either by careful sampling or through specialized 
library preparation methods.  
One common purpose for somatic mutation detection in humans and dogs is in cancer 
studies to identify putative disease causing or risk variants (Watson et al. 2013; Gardner 
et al. 2016). In cancer studies, somatic mutations are typically identified by employing 
whole genome or whole exome sequencing on DNA obtained from tumour and normal 
patient-matched tissue samples (Lawrence et al. 2013; Watson et al. 2013; Alioto et al. 
2015). A mutation is determined as somatic if it was not identified as a germline variant 
that was present in the cells of normal tissue. As cancers typically consist of many ‘sub-
clones’, each with their own unique set of somatic mutations, paired-end, deep 
coverage (~100X) sequencing is required to detect somatic mutations from technical 
artefacts (Alioto et al. 2015; Hsu et al. 2017). Furthermore, as the technique of 
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sequencing tumour-normal pairs requires a population of tumour-affected cells, this 
limits its use in a clinical setting for the early detection of cancer or for non-tumourous 
cancers (e.g. blood cancers).  
A method for the detection of somatic mutations in a cell without the need for 
descendant cells to increase DNA template number is single cell sequencing. Single cell 
sequencing was first conducted on mammalian cells for the whole genome (scDNA-seq) 
in 2011 and transcriptome (scRNA-seq) in 2009 (Tang et al. 2009; Navin and Hicks 
2011). Single cell sequencing has since also been applied to metagenomics and 
epigenomics. The technology employs similar processes to standard ‘bulk’ sequencing, 
with some additional steps. Cells need to be isolated (e.g. through microfluidics), whole 
genomes are amplified to obtain enough starting template quantities and additional 
barcoding of DNA fragments is required in library preparation. Barcodes are later used 
to identify the sequence’s cell of origin during downstream processing (Wang and Navin 
2015). Although the technology has improved significantly in the last 10 years, technical 
errors may be introduced during the amplification step and such errors remain a major 
source of false positives in this technology (Wang and Navin 2015). Despite this, single 
cell sequencing technologies provide opportunity to study other biologically relevant 
somatic mutations other than cancer, such as neuronal mutations and somatic 
mutations associated with aging (Lodato et al. 2015; Enge et al. 2017). With further 
development, the technologies show potential for use in early clinical diagnosis of 
cancers caused by somatic mutations (Navin and Hicks 2011). 
1.5. The effects of de novo mutations 
All de novo mutations can be classed as having an advantageous, neutral or deleterious 
consequence to an individual’s fitness. Fitness can be defined as the ability for an 
individual to survive and reproduce in the environment in which they reside in (Crow 
2000). Identifying the distributions of fitness effects for germline mutations aids in better 
understanding the dynamics between the occurrence of new genetic variation and the 
fitness of a population (Keightley and Eyre-Walker 2007). In general, advantageous 
mutations are rare but over time, contribute to ongoing adaptive evolution and 
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speciation (Eyre-Walker and Keightley 2007; Keightley 2012). Mutations that are highly 
deleterious undergo purifying selection and do not persist in populations for long periods 
of time. This is particularly relevant for sporadically occurring CNVs and aneuploidies, 
which may affect larger portions of the genome (Acuna-Hidalgo et al. 2016). Mutations 
that are mildly advantageous or deleterious are under lower selective pressure and 
persist in populations longer. Particular attention has been paid by the research 
community to the accumulation of mildly deleterious alleles, which are thought to 
collectively contribute to common neurodevelopmental diseases such as intellectual 
disability, autism spectrum disorders and schizophrenia (Vissers et al. 2010; O’Roak et 
al. 2011; Veltman and Brunner 2012; Poultney et al. 2013). 
1.5.1. New mutations and the evolution of canine phenotypes 
The evolutionary process that allowed the rapid phenotypic evolution of the domestic 
dog from the grey wolf is of interest because of the amount of phenotypic diversity that 
has been developed in a relatively short period of time. The event of canine 
domestication presents a valuable model for understanding the process and relationship 
that influences gene variation and phenotypes as species evolve. Genetic and 
paleontological evidence suggests that canine domestication occurred  ~15,000 - 
33,000 years ago, however most of the 400 modern dog breeds were only developed in 
the last couple of centuries (Vilà et al. 1997; Savolainen et al. 2002; Germonpré et al. 
2009a; Axelsson et al. 2013; Dreger et al. 2016). The phenotypic diversity is thought to 
be derived from genetic diversity that was already present in the wolf, however the rate 
and contribution from de novo mutations remains elusive (Wayne and Ostrander 1999). 
De novo mutations in KIT have been identified as a cause of white spotting in 
subpopulations of German Shepherd and spotted Weimaraner dogs (Gerding et al. 
2013; Wong et al. 2013). The majority of other new mutations that have been reported 
contribute to diseases including ichthyosis, bleeding disorders and progressive retinal 
atrophy (Brooks 1999; Vilboux et al. 2008; Kropatsch et al. 2016; Bauer et al. 2017). De 
novo mutations that result in observable or measurable phenotypes such as coat colour 
or disease are easier to detect. However, as not all de novo mutations have a strong 
impact on visible phenotypes, many are not likely to be detected without NGS efforts. 
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1.5.2. De novo mutations and disease 
Epidemiological studies have revealed sporadically occurring heritable diseases in both 
people and animal populations, with risk factors such as parental age increasing the 
likelihood of disease (Veltman and Brunner 2012). When there is no prior family history 
of a disorder expressed in a proband, researchers have recognised that causative 
genes are likely to be located in genomic regions that are more prone to mutations than 
others (these regions are often termed ‘mutational hotspots’) (Kong et al. 2012; Acuna-
Hidalgo et al. 2016).  Several disorders where new mutations are prevalent in their 
respective causative genes include Duchenne muscular dystrophy, haemophilia A and 
B, retinal atrophies and Huntington’s disease (Haldane 1946; Myers et al. 1993; Grimm 
et al. 2012; Kropatsch et al. 2016). Various types of causative mutations have been 
identified at these loci, from simple single nucleotide  mutations, CNVs, to deletions and 
inversions caused by non-allelic homologous recombination (Myers et al. 1993; Rossetti 
et al. 2011; Grimm et al. 2012).  
Before the advent of whole genome sequencing, patients with the aforementioned 
diseases were unlikely to be diagnosed within their lifetime since the responsible de 
novo mutations are usually unique to an individual. If the effect on fitness is great, 
affected individuals are unlikely to propagate the mutation and this impacts the ability to 
conduct family or population-based mapping studies. Collectively, patients with 
spontaneous disease contribute importantly to overall disease prevalence. For example, 
of all reported Mendelian phenotypes (~5,129), ~32% have no reported underlying gene 
(OMIM, 2018). Such figures are roughly similar across domestic animal species 
including the dog (~23%), cat (~35%), bovine (~41%) and pig (~58%, OMIA, 2018). 
Many unmapped traits are believed to be caused by new mutations (Chong et al. 2015). 
Whole genome and exome trio sequencing studies are regarded as an effective method 
of diagnosing sporadic genetic disorders and are expected to become common in 
clinical practice in the foreseeable future (Zhu et al. 2015; Francioli et al. 2017; 
Cummings et al. 2017). Already, these techniques have been used to successfully map 
traits including common human diseases such as autism spectrum disorders and 
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schizophrenia and have been successfully used in animal disease studies (Sayyab et 
al. 2016; Chew, Haase, Bathgate, et al. 2017).  
Aneuploidy is most frequently documented in humans as unassisted survival is severely 
impaired (Munné et al. 2004, 2016). Virtually all aneuploidies result from de novo 
events, as the effects of such mutations on fitness are so severe that individuals with 
these disorders are unable to reproduce. As with other CNVs, disease severity is 
impacted by a gene dosage effect caused by extra or missing chromosomes. The most 
common aneuploidy is trisomy 21 (Down syndrome), with a prevalence of one in 800 
births (de Graaf et al. 2015). Other autosomal aneuploidies include trisomy 13 (Patau 
syndrome) and trisomy 18 (Edwards syndrome). Sex chromosome aneuploidies are 
also prevalent in human populations. They can be in the form of monosomy (Turner 
syndrome - X0) or trisomy (Jacob’s syndrome -XYY; Klinefelter syndrome – XXY; and 
Triple X syndrome - XXX). Other forms of polysomies exist but are much more rare 
(other forms of Klinefelter syndrome - XXYY, XXXY, XXXXY; Tetrasomy X – XXXX and 
Penta X syndrome - XXXXX) (Visootsak and Graham 2006).  
In addition to the diseases caused by germline mutations, somatic mutations that are 
acquired throughout an individual’s life can become pathogenic and cause disease. 
Reported diseases include mutations that occur in the embryo (e.g. Proteus syndrome), 
or later in life (e.g. neurofibromatosis and McCune-Albright Syndrome) (Erickson 2003; 
Poduri et al. 2013). The most notorious and prevalent group of diseases caused by 
somatic mutations is cancer. Cancers can occur when disruptive mutations are acquired 
in proto-oncogenes, tumour suppressor genes or genes involved in DNA repair. These 
genes are responsible for normal cellular identity, differentiation and growth. When 
these normal cellular processes are disrupted, cells become abnormal and can have 
uncontrollable growth. The uncontrolled growth leads to formation of tumours, which is 
characteristic of many cancer-types (e.g. breast, lung, lymphoma) except for some 
blood cancers (e.g. leukemia). Disease can occur if the tumour is malignant and affect 
the ability of the organ or tissue it is residing in to function normally. In some cases, 
cells of the primary cancer can metastasize and form new tumours in other parts of the 
body. 
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Cancers are complex diseases and are genetically heterogeneous across individuals 
and even within the tumour cells of a single patient. Their heterogeneity stems from the 
stochastic nature and accumulation of somatic mutations. Most somatic mutations 
present in surviving cells are either neutral or mildly deleterious. The cells containing 
mildly deleterious mutations can clonally expand and harmful mutations can further 
accumulate in cancer driver genes. For this reason, age is a major risk factor for the 
development of many cancers (Risques and Kennedy 2018). Once cells become 
cancerous, tumours can develop and clonally expand into more aggressive forms. In the 
past decade, researchers have employed NGS technologies to determine the 
evolutionary trajectories of cancer to identify major genetic aberrations and the 
molecular interactions between cancer driving genes (Youn and Simon 2011; 
Krzywinski 2016; Peterson and Kovyrshina 2017). This knowledge can ultimately be 
used in a clinical setting such as use of identified predictive or prognostic biomarkers to 
enhance accuracy of diagnosis and effectiveness of personalised treatment plans. 
1.6. Rates and distribution patterns of new mutations within and across species 
Despite the challenges in identifying de novo mutations as previously described, it is 
evident that mutation rates vary across species, within species, within families and even 
across chromosomes of an individual (Ellegren et al. 2003; Conrad et al. 2011; 
Hodgkinson and Eyre-Walker 2011). In the current section, we describe characteristics 
of germline mutations across species only. Direct estimates of mammalian per base 
mutation rates fall around 10-8, however rates in other species can vary at an order of 
1,000 fold to this value (Lynch et al. 2016). Mutations are non-random and are 
influenced by different genomic contexts. Genome length and sequence constitution are 
unique to each species and this partially contributes to the differences observed in per 
species mutation rates. Variation in mutation rates also suggest that there are 
differences in the efficiency of DNA replication and repair across organisms (Lynch et 
al. 2016). 
Although variation in rates exists, mutational patterns are shared among species. For 
instance, compared to non-GC rich contexts, mutations in CpG dinucleotide islands are 
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reported to occur 30 times more frequently in great apes, 15 times more in other 
mammals and 10 times more in birds  (Keightley et al. 2011; Hodgkinson and Eyre-
Walker 2011; Smeds et al. 2016). Apart from GC contexts, the mutation rate is also 
influenced by the adjacent nucleotides by two to threefold for reasons that are not 
completely understood (Hwang and Green 2004). Local disruptions to DNA such as 
recombination sites and spontaneously occurring indels can regionally influence 
mutation rates. In eukaryotes and some bacteria, SNP mutations are more frequent 
within ~50-300 bp of an indel (Tian et al. 2008; Zhu et al. 2009; Hollister et al. 2010). 
Similarly, recombination hotspots have been found to coincide with substitution mutation 
hotspots (Duret and Arndt 2008).  
Parent of origin and age of conception has been identified as major factors that 
influence mutation rates. One of the first researchers to acknowledge gender 
differences was Haldane in 1946, who noted that the haemophilia gene was more 
mutagenic in men than in women (Haldane 1946). With modern technologies, Kong et 
al. 2012 later confirmed this, estimating that two additional mutations are transmitted to 
the offspring per year with increasing age of conception of the father (Kong et al. 2012). 
Whilst a similar trend is observed for mutations of maternal origin, the rate is much 
lower at 0.24 new mutations per additional year of the mother’s age (Goldmann et al. 
2016). This male bias is also observed in chimpanzees but at an even higher rate, with 
an estimated three mutations per year of the father’s age (Venn et al. 2014). This 
mutational bias could reflect the reduction in the capability of DNA replication and repair 
during cell division as an individual ages. In females, oogenesis begins during foetal 
development where all a woman’s primary oocytes are formed and arrested at prophase 
I. Further division is reinitiated at puberty when a woman begins her menstrual cycle 
and continues until she reaches menopause. On the other hand, the entire process of 
spermatogenesis in men starts at puberty and continually occurs until the death of the 
individual (Rahbari et al. 2016). 
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1.7. Aims of this thesis 
In this thesis, we use modern techniques and technologies to directly observe de novo 
mutations in the dog. New mutations are very rare events; hence, methods used to 
identify them require high sensitivity and specificity. Unlike typical parent-offspring 
sequencing studies in humans which obtain sequencing depths of ~30X, we utilize 
sequencing datasets with lower average coverage (less than 15X). For this reason, we 
first compare popular SNP calling programs and pipelines to obtain the most suitable 
method applicable to datasets used. The results of this study enabled us to develop an 
optimised pipeline to obtain direct estimates of the per base mutation rate in the dog 
and categorise their distribution throughout the canine genome to enhance our 
understanding of canine evolution. Lastly, we studied two spontaneously occurring 
genetic diseases in the dog, aiming to map spontaneous deleterious mutations in two 
breeds and demonstrate that techniques used could be enforced for clinical diagnosis.  
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Chapter 2. A performance comparison of popular single 
nucleotide variant detection methodologies applied to low 
coverage whole genome sequencing data  
2.1. Abstract 
Next generation sequencing platforms have become essential tools for understanding 
DNA in a wide range of contexts. Their success heavily relies on the accuracy, 
sensitivity and specificity of methods used to discern differences between the reference 
genome and genomes under investigation. Here we compare the relative performances 
of five popular single nucleotide variant callers with and without their associated 
recommended hard filtering criteria. We compare: FreeBayes; the Genome Analysis 
Tool-kit’s Haplotype Caller and Unified Genotyper; SAMtools; and VarScan. We tailor 
this comparison to suit smaller projects with modest sample numbers (n = 10) and 
coverage (~10X) to fill a current gap in the literature. Other comparison studies are 
generally applicable only to larger projects in model species, where there is access to 
large amounts of sequencing data and curated callsets for base and variant quality 
score recalibration. We estimated the accuracy, sensitivity and specificity of each 
pipeline according to the genotype concordance rate and number with the “truth” 
dataset for 10 canine samples. The truth dataset was defined as genotypes obtained 
from the CanineHD BeadChip array. Whole genome sequencing data was performed on 
the Illumina HiSeq2000 or HiSeq2500 platform as 100-101 base pair, paired end reads 
to an average sample coverage of 10.3X. With the exception of GATK Haplotype Caller, 
applying recommended hard filters did not improve the performance of genotyping 
concordance at the tested levels of minimum coverage. The default VarScan pipeline 
with no additional filters applied (VarScan uses SAMtools mpileup, without base 
alignment quality computation) generally outperformed other callers in terms of 
accuracy, sensitivity and specificity. The results of this study demonstrate that hard 
filtering of variant calls from low-powered genome studies can impair accuracy, 
sensitivity and specificity of callsets and provides some benchmark performance metrics 
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on a range of low coverage levels. These can be applied to future studies to aid optimal 
variant detection. 
2.2. Introduction 
Next-generation sequencing (NGS) technologies have provided scientists with 
unprecedented access to understanding DNA, one of the fundamental molecules of life. 
The range of applications has facilitated many discoveries that were made in research 
fields as diverse as ecology, agriculture, evolution, population diversity and human 
health (Schuster 2007; Mardis and Salzburg 2008; Ekblom and Galindo 2011). As 
sequencing technologies improve and the cost to sequence each nucleotide decreases, 
NGS is beginning to emerge from its role as a pure research methodology to become a 
common practice strategy for use in personalized medicine (O’Rawe et al. 2013; Hwang 
et al. 2015). 
The successful use of NGS in research and in practical applications relies heavily on 
our ability to accurately detect, categorize and genotype true biological variants of 
interest in genome data. This is a complex feat as sequencing errors, alignment 
artefacts and other sources of error can be indistinguishable from true biological 
variation. Each NGS sequencing platform is associated with an expected error rate and 
are prone to specific known types of errors. For example, Illumina’s short read 
sequencing technologies (36 – 250 base pairs (bp)) have an overall estimated accuracy 
of >99.5% (Bentley et al. 2008) and produce more substitution (0.11 – 0.28%) than 
insertion-deletion (indel) errors (3.2 x 10-6 – 2.5 x 10-5 %) (Minoche et al. 2011).  
Platforms which produce longer reads are better at resolving larger structural changes 
but are usually associated with higher rates of error. IonTorrent platforms 
(ThermoFisher Scientific) produce read lengths of 400 bp, are more prone to indel 
errors and have difficulty in accurately sequencing homopolymers larger than 6 – 8 bp 
long (Loman et al. 2012; Forgetta et al. 2013). Newer, very long read sequencing 
platforms such as those offered by PacBio (>10kb) and Oxford Nanopore Technologies, 
also have a tendency towards indel errors and have overall error rates of up to 15% 
(Carneiro et al. 2012). 
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To avoid the inclusion of these erroneous variants in data analyses, many variant calling 
algorithms have been developed.  Most existing variant calling pipelines use statistical 
inference to determine the likelihood of a true biological variant existing at any one site 
(reviewed in Nielsen et al. 2011). Depending on the sequencing platform used and the 
type of variants interrogated (germline or somatic and mutation type), several different 
quality score types are considered. Variant callers focussing on single nucleotide 
polymorphism (SNP) and indels typically account base quality, mapping quality and the 
local assembly quality metrics to determine the most likely genotype and then to provide 
an associated quality score (a “genotype likelihood”). Popular structural variant calling 
programs may assess split reads, read pair mapping span, read pair relative orientation 
and relative read depth (Tattini et al. 2015). While structural variation remains more 
challenging to accurately genotype using current technologies than SNPs and indels, it 
is generally accepted that we have not yet perfected small variant calling and that no 
single approach will work best across all datasets.  
Contemporary algorithms further improve the accuracies of calls within individuals by 
incorporating population-level data. For example, a multi-sample calling mode can be 
employed, where each locus is assessed across many samples simultaneously to 
develop a better expectation of whether the site is truly biologically polymorphic. Allele 
frequencies, genotype frequencies and patterns of linkage disequilibrium (LD) obtained 
from the observation of multiple samples can improve the confidence of a true biological 
variant at any given site. LD can be used to impute missing data and infer genotypes, 
improving calling sensitivity (Nielsen et al. 2011; Wang, Lu, et al. 2013). For well-
curated species such as human and mice, prior information can be obtained from public 
datasets such as dbSNP (https://www.ncbi.nlm.nih.gov/SNP/) and HapMap 
(http://www.hapmap.org/). When a set of known variants is not available, which is often 
the case in non-model organisms, high quality variants may be computed from the data 
at hand. An initial round of variant calling creates a callset that can be used to ‘teach’ 
the calling algorithm the quality score profiles of poor and good quality variants specific 
to the data in hand, enabling recalibration of genotype likelihood scores (McKenna et al. 
2010). 
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The extent to which multi-sample calling improves calling sensitivity over single-sample 
calling depends primarily on the number of samples and average coverage per sample. 
One study observed that single-sample calling yielded higher calling sensitivity than 
multi-sample calling in samples with low sequencing depths (5X)(Cheng et al. 2014). 
This result was independent of the minor allele frequency of the variant in the studied 
population. At low sequencing depths of 5X, multi-sample calling provided a significant 
improvement in sensitivity (~20%) only for low frequency and rare variant loci. This 
improvement required an additional 1,092 samples obtained from the 1,000 Genomes 
Project. In Cheng et al. (2014), the algorithm sensitivity to call variants always improves 
as the average coverage increases. Despite this, many researchers still opt for 
sequencing more samples at lower coverage (less than 10X) as this is believed to 
provide superior power for detecting common population variants relative to sequencing 
fewer samples at higher depths (Le and Durbin 2011; Sims et al. 2014; Gilly et al. 
2017).  
Although there are many variant caller comparison studies suited to model species with 
large datasets (for examples, see Liu et al. 2013; Cheng et al. 2014; Cornish and Guda 
2014; Pirooznia et al. 2014), there is limited information on the performance of variant 
calling pipelines that are tailored to smaller studies where prior observation of variants 
beyond the data of a single sequenced individual cannot be obtained and used for 
quality recalibration. For many laboratories, obtaining NGS data on multiple samples is 
not economically feasible and known variant data may not be available, especially for 
non-model species. In these situations, the strategy used to remove sequencing errors 
often relies on hard filtering raw data. Hard filtering is defined as setting a threshold 
(usually arbitrary) for a specific parameter of the data and variants which do not meet 
this value are removed from further analysis. Commonly used hard filtering parameters 
include base quality, mapping quality, coverage and strand bias (Van der Auwera et al. 
2013; Koboldt et al. 2013; Garrison 2015; Willet, Haase, et al. 2015b). Without 
sequence redundancy in low coverage data to appropriately represent sites that are 
more problematic to sequence such as GC rich and heterodimer prone fragments, hard 
filtering approaches may be too stringent and lead to false negative calls.  
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When hard filtering is applied, selecting appropriate threshold values is crucial to the 
success of whole genome sequencing (WGS) analysis in smaller studies or those using 
non-model species of interest. The needs will be affected by the type of analysis (for 
example, mapping analysis versus mutation detection analyses). The development of a 
validated pipeline that is well suited to a given dataset is time consuming and 
expensive, as additional methods of sequencing are needed to validate calls. For this 
reason, many researchers opt to employ recommended hard filtering cut-off values to 
define high quality variants when using popular variant calling programs (hard filtering 
recommendations are described in Methods and Supplementary Table S2).   
Our goal is to compare five popular variant callers: FreeBayes (Garrison and Marth 
2012); GATK Unified Genotyper (GATK UG) (McKenna et al. 2010); GATK Haplotype 
Caller (GATK HC) (McKenna et al. 2010); SAMtools (Li et al. 2009) and VarScan 
(Koboldt et al. 2013) and to observe the relative performance of pipelines after variants 
are filtered using recommended hard filtering criteria (Van der Auwera et al. 2013; 
Koboldt et al. 2013; Garrison 2015; Willet, Haase, et al. 2015b). The variant callers 
selected are tailored for short read data, such as those provided by Illumina platforms. 
Illumina currently has the largest market share in NGS platforms (Timmerman 2015). 
We apply these callers in single-sample mode to observe the sensitivity and specificity 
achieved when cut-off criteria are applied (hard filtering pipelines). We also observe the 
performance of callers without hard filtering (raw pipelines). Samples were 10 canine 
samples that had been subjected to WGS on popular Illumina HiSeq platforms offering 
genomes with a range or mean coverage from low to moderate (6 – 16X). To measure 
the relative calling quality of the algorithms, we assessed the concordance between 
genotyping calls made by the pipelines with genotypes called at 173,650 SNP markers 
using results on the same individuals from the CanineHD BeadChip array commercially 
provided by Neogen. Using these results as guidelines, researchers working with small 
(low coverage and number of samples) genome sequencing studies can select and 
adjust pipelines to suit their project goals. 
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2.3. Methods 
2.3.1. Samples 
Ten dogs (Canis lupus familiaris) that included three Australian Cattle Dogs, four 
Miniature Schnauzers and three Hungarian Puli were used in this study. These data 
formulate four unique parent-offspring trios. EDTA-stabilized whole blood or tissue was 
collected from the Australian Cattle Dogs and Miniature Schnauzers (See Table S1 for 
sample information). Genomic DNA was extracted using the illustra Nucleon BACC 2 kit 
using the manufacturer’s recommended protocols (GE Healthcare).  Hungarian Puli and 
two Miniature Schnauzer genotyping array and WGS data were obtained from previous 
studies (Willet, Makara, et al. 2015; Chew, Haase, Willet, et al. 2017). This study was 
conducted with approval from the Animal Ethics Committee at the University of Sydney 
(approval number N00/9–2009/3/5109 and N00/10-2012/3/5837 2015/902). See Table 
S1 for sample information.  
2.3.2. Genotyping array data and the truth dataset 
Samples were genotyped at 173,650 SNP loci on the CanineHD BeadChip array 
(Illumina) by GeneSeek (Lincoln, NE). Identity by descent proportions were obtained 
using PLINK (Purcell et al. 2007) and these calculations were used to confirm the 
pedigree relationships stated by registry data (Australian National Kennel Council) 
among each parent-offspring trio. SNPs genotyped on this array platform were used as 
the ‘truth dataset’ in this study. NCBI’s remapping service 
(https://www.ncbi.nlm.nih.gov/genome/tools/remap) was used to convert CanFam 2.0 to 
CanFam 3.1 array coordinates to make comparison with NGS genotypes consistent. To 
ensure that only accurately genotyped SNPs were considered, markers that did not 
adhere to Mendelian inheritance laws were excluded from the analysis.  
2.3.3. Next-generation sequencing 
WGS data was generated on the Illumina HiSeq2000 (n = 8) or the Illumina HiSeq2500 
(n = 2) by the Ramaciotti Centre, University of New South Wales, Kensington. Libraries 
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were prepared with the Illumina TruSeq kit. Each sample was barcoded and sequenced 
as 100 or 101 base-pair, paired-end reads on either one half or one full lane of the 
sequencing platform. See Table S1 for sample information.  
The Burrows-Wheeler Alignment mem (BWA-mem) tool outperforms other popular short 
read aligners and is recommended for pairing with multiple variant calling programs 
including those used in this study (Li and Durbin 2009; Van der Auwera et al. 2013; 
Cornish and Guda 2014; Layer et al. 2014; Faust and Hall 2014). Here we use BWA-
mem to align raw reads as pairs to the CanFam 3.1 reference genome for each sample 
using default parameters (Hoeppner et al. 2014). Polymerase chain reaction (PCR) 
duplicates were marked using Picard (http://picard.sourceforge.net). Local realignment 
around indels was performed using GATK (McKenna et al. 2010; DePristo et al. 2011).  
2.3.4. Variant Calling and Hard Filtering Criteria 
For each of the callers considered (FreeBayes, GATK HC, GATK UG, SAMtools and 
VarScan), we used recommended criteria (Figure 2.1) in the single sample mode to call 
variants and obtain genotypes (raw pipeline, caller-R). Next, we applied recommended 
hard filtering criteria to obtain high quality SNP genotypes (caller-F, Figure 2.1 and 
Table 2.1). Supplementary Table S2 provides a description of the parameters used in 
variant calling. For all pipelines, we defined indels or loci that were not bi-allelic as not 
called, as these are not assayed on the ‘truth’ platform used. Due to the stochastic 
nature of locus coverage in WGS experiments, we assessed genotype calls at a range 
of minimum base coverage thresholds. Raw base coverage at marker loci were 
obtained using SAMtools bedcov. Eleven different minimum coverage levels were used, 
ranging from zero coverage to 20X with an increment of 2X.  
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Figure 2.1. Representation of the ten variant calling pipelines used in this study.  
Five variant callers were used (FreeBayes, GATK HC, GATK UG, SAMtools, VarScan). 
The row labelled “Raw” indicates the options used for raw variant calling for each 
variant calling program, before hard-filters were applied. The row labelled “Hard filters” 
include additional hard-filtering steps performed for each variant calling program. For 
VarScan, we initially included all loci covered by at least one read and performed 
minimum coverage cut-off post variant calling. For detailed explanations of the filtering 
parameters, see Supplementary Table S2 and the associated software documentation.   
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Table 2.1. Variant callers and recommended hard filtering criteria used in this 
study. 
Default parameters for each variant caller were used in the raw pipelines. 
Program Variant caller Version Hard filtering recommendation 
GATK  Haplotype Caller 3.6.0 (Van der Auwera et al. 2013) 
GATK  Unified Genotyper 3.6.0 (Van der Auwera et al. 2013) 
SAMtools mpileup 0.1.19 (Willet, Haase, et al. 2015b) 
FreeBayes FreeBayes 1.0.2-33 (Garrison 2015) 
VarScan* SAMtools mpileup 
mpileup2cns 
2.3.9 (Koboldt et al. 2013) 
* VarScan depends on the input from SAMtools’ variant caller mpileup, without 
probabilistic realignment for the computation of base alignment quality (BAQ). The raw 
VarScan pipeline output is based on this and does not include the use of mpileup2cns. 
2.3.5. Refinement of the truth dataset 
We used genotypes called by each of the 10 pipelines to further refine the truth dataset. 
Loci that exhibited no genotype concordance across all 10 individuals and five variant 
callers at any one locus were removed from the truth dataset. This method aids in 
removing additional markers that were affected by CanFam 2.0 and CanFam 3.1 
reference assembly orientation differences as well as markers that were incorrectly 
genotyped on the array.  
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2.3.6. Comparison metrics 
We performed a paired, two-tailed t-test to determine whether the total concordance 
rates (2.1) were significantly different amongst the 10 pipelines tested regardless of 
minimum coverage requirement set. We then compared total concordance rates (%) 
amongst the 10 pipelines and across the 11 different coverage cut-off levels. For each 
of the variant callers, we compared their raw pipeline to their corresponding pipeline 
including hard filters to determine if filtering improved genotype concordance. To 
estimate the sensitivity, specificity and accuracy of each variant calling pipeline, we 
compared the total number of loci where the genotype called by the pipeline agreed with 
the truth dataset (concordant) and where the genotype called differed from the truth 
dataset (discordant). We calculated the standard deviation of the total number of 
concordant loci at each minimum coverage requirement level as a measure of variance 
between pipelines. Genotyping rates (including concordant and discordant genotype 
calls) are in supplementary Table S3. To determine if there are genotyping biases, we 
compared these concordance metrics for homozygous (2.2) and heterozygous (2.3) 
array genotypes separately.  
𝑻𝒐𝒕𝒂𝒍 𝒄𝒐𝒏𝒄𝒐𝒓𝒅𝒂𝒏𝒄𝒆 𝒓𝒂𝒕𝒆   
 =  
∑ 𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒄𝒐𝒏𝒄𝒐𝒓𝒅𝒂𝒏𝒕 𝒈𝒆𝒏𝒐𝒕𝒚𝒑𝒆𝒔 𝒄𝒂𝒍𝒍𝒆𝒅 𝒃𝒚 𝒕𝒉𝒆 𝒑𝒊𝒑𝒆𝒍𝒊𝒏𝒆𝟏𝟎𝒏=𝟏  
∑ 𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒍𝒐𝒄𝒊 𝒊𝒏 𝒕𝒉𝒆 𝒕𝒓𝒖𝒕𝒉 𝒅𝒂𝒕𝒂𝒔𝒆𝒕𝟏𝟎𝒏=𝟏
 𝒙 𝟏𝟎𝟎   (2.1) 
 
𝑯𝒐𝒎𝒐𝒛𝒚𝒈𝒐𝒖𝒔 𝒄𝒐𝒏𝒄𝒐𝒓𝒅𝒂𝒏𝒄𝒆 
=  
∑ 𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒉𝒐𝒎𝒐𝒛𝒚𝒈𝒐𝒖𝒔 𝒄𝒐𝒏𝒄𝒐𝒓𝒅𝒂𝒏𝒕 𝒈𝒆𝒏𝒐𝒕𝒚𝒑𝒆𝒔 𝒄𝒂𝒍𝒍𝒆𝒅 𝒃𝒚 𝒕𝒉𝒆 𝒑𝒊𝒑𝒆𝒍𝒊𝒏𝒆𝟏𝟎𝒏=𝟏
∑ 𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒍𝒐𝒄𝒊 𝒘𝒊𝒕𝒉 𝒉𝒐𝒎𝒐𝒛𝒚𝒈𝒐𝒖𝒔 𝒈𝒆𝒏𝒐𝒕𝒚𝒑𝒆𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒕𝒓𝒖𝒕𝒉 𝒅𝒂𝒕𝒂𝒔𝒆𝒕𝟏𝟎𝒏=𝟏
   (2.2) 
 
𝑯𝒆𝒕𝒆𝒓𝒐𝒛𝒚𝒈𝒐𝒖𝒔 𝒄𝒐𝒏𝒄𝒐𝒓𝒅𝒂𝒏𝒄𝒆 
=  
∑ 𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒉𝒆𝒕𝒆𝒓𝒐𝒛𝒚𝒈𝒐𝒖𝒔 𝐜𝒐𝒏𝒄𝒐𝒓𝒅𝒂𝒏𝒕 𝒈𝒆𝒏𝒐𝒕𝒚𝒑𝒆𝒔 𝒄𝒂𝒍𝒍𝒆𝒅 𝒃𝒚 𝒕𝒉𝒆 𝒑𝒊𝒑𝒆𝒍𝒊𝒏𝒆𝟏𝟎𝒏=𝟏  
∑ 𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒍𝒐𝒄𝒊 𝒘𝒊𝒕𝒉  𝒉𝒆𝒕𝒆𝒓𝒐𝒛𝒚𝒈𝒐𝒖𝒔 𝒈𝒆𝒏𝒐𝒕𝒚𝒑𝒆𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒕𝒓𝒖𝒕𝒉 𝒅𝒂𝒕𝒂𝒔𝒆𝒕𝟏𝟎𝒏=𝟏
  (2.3) 
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2.4. Results 
2.4.1. Truth and whole genome sequencing variant dataset 
A total of 171,672 unique markers were considered in each of the 10 pipelines and 10 
individuals after removing 796 SNPs which: did not conform to Mendelian inheritance; 
40 that could not be converted to the CanFam 3.1 reference assembly; and a further 
712 markers that had no genotype concordance with any of the 10 pipelines and 10 
individuals. Loci which were genotyped on both WGS data and the CanineHD BeadChip 
array differed depending on the individual, variant caller, pipeline and coverage.  
Whole genome sequencing on the Illumina HiSeq2000 or HiSeq2500 produced an 
average of 273 million reads per sample, with 99.13% of these successfully mapping to 
the CanFam 3.1 reference genome. This corresponds to an average mapped coverage 
of 10.3X.  
2.4.2. Comparison of genotype concordance rates of the 10 variant calling 
pipelines to truth dataset  
We found that the VarScan-R pipeline generally had significantly better genotype 
concordance than all other pipelines studied (PT-TEST < 0.05, Table 2.2). The VarScan-R 
pipeline uses SAMtools mpileup without BAQ and achieved concordance rates of 98.37 
– 99.67%. The GATK UG-R pipeline achieve similar levels of genotype concordance at 
higher levels of minimum coverage requirement (10X, see Table S4 for percent 
concordances for all pipelines and minimum coverage requirements). SAMtools-F 
outperformed the other pipelines at 20X minimum coverage requirement. The 
FreeBayes-F and VarScan-F pipelines underperformed significantly in comparison to 
the other eight pipelines tested (PT-TEST < 0.05), especially when lower minimum 
coverage requirements were set (Table S4). We also observed the effect on genotype 
concordance when the minimum coverage requirement increased (Figure 2.2 and Table 
S4). For all pipelines, genotype concordance rates improved as the minimum coverage 
requirement increased for both raw and filtered variants, except at 20X where 
improvement was only seen for FreeBayes-F, SAMtools-F and VarScan-F.
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Table 2.2. P-values from paired, two-tailed t tests on average genotype concordance rates of 10 different 
pipelines using five different variant callers with and without hard filtering (FreeBayes, GATK HC, GATK UG, 
SAMtools and VarScan) compared against genotypes obtained using the CanineHD BeadChip array. 
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FreeBayes Raw 
 
0.001 0.061 0.334 0.018 0.242 0.042 0.173 0.016 0.002 
FreeBayes Filtered 
  
0.001 0.001 0.001 0.001 0.002 0.001 0.001 0.001 
GATK HC Raw 
   
0.182 0.003 0.001 0.017 0.041 0.020 0.002 
GATK HC Filtered 
    
0.003 0.117 0.024 0.258 0.011 0.002 
GATK UG Raw 
     
0.001 0.215 0.011 0.040 0.001 
GATK UG Filtered 
      
0.017 0.569 0.008 0.002 
SAMtools Raw 
       
0.041 0.001 0.002 
SAMtools Filtered 
        
0.020 0.001 
VarScan Raw 
         
0.002 
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Figure 2.2. Percent concordance of all genotypes (homozygous and heterozygous) called by 10 different 
pipelines using five different variant callers with and without hard filtering (FreeBayes, GATK HC, GATK UG, 
SAMtools and VarScan) compared against genotypes obtained using the CanineHD BeadChip array. 
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2.4.3. Comparison of genotype concordance rates between raw pipelines and 
corresponding pipelines that include hard filters  
For each variant caller, we compared their raw pipeline to their corresponding pipeline 
including hard filters applied to observe the effect of hard filters to genotype 
concordance. In general, applying hard filters to variants using recommended criteria 
did not improve genotype concordance rates. The exceptions where applying filters did 
improve genotype concordance occurred for GATK HC-F for low (0 – 2X) and higher 
minimum coverage and SAMtools-F for higher levels (14 – 20X) of minimum coverage 
requirements (Figure 2.2 and Table S4). 
2.4.4. Total concordance and discordance and standard deviation of genotypes 
called by each of the pipelines to the truth dataset 
To estimate the sensitivity and specificity of each pipeline, we calculated the number of 
concordant (Table 2.3) and discordant genotypes (Table 2.4) to the genotypes of the 
truth dataset. The VarScan-R pipeline called the most number of concordant genotypes 
at low minimum coverage requirements (0 – 8X). At moderate to higher levels of 
minimum coverage requirements (10 – 20X), GATK UG-R and VarScan-R both called 
the highest number of total concordant genotypes. However, as standard deviation 
decreased as the level of minimum coverage requirement increased, the number of 
concordant genotypes was similar between most pipelines (Table 2.3).  
A similar trend was observed for the number and standard deviation of discordant 
genotypes across the 10 pipelines and minimum coverage requirement levels.  The 
VarScan-R pipeline had the lowest number of discordant genotypes at lower minimum 
coverage requirement levels (0 – 8X). At moderate to higher minimum coverage 
requirement levels (10 – 20X), GATK UG-R, SAMtools-F and VarScan-R had the 
lowest number of discordant genotypes. Variation amongst the pipelines was minimal at 
higher levels of minimum coverage requirement (Table 2.4). Like the total number of 
concordant genotypes, standard deviation and minimum coverage requirement levels 
had an inverse relationship. 
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2.4.5. Homozygous verse heterozygous concordance 
To identify genotyping biases, we separately explored the rate of homozygous and 
heterozygous genotypes called by each of the 10 pipelines that were concordant with 
the truth genotypes derived from the array platform. For all variant calling pipelines and 
levels of coverage, homozygous concordance rates were higher than heterozygous 
concordance rates (Figure 2.3 and Figure 2.4). Heterozygous genotype concordance 
rates were more heavily influenced by the level of minimum coverage requirement. The 
difference in the levels of concordance between homozygous and heterozygous 
genotypes decreased as the level of coverage increased.  
The highest rates of homozygous concordance were achieved with the VarScan-F at 
lower to moderate levels of minimum coverage (0 – 12X, 99.86 – 99.85%) and the 
SAMtools-F pipeline at higher levels of minimum coverage (14 – 20X, 99.85 – 99.85%, 
Figure 2.3). Table S5 contains percentages of homozygous concordance for all 10 
pipelines and minimum coverage requirement levels. Heterozygous concordance rates 
were highest using the VarScan-R (0 – 8X, 16 – 18X) and GATK UG-R (10 – 14X and 
20X, Figure 2.4). Table S6 contains percentages of heterozygous concordance for all 
10 pipelines and minimum coverage requirement levels. 
We compared homozygous and heterozygous concordance rates for each variant caller 
between the raw and corresponding pipeline that includes hard filters applied. With a 
few exceptions, applying hard filters to variants improved homozygous concordance 
rates (Table S5). Applying hard filters generally worsened heterozygous concordance 
rates, except for GATK HC at most minimum coverage requirement levels (Figure 2.4 
and Table S6).  
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Figure 2.3 Percentage concordance of homozygous genotypes called by raw and filtered pipelines using five 
different variant callers (FreeBayes, GATK HC, GATK UG, SAMtools and VarScan) compared against genotypes 
obtained using the CanineHD BeadChip array. 
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Figure 2.4. Percentage concordance of heterozygous genotypes called by raw and filtered pipelines using five 
different variant callers (FreeBayes, GATK HC, GATK UG, SAMtools and VarScan) compared against genotypes 
obtained using the CanineHD BeadChip array.
  
61 
To compare the differences in sensitivity between homozygous and heterozygous 
genotypes that were concordant to the truth dataset, we observed the number of 
homozygous and heterozygous concordant genotypes separately (Table 2.5 and Table 
2.6 respectively). In general, FreeBayes-R and VarScan-F had the highest number of 
homozygous concordant genotypes. We observed that the GATK UG-R and VarScan-R 
pipelines had the highest number of heterozygous concordant genotypes. 
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We compared the difference in specificity between homozygous and heterozygous 
genotypes that were concordant to the truth dataset by observing the total number of 
discordant calls for homozygous and heterozygous genotypes separately (Table 2.7 
and Table 2.8) .  For homozygous concordant genotypes, VarScan-F had the least 
number for lower to moderate levels of coverage (0 – 12X), whilst SAMtools-F had the 
least number for higher levels of coverage (14 – 20X).  For heterozygous concordant 
genotypes, VarScan-R had the lowest number for lower levels of minimum coverage 
requirement levels (0 – 8X). VarScan-R and GATK UG-R had the lowest number of 
discordant heterozygous concordant genotypes at higher levels of coverage (10 – 20X). 
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2.5. Discussion 
Selecting the best variant calling algorithm and parameters to classify true biological 
variants from sequencing errors is notoriously difficult. Many variant calling comparison 
studies that cater towards projects in model species with large datasets and high levels 
of average coverage (~30X) have been performed for calling SNPs in Illumina NGS 
data (Bauer 2011; Liu et al. 2013; Cheng et al. 2014; Cornish and Guda 2014; Pirooznia 
et al. 2014). In this study, we aimed to compare 10 variant calling pipelines that include 
five variant callers (FreeBayes, GATK HC, GATK UG, SAMtools and VarScan) with and 
without recommended hard filters applied. We applied the pipelines to data that is 
representative of a non-model species and smaller study with a lower coverage dataset 
(~10X). The metrics of performance provided in this study including the genotype 
concordance rate, total number of concordant and discordant genotypes to estimate 
sensitivity and specificity can be used as a guide to determine the optimal variant calling 
pipeline for other small studies with similar datasets.  
The VarScan-R pipeline was generally the most accurate as measured by total 
genotype concordance to the truth dataset (PT-TEST < 0.05, Figure 2.2), achieving 
concordance rates of 98.37 – 99.37% across the minimum coverage requirements 
tested (0 – 20X). The VarScan variant caller is identical to the SAMtools pipeline, both 
using SAMtools’ mpileup except that BAQ computation is disabled for VarScan. As the 
VarScan authors observe (Koboldt et al. 2013), we also found that BAQ is too stringent 
by comparing VarScan-R and SAMtools-R. VarScan-R was generally the most sensitive 
and specific caller estimated by the highest number of total concordant and lowest 
number of total discordant genotypes. The superior performance of VarScan-R 
compared to other nine pipelines is evidently due to its performance compared to the 
other pipelines at lower minimum coverage requirement levels (less than 10X). At low 
levels of coverage, the standard deviation of the total number of concordant and 
discordant genotypes was relatively high. Studies with low average sample coverages 
should consider the VarScan-R pipeline as it outperformed all other 9 pipelines in 
genotype concordance, estimated sensitivity and specificity.  
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At minimum coverage requirement of 10X and over, genotype concordance rates 
become similar and at 20X each pipeline is within 0.1% of each other, except for 
VarScan-F and FreeBayes-F which were substantially lower (Table S4). Standard 
deviation in total concordance and discordance also continually decreases and the 
difference between the 10 tested pipelines became minimal (Table 2.3 and  
Table 2.4). GATK UG-R and SAMtools-F had better or similar total accuracy, sensitivity 
and specificity than VarScan-R at minimum coverage requirement of 10X and higher 
(Figure 2.2, Table 2.3 and  
Table 2.4). As the truth dataset comprised of only commonly occurring SNP loci, there 
is a potential bias where a called variant is more likely to be true, inflating genotype 
concordances across all pipelines and coverage levels. Subsequent studies should 
include known rare and de novo variants to reduce this source of bias.  
Minimum coverage requirement levels had a high impact on the accuracy, sensitivity 
and specificity of the caller, as has been previously described (Cheng et al. 2014). The 
variance across the 10 pipelines decreased as minimum coverage requirement 
increased and most pipelines performed quite similarly at higher minimum coverage 
levels (Table 2.3 and  
Table 2.4). Besides the variant calling pipeline, the minimum coverage requirement 
level should be carefully considered depending on the average coverage of the samples 
and project goals as coverage had the greatest impact on calling sensitivity and 
specificity (Table S3 contains genotyping rates for each minimum coverage requirement 
level for each of the 10 pipelines).  
Applying the recommended hard filtering criteria to variants generally did not improve 
the accuracy of genotype concordance to the genotypes of the truth dataset in this 
study (Figure 2.2). The only exceptions include GATK HC and SAMtools where filtering 
did improve genotype concordance at some levels of low and high minimum coverage 
requirement (Figure 2.2 and Table S4). In Figure 2.2, the difference in genotype 
concordance rate between the raw and pipeline with hard filters applied becomes 
smaller as minimum coverage requirement increases. We suspect that many of the 
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developed hard filtering pipelines were developed for samples with higher coverage, 
where metrics that are used in filtering can be calculated more accurately.  
Obtaining high genotyping accuracy (>99.99%) is extremely difficult for relatively low 
coverage data. As other studies have observed (Sims et al. 2014; Willet, Haase, et al. 
2015a; De Summa et al. 2017), we found a higher rate of homozygous than 
heterozygous concordance to array genotypes, especially when hard filters are applied. 
Heterozygous genotyping heavily influences the total concordance rate and is 
dependent on the minimum coverage cut-off value used. Apart from the FreeBayes-F 
and VarScan-F pipelines, heterozygous concordance rates drastically improve at ≥10X, 
and become comparable to homozygous concordance rates at ≥12X (the difference 
between homozygous and heterozygous concordance rates is 0.93 – 1.7%, depending 
on the variant caller at this coverage level, Figure 2.4). Bias towards homozygous 
genotypes is evidently caused by low average sample coverage. At low coverage (less 
than 10X), distinguishing sequencing errors from true alternative variants becomes 
difficult without the additional support for the alternative allele of multiple reads and we 
observed that applying hard filters for all five variant calling pipelines was too stringent.  
Researchers with low coverage, short read, whole genome sequencing data should 
select tools and variant calling filtering parameters based on the desired sensitivity and 
specificity that is appropriate for the research question. For example, when the research 
question is to identify genetic variants associated with disease, higher sensitivity is more 
desirable than higher specificity, within reason. From this study, this is achieved by 
sequencing samples with at least an average depth of 10X to ensure that high 
genotyping rates are achieved. Applying no additional hard filters generally increases 
the number of non-reference alleles that are captured. On the contrary, when 
genotyping accuracy is desired, including hard filters with SAMtools or VarScan can 
reduce the number of false positive genotypes called. 
This study provides reference metrics that can be used to tailor recommended hard 
filtering pipelines towards specific project goals. Its use would be suitable for projects 
with small sample sizes and WGS depth (~10X) that wish to call SNPs from Illumina 
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NGS data.  For low coverage data, hard filtering generally reduces sensitivity to detect 
SNPs, particularly at heterozygous loci. The most value is achieved for samples with a 
minimum average coverage of 10X per sample, as sensitivities and specificities 
drastically improve up until this level, where improvement with each additional coverage 
level begins to plateau.  
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Chapter 3. Direct estimate of the de novo mutation rate in the 
domestic dog 
3.1. Abstract 
All genetic variation that drives evolution and contributes to disease once arose from a 
spontaneously occurring new DNA mutation. In this chapter, we characterise the rate 
and distribution of autosomal germline mutations in one of the most phenotypically 
diverse species, the domestic dog. By characterising de novo mutations, their 
contributions to canine health and evolution can be better understood. There are 
currently over 400 recognised dog breeds, many of which were created only in the last 
couple of centuries. Through parent-offspring whole genome sequencing, we estimate 
the probability of de novo mutation to be 3.9 x 10-9 per nucleotide per generation. This 
corresponds to 81 – 112 new nucleotide mutations in each individual canine genome 
that is 2.4 x 109 nucleotides in size. The observed transition to transversion ratio in the 
canine is 2.3 units, like other vertebrate species. The rate of de novo mutations per 
generation is slightly higher in the dog than the rate of all other studied species 
including humans, mice, chimpanzees and birds. We theorize that the elevated de novo 
mutation rate may have contributed to the rapid phenotypic diversification of the 
domestic dog.  
3.2. Introduction 
The dog (Canis lupus familiaris) is believed to be the first animal to be domesticated 
and today there are over 400 recognised breeds that were developed for a variety of 
social and economic purposes (Karlsson and Lindblad-Toh 2008; Axelsson et al. 2013). 
The sole ancestor of the domestic dog is the grey wolf (Canis lupus) (Vilà et al. 1997). 
The timing, location and process of dog domestication has been heavily debated and 
many studies have been performed to understand how the species evolved to become 
one of the most phenotypically diverse living land animals (Vonholdt et al. 2010; Boyko 
et al. 2010; Larson et al. 2012; Callaway 2013; Axelsson et al. 2013; Freedman et al. 
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2014). Whilst many of the previous studies have provided extensive insight into 
understanding how rapid canine evolution occurred from the perspective of existing 
ancestral variation and intense artificial selection, no study has yet considered the 
contribution of de novo mutations to canine evolution.  
The earliest archaeological evidence of dog domestication include the discovery of 
~32,000 to 36,000 year old dog-like fossil remains in Siberia, Belgium and the Czech 
Republic  (Germonpré et al. 2009b; Ovodov et al. 2011; Germonpré et al. 2015). 
However, it is uncertain whether the fossils represent domestic dogs, animals from 
failed attempts at domestication, or simply rare, morphologically unique extant wolves 
(Freedman et al. 2014). Dog fossils found at burial sites in Israel and Germany are 
regarded as more indicative of domestication because their burial reflects their 
importance in human civilization at the time. Buried canine fossils are dated to be 
between 11,500 to 16,000 years old (Davis and Valla 1978; Boyko 2011). Studies of 
wolf and dog mitochondrial DNA variation have previously suggested that dogs were 
domesticated over 100,000 years ago (Vilà et al. 1997; Wayne and Ostrander 1999). 
Later genetic studies on genomic SNP variation indicate that it is more probable that 
dogs were domesticated from populations of wolves of either Middle Eastern or 
Southeast Asian origin only 10,000 years ago (Pang et al. 2009; Vonholdt et al. 2010). 
Such genetic studies rely on assumptions of the number of founding events and levels 
of admixture between wolves, but the true values of these cannot be known for certain. 
It is likely that the process of domestication was long and complex, involving multiple 
ancestral populations and multiple back crossing events with wolves.  
Although an agreement on the origins of the dog has not yet been reached, it is evident 
through observed patterns of linkage disequilibrium (LD) that there were two significant 
bottlenecking events in dog evolutionary history (Lindblad-Toh et al. 2005; Boyko 2011). 
The first bottleneck reflects the initial domestication of dogs from wolves. The creation 
of modern dog breeds was brought about in the second bottlenecking event, involving 
intense artificial selection and breeding within closed populations (Lindblad-Toh et al. 
2005). The second bottlenecking event has only occurred in the last few centuries and 
has resulted in more than 400 breeds that are recognised worldwide today (Dreger et al. 
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2016). Numerous specialized breeds were formed to suit a specific purpose such as for 
guarding, herding, retrieving, hunting and racing. Many other breeds were developed for 
aesthetic and behavioural traits suited for companionship.  
The two significant bottlenecking events have led to unique patterns of LD in the dog. 
LD extending several megabases can be found when analysing dogs of a single breed. 
Dogs across multiple breeds share a much shorter range of LD that only extends tens of 
kilobases (Lindblad-Toh et al. 2005; Stern et al. 2013; Friedenberg and Meurs 2016). 
This unique genetic architecture of the dog has led scientists to recognise the 
advantages of mapping traits more efficiently in this species, as fewer individuals and 
genetic markers are required compared to other species (Karlsson et al. 2007). 
Genome wide association studies (GWAS) have led to the successful mapping of many 
genes underlying a variety of canine phenotypes, some of which are shared across 
breeds through introgressive breeding. Gene variants or haplotypes in FGF4 for 
Dwarfism (chondrodysplasia), THBS2 for short-snouts (brachycephaly) and MSRB3 for 
floppy ears are examples of successful mapping of traits shared across multiple breeds 
through GWAS (Parker et al. 2009; Bannasch et al. 2010; Boyko et al. 2010; Boyko 
2011).  
Despite these successes, there is an unexpectedly large number of Mendelian traits 
that have no reported underlying causal variant (~23% of reported Mendelian traits have 
no known underlying causal variant; OMIA, 2018). Similar figures are observed in 
humans (32%; OMIM, 2018), despite humans being one of the most comprehensively 
studied species. Many of these unmapped variants are thought to be de novo mutations 
which are not in LD with common genetic markers and hence cannot be found through 
GWAS (Chong et al. 2015). De novo mutations have been implicated in the 
spontaneous occurrence of several canine phenotypes including visible traits such as 
white spotting in subpopulations of German Shepherd dogs and Weimaraners (Gerding 
et al. 2013; Wong et al. 2013); and spontaneously occurring diseases such as 
ichthyosis, bleeding disorders and progressive retinal atrophy (Brooks 1999; Vilboux et 
al. 2008; Kropatsch et al. 2016; Bauer et al. 2017). It is likely that many other de novo 
variants cause more subtle influences on phenotype and thus remain undetected.  
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two unique parent-offspring trios. Each unique parent-offspring trio can be referred to 
by the identification number (ID) of the child: USCF134, USCF136, USCF1014, 
USCF1119 and USCF1294. See Table S1 for pedigree information. 
 
Genomic DNA was extracted from EDTA-stabilized whole blood obtained from the 12 
samples using the phenol-chloroform method or the illustra Nucleon BACC2 kit 
following the manufacturer’s protocol (GE Healthcare). This research was conducted 
with the consent of the animal’s owners and with animal ethics approval granted by the 
Animal Ethics Committee at the University of Sydney (approval number N00/9–
2009/3/5109 and N00/10-2012/3/5837 2015/902). 
3.3.2. Whole genome sequencing 
Whole genome sequencing was performed for each sample using the Illumina HiSeq 
2000 (Illumina, San Diego, CA) by the Ramaciotti Centre at the University of New South 
Wales, Kensington. Libraries were prepared with the Illumina PCR-free TruSeq kit 
according to the vendor’s instructions. Each sample was sequenced as 100-101 base 
pair (bp), paired-end reads using either half or a full lane of the flow cell.  
All bioinformatics analysis was performed on the University of Sydney’s High-
Performance Computing Cluster (Artemis). Raw reads were aligned to the canine 
reference genome (CanFam 3.1) as pairs using the Burrows-Wheeler Alignment (BWA)-
mem algorithm version 0.7.15 with default parameters (Li and Durbin 2009). 
Polymerase chain reaction (PCR) duplicates were marked with samblaster, version 
0.1.22 (Faust and Hall 2014). Local realignment around insertion-deletions (indels) was 
performed using the Genome Analysis Toolkit (GATK), version 3.6.0 (McKenna et al. 
2010; DePristo et al. 2011). The number of mapped and unmapped reads was obtained 
using SAMtools idxstats.  
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3.3.3. Variant calling and genotyping 
To ensure a high level of variant calling accuracy, we obtained sites where genotypes 
were concordant between two popular variant callers: GATK (version 3.6.0) and 
SAMtools (version 1.6) (Li et al. 2009; McKenna et al. 2010). Both of these callers are 
consistently found to be the best amongst other popular callers at accurately genotyping 
SNVs in Illumina data when used in conjunction with BWA-mem as the aligner (Cheng 
et al. 2014; Cornish and Guda 2014; Hwang et al. 2015). Raw variants at all sites were 
first called with GATK’s Haplotype Caller (HC) (McKenna et al. 2010; Van der Auwera et 
al. 2013). The minimum phred-scaled emission and calling confidence threshold was 
set at 50, which is higher than the recommended values of 10 and 30 respectively (Van 
der Auwera et al. 2013). We chose a higher calling confidence to obtain highly confident 
genotype calling accuracy. GATK HC raw SNPs were excluded using GATK’s 
VariantFiltration tool if Quality Depth < 2.0, Fisher Strand > 60.0, Mapping Quality < 
40.0, HaplotypeScore > 13.0, MappingQualityRankSum < -12.5 and ReadPosRankSum 
< -8.0, as previously recommended (Van der Auwera et al. 2013). SAMtools mpileup 
and bcftools (version 1.6) was used to call and genotype SNPs, excluding bases and 
reads with base quality < 20 and mapping quality < 20. Only properly paired reads were 
considered. As recommended by SAMtools, a coefficient of 50 was applied to reduce 
the effect of reads with excessive mismatches. Using vcffilter (version 1.0.0), we further 
filtered SAMtools mpileup SNP calls and excluded sites with QUAL < 50 and MQ < 40.  
A single, high quality set of genotypes for each locus and individual were obtained for 
sites if genotypes were concordant between both filtered GATK HC and SAMtools 
callsets. This was obtained using bcftools isec with default parameters. Sites were 
retained if coverage was greater than or equal to 10, and less than or equal to two times 
the average coverage of the individual. The maximum coverage is applied to avoid 
regions with duplications as previously recommended (Willet, Haase, et al. 2015b). We 
filtered each locus by coverage using vcflib’s vcffilter (version 1.6). 
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3.3.4. Direct estimate of the per base mutation rate in dogs 
To estimate the per base mutation rate in dogs, sites passing filters in variant calling 
were further filtered by genotype. Sites where both parents were homozygous for the 
reference allele and where the child was either homozygous reference (non-de novo 
site) or heterozygous (de novo site) were obtained using vcflib’s vcffilter tool. We term 
these sites the total number of observable sites passing all filtering requirements used 
in this study. After visual inspection of potential de novo sites using SAMtools tview (Li 
et al. 2009), we noticed that some parents contained poor quality alternative bases 
despite being called as homozygous reference. As these are more likely to represent 
non-de novo sites, we manually excluded these from further analysis.  
In each trio, we defined the per base mutation rate to be: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓  𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑑𝑒 𝑛𝑜𝑣𝑜 𝑆𝑁𝑃 𝑠𝑖𝑡𝑒𝑠 𝑝𝑎𝑠𝑠𝑖𝑛𝑔 𝑓𝑖𝑙𝑡𝑒𝑟𝑠 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑑𝑒 𝑛𝑜𝑣𝑜 𝑎𝑛𝑑 𝑛𝑜𝑛 − 𝑑𝑒𝑛𝑜𝑣𝑜 𝑠𝑖𝑡𝑒𝑠 𝑝𝑎𝑠𝑠𝑖𝑛𝑔 𝑓𝑖𝑙𝑡𝑒𝑟𝑠
 
 
De novo mutation events were categorised as either Ti or Tv events and a 
transition:tranversion (Ti:Tv) rate was calculated. 
3.3.5. Characterising de novo mutations 
We characterised sites that passed all quality filters according to their occurrence within 
any of seven local genomic features: coding exonic sequence (CDS), CpG island, 
intergenic, intronic, conserved, 3’ untranslated region (3’ UTR) and the 5’ untranslated 
region (5’ UTR). Using UCSC’s Table Browser (https://genome.ucsc.edu/), we obtained 
CDS, intronic, 3’ UTR and 5’ UTR regions using the refGene and xenoRefGene tracks 
in BED file format. Intergenic regions were defined as regions in the reference genome 
that were not already defined as CDS, intronic, 3’ UTR and 5’ UTR and were obtained 
using a custom perl script. Conserved regions of the genome were defined as regions 
with a phastCons score of > 0.5, calculated using reference genomes of 33 placental 
mammals. PhastCons scores that were calculated relative to the human genome 
(GRCh37/hg19) were obtained from UCSC (Pollard et al. 2010). Positions were 
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converted to the CanFam 3.1 reference genome using UCSC’s LiftOver tool.  We 
determined whether the per base mutation rate was significantly different between each 
feature by performing a paired, two tailed t-test.  
3.4. Results 
3.4.1. Whole genome sequencing 
Sequencing on the Illumina HiSeq 2000 platform for the 12 samples used in this study 
produced between 175,095,946 – 469,840,272 reads, 98.2 – 99.6% of which were 
aligned to the CanFam 3.1 reference genome. This is equivalent to an average raw 
coverage of 6.6 – 17.9X per individual (Table S2). The average raw coverage per 
unique parent-offspring trio ranged between 8.4 – 13.5X.  
3.4.2. Variant calling and per base mutation rate estimates 
The number of observable loci that passed all filtering criteria used in this study ranged 
between 64,397,375 – 1,010,866,409 bp for the five trios observed which corresponds 
to 2.9 – 45.9% of the canine reference autosomes (~2.2 gigabases, Table S3 contains 
the number of observable loci per trio, per autosome).  The number of de novo 
mutations detected ranged from 3 – 51 nucleotide variants for each offspring in the five 
unique parent-offspring trio (Table S4 contains physical position and genotypes for 
parent-offspring trios at observed de novo sites). There was one identical de novo 
mutation identified between full siblings USCF134 and USCF136 at chromosome 18 
position 28,418,247 (CanFam 3.1). 
The per-base mutation rate was estimated to be 3.9 x 10-8 (95% confidence interval 3.5 
– 4.4 x 10-8) per meiosis (Table 3.1). This is equivalent to 81 – 112 nucleotide mutations 
in the canine genome (2.4 gigabases in size). The average Ti:Tv rate was estimated to 
be 2.3 (95% confidence interval 1.3 – 3.3). The trio that included USCF1119 as the child 
was excluded from Ti:Tv analyses as no transversions were identified.  
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Table 3.1. Per base mutation, transition and transversion rate estimates for the 
domestic dog in five unique parent-offspring trios.  
The trio including the offspring USCF1119 was not included in the average transition 
and transversion rate as no transversions were detected. 
Offspring 
identifier in 
Trio 
observed 
Per base 
mutation rate 
estimate per 
generation 
Ti  Tv Ti:Tv 
USCF134 4.3 x 10-8 12 8 1.5 
USCF136 3.9 x 10-8 6 4 1.5 
USCF1014 3.4 x 10-8 22 7 3.1 
USCF1119 4.7 x 10-8 3 0 NA 
USCF1294 3.5 x 10-8 26 9 2.9 
Average 3.9 x 10-8 14 6 2.3 
Minimum 3.4 x 10-8 3 0 1.5 
Maximum 4.7 x 10-8 26 9 3.1 
Standard 
Deviation 
4.9 x 10-9 8.9 3.3 0.75 
 
Of the 97 de novo mutations collectively observed in the five parent-offspring trios, 
71.1% were transition mutations (Figure 3.2). Transition mutations constitute mutations 
between either A and G nucleotides representing 33.0% of those observed in our data 
or mutations between C and T nucleotides that represented 38.1% of observed 
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occurrences of transitions in our data. The remaining 28.9% of all de novo mutation 
events comprised transversion mutations. Transversions include mutations between A 
and C nucleotides (9.3%), A and T (9.3%), C and G (1.0%) and G and T (9.3%) 
mutations.  
 
Figure 3.2. Percentage of transition and transversion mutations observed in four 
parent-offspring trios. 
 
3.4.3. Characteristics of observed de novo mutations 
Observed de novo and non-de novo mutation events were categorised as representing 
any of seven genomic features (see previous description) and the per-base de novo 
mutation rate was calculated for each genomic feature category (Table 3.2). Total 
number of event observations for each genomic feature can be obtained in Table S5.  
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Table 3.2. Per base mutation rate estimates (x 10-8) within coding, CpG islands, 
intergenic, intronic, conserved, 3’ UTR and 5’ UTR features in dogs using five 
unique parent-offspring samples. 
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USCF134 0 0 5.2 4.1 8.4 0 0 
USCF136 0 0 5.6 2.9 8.4 0 0 
USCF1014 1.3 9.1 3.2 3.2 2.3 0 0 
USCF1119 0 0 3.2 3.9 0 0 0 
USCF1294 1.1 0 4.4 2.2 2.0 0 4.4 
Average 4.8 1.8 4.3 3.3 4.2 0 8.7 
 
A paired, two tailed t-test was performed to determine if the per base mutation rate was 
significantly higher or lower between the seven genomic features observed. The total 
number of loci observed for each feature can be found in Table S5. The 3’ UTR feature 
had significantly less mutations per base than both intergenic and intronic features (P < 
0.05).  
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Table 3.3. P-values obtained from paired, two tailed t-tests performed between 
seven genomic features to determine if the per base mutation rate was 
significantly different between each feature in the dog. 
 
Coding CpG 
Island 
Intergenic Intronic Conserved 3’ UTR 5’ UTR 
Coding 
 
0.458 0.894 0.657 0.900 0.179 0.627 
CpG Island  
 
0.494 0.458 0.900 0.374 0.691 
Intergenic   
 
0.178 0.948 0.001 0.639 
Intronic    
 
0.608 0.001 0.575 
Conserved     
 
0.074 0.657 
3’ UTR      
 
0.374 
 
3.5. Discussion 
The result of this study was a per-base, per-generation germline mutation rate in dogs 
of 3.9 x 10-8 (95% confidence interval 3.5 – 4.4 x 10-8), which is slightly higher than rates 
estimated for other vertebrates including humans, chimpanzees, laboratory mice and 
birds (Table 3.4) (Campbell and Eichler 2013; Venn et al. 2014; Uchimura et al. 2015; 
Smeds et al. 2016; Narasimhan et al. 2017). The practical consequence is an 
expectation of approximately 81 – 112 de novo nucleotide changes (also called “private 
mutations”) in each individual genome. The number of transitions outnumber the 
number of transversions (Ti:Tv) by 2.3 fold, (95% confidence interval 1.3 – 3.3). This 
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figure is similar to estimated Ti:Tv rates of other vertebrate species (Table 3.4) 
(Campbell and Eichler 2013; Venn et al. 2014; Uchimura et al. 2015; Smeds et al. 2016; 
Narasimhan et al. 2017).  
Table 3.4. Relative predicted de novo mutation rate estimates for dogs, humans, 
mice, chimpanzees and birds. 
Human, mice, chimpanzee and bird figures were obtained from several recent studies 
(Campbell and Eichler 2013; Venn et al. 2014; Uchimura et al. 2015; Smeds et al. 2016; 
Narasimhan et al. 2017). 
 Dogs Humans Mice Chimpanzees Birds 
Per base per 
generation 
mutation rate 
3.93 x 10-8 1 – 3 x 10-8 5.4 x 10-9 1.2 x 10-8 4.6 x 10-9 
Ti: Tv 2.3 2.2 2.1 2.2 2.7 
 
It is plausible that elevated mutation rate in the dog in addition to relatively large litter 
sizes (mean litter size is 5.4 for purebred dogs) (Sverdrup Borge et al. 2011) and 
shorter generation times in comparison to other studied species and domesticated 
animals may have facilitated more rapid phenotypic diversification of the dog. We 
observed a common de novo mutation at chromosome 18, position 28,418,247 
(CanFam 3.1) in both siblings (USCF134, USCF136) within a nuclear family (Table S1). 
This could demonstrate that de novo mutation events that occur in early stages of 
spermatogenesis or oogenesis in the parents can propagate to more offspring at a time, 
resulting in more rapid dissemination of new genetic variation.  
Studies in de novo mutation rates in humans and chimpanzees have suggested that de 
novo mutations occur more frequently in the offspring as the age at conception of the 
parents increases, especially of the father (Kong et al. 2012; Venn et al. 2014). Sperm 
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are created through multiple rounds of spermatogenesis throughout a mature male’s 
life, unlike in females where oogenesis begins during foetal development. The process 
of DNA replication in aging individuals is thought to foster more DNA replication 
mistakes, and hence result in more observable de novo mutations in the offspring. Age 
of conception information was unavailable for the current study. Trios including a wide 
range of ages of parents at the time their offspring was conceived should be included in 
future studies to determine parent of origin effects on the mutation rate as a function of 
age. Additionally, as different breeds of dog are known to have different average 
lifespans, future studies should be repeated on a per breed bases, and subsequently, 
an assessment of variance of the mutation rate across breeds can be determined. This 
may suggest how much the mutation rate could influence the rate of evolution in some 
breeds compared to others. 
Differences in the average mutation rate that may be observed across species is likely 
to be influenced by technical nuances. This includes sequencing technologies and 
bioinformatics pipelines employed to process the raw sequencing data. The studies 
discussed here applied a whole genome approach using Illumina sequencing 
technologies (Venn et al. 2014; Uchimura et al. 2015; Smeds et al. 2016; Narasimhan et 
al. 2017). However, the sequencing depth varied from approximately 10 to 40X 
coverage. A coverage of at least 10X is deemed to be sufficient for providing accurate 
variant calling, however slight improvements are still evident with increasing coverage 
(Cheng et al. 2014). Variant calling accuracy is also variable across variant calling 
algorithms and quality filtering parameters enforced (for performance metrics see 
Cheng et al. 2014). In order to minimize the effects technical biases when assessing 
mutation rate differences between species, future studies should ensure that 
sequencing technologies and bioinformatics pipelines used are consistent for all 
samples of all species studied. Future studies should also consider a de novo assembly 
rather than a reference genome mapping approach to mitigate potential biases from 
differences in the quality of reference genomes across species. Reference genomes 
that are more complete and representative of a population enable improved mappability 
of raw sequencing reads as mapping is dependent on sequence similarity (Degner et al. 
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2009; Brandt et al. 2015). This would therefore affect all downstream processing, 
including variant calling and de novo mutation calling accuracy. 
Improved estimates of average mutation rates per species can benefit several practical 
applications that ultize per base mutation rates. For instance, the timing of species 
divergence is calculated by using the mutation rate as a molecular clock in the study of 
ancestral DNA sequences. We provide an alternative means for scientists to estimate 
dog divergence from the grey wolf and this might inform debate on dog domestication. 
Better estimates of de novo mutation rate and transition to transversion ratios are 
expected to improve future de novo detection studies via the more accurate application 
of priors in computational prediction algorithms (Ramu et al. 2013; Francioli et al. 2017).  
De novo mutations are never in LD with genetic markers and are notoriously difficult to 
map through GWAS.  Hence, accurate identification and calling of de novo mutations is 
essential for clinical diagnosis for patients with spontaneously occurring genetic 
diseases. 
To better understand the potential effects on phenotype and evolution arising from the 
of de novo mutations that we identified, we categorised the observed variants into any 
of seven genomic features: protein-coding, CpG island, intergenic, intronic, conserved, 
3’ UTR and the 5’ UTR. We did not detect any significant difference in the mutation rate 
between each feature, other than mutations in 3’ UTR regions are significantly less 
common compared with those occurring in intergenic and intronic features (PT-TEST < 
0.05, Table 3.3). We observed no difference in the per-base mutation rate in CpG 
dinucleotide islands compared with other genomic features. This is an unexpected 
finding as methylated CpG islands have previously reported to be more mutagenic 
(Cooper and Youssoufian 1988). In humans, the per-base mutation rate has been 
observed to be 10 – 18 times higher in CpG dinucleotides compared with non-CpG 
dinucleotides (Kondrashov 2002; Lynch 2010; Kong et al. 2012; Narasimhan et al. 
2017). Higher mutation rates in CpG islands have also been observed in other animals 
including apes (30 times higher), mammals (15 times higher) and birds (10 times 
higher) (Keightley et al. 2011; Hodgkinson and Eyre-Walker 2011; Smeds et al. 2016). 
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The disparity in relative CpG island mutation rates in dogs compared to other mammals 
are most likely caused by technical limitations of this study. Next generation sequencers 
such as Illumina platforms rely on PCR amplification techniques that require specific 
optimisation in order to successfully sequence GC rich DNA (Reuter et al. 2015). The 
sequencing difficulty was evident in this study, with only ~5.5 million high-quality 
observed nucleotides occurring in CpG islands considered compared with 37,355,082 
that exists in the canine reference genome (Table S5). The rate of C to G transversion 
(1.0% of all mutations) is also likely to have been affected by this sequencing bias 
(Figure 3.2). To better characterise relative occurrences of de novo mutations across a 
variety of genomic features, future studies would benefit from the inclusion of parent-
offspring trios sequenced at higher coverage. The reliable identification of de novo 
mutations across the whole genome requires a high level of variant calling and 
genotyping accuracy. Such accuracy and coverage can be achieved through via higher 
levels of sequencing depth (>30X) (Francioli et al. 2017). However, the relatively high 
costs of sequencing currently impede on the opportunities to perform de novo mutation 
characterisations in non-model species. 
To the author’s knowledge, we are first to describe and directly observe de novo 
mutation rates in the domestic dog using a genome-wide strategy.  The estimated rates 
reveal an elevated de novo mutation rate for canines in comparison to other studied 
species to date, indicating a possible mechanism for the rapid generation of phenotypic 
diversity in the evolution of the domestic dog from the grey wolf. We have provided 
metrics in relation to de novo mutation rates in the dog that might be used as a 
molecular clock. This will enable scientists to better elucidate the timing of dog 
domestication. Metrics that we have provided can also be used as better priors for use 
in variant calling algorithms for more accurate genotyping of de novo mutations.  
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Chapter 4. The Genetics of Progressive Retinal Atrophy in 
the Hungarian Puli 
4.1. Synopsis - Exclusion of known progressive retinal atrophy genes for 
blindness in the Hungarian Puli  
In this chapter, we begin to explore the contribution of de novo mutations in canine 
disease and demonstrate how next generation sequencing data can be used to study 
low frequency variants that are associated with disease. Low frequency variants, such 
as de novo mutations that are involved in rare disease, are difficult to detect with 
traditional genome wide association analyses. In addition, studies on rare diseases are 
challenged with having a limited number of case samples. The research in chapter 4 is 
focussed on progressive retinal atrophy in the Hungarian Puli. In section 4.1, we present 
published research which reports that this form of disease is potentially novel, by 
performing comprehensive testing of reported canine progressive retinal atrophy genes.  
The supplementary materials associated with the original publication have been 
included in section 4.1.1 to provide the reader with greater context for this chapter.   

CanineHD BeadChip (Illumina) (genotyping array data of
all 14 individuals used in this study have been deposited in
NCBI’s Gene Expression Omnibus under the accession num
ber GSE87642). Coding exons and untranslated regions of
genes that co located with loci conforming to an autosomal
recessive inheritance pattern (Table S2) were then Sanger
sequenced for the two affected dogs. A full description of
materials and methods can be found in Appendix S1.
Conclusions: Exhaustive screening of 53 candidate loci in a
Hungarian Puli family segregating blindness identified no
coding variants for the phenotype of interest. Two candi
date genes in loci concordant with recessive inheritance
were identified (RLBP1 position chr3:52 260 877
52 278 803 and NR2E3 chr30:35 378 421 35 381 822,
CanFam 3.1; Fig. 1). Sanger sequencing of exons and
untranslated regions revealed no variation to the reference
genome. An additional eight recessively inherited SNPs in
other regions of the genome were found in PDE6A, RD3,
PRCD and MERTK using whole genome sequencing data;
however these were either intronic or non coding variants
and are not likely to cause disease (Table S3). This study
provides the basis for mapping and further screening of
potentially novel canine PRA genes followed by testing in
a wider sample cohort.
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4.1.1. Supplementary materials for section 4.1  
Materials and Methods 
Samples  
Two affected half sibling Hungarian Puli dogs (USCF516, USCF519) and 12 other 
individuals including their parents (USCF347, USCF524, USCF525) from the same 
kennel were used in this study (Figure S1). USCF516 and USCF519 were diagnosed 
with progressive retinal atrophy (PRA) by registered specialists in veterinary 
ophthalmology based on vascular attenuation in the eye, hyper-reflectivity and reduced 
myelination in the optic nerve head. The parents also underwent testing and were 
confirmed to be PRA clear. The remaining 9 dogs who were over 5 years of age had 
normal vision. Dogs with PRA reach complete blindness at 6 months – 4 years, hence 
we considered these 9 dogs to be PRA clear. EDTA-stabilized blood was collected from 
all 14 dogs and genomic DNA was extracted using the illustra Nucleon BACC2 kit (GE 
Healthcare). This study was carried out with the consent of the dog’s owners’ and with 
Animal Ethics approval granted by the Animal Ethics Committee at the University of 
Sydney (N00/9–2009/3/5109).  
Candidate gene selection  
A comprehensive list of 53 candidate genes was screened for PRA causative variants. 
Candidates were selected from a toolset that was developed to allow rapid screening of 
dog families with PRA (Winkler et al. 2016). Genes include PRA associated genes 
identified in multiple dog breeds and genes associated with analogous disease in 
humans. Additional genes were selected from another PRA-screening study involving 
multiple dog breeds and a review (Downs et al. 2014; Miyadera et al. 2012). Exhaustive 
screening for candidate mutations was performed with two methods – putative variant 
detection in in whole genome sequencing data and Sanger sequencing exons of genes 
that resided in loci concordant with autosomal recessive inheritance. The second 
method ensures that candidate genes within putative loci are completely and accurately 
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sequenced, especially where there is no – low coverage in whole genome sequencing 
data.  
Whole genome sequencing and putative mutation detection  
One father-mother-proband trio (USCF525, USCF347, USCF516) and the additional 
half sibling case (USCF519) were whole genome sequenced by the Ramaciotti Centre, 
University of New South Wales, Kensington. Library preparation was performed with the 
Illumina TruSeq DNA PCR-free kit. The four samples were barcoded and sequenced on 
two lanes as 101 base paired-end reads on the Illumina HiSeq 2000 (Illumina, San 
Diego, CA).  
For each sample, reads were aligned as pairs using the Burrows-Wheeler Alignment 
tool with default parameters (Li & Durbin 2009). Polymerase chain reaction (PCR) 
duplicates were marked using Picard (http://picard.sourceforge.net). Local realignment 
around insertion-deletions (INDELs) was performed using GATK (McKenna et al. 2010; 
DePristo et al. 2011). Raw SNP and INDEL variants were called in the 53 candidate 
genes (Table S1) using Unified Genotyper provided by GATK (McKenna et al. 2010). 
The VariantFiltration tool was used to filter for high quality variants using recommended 
hard filtering parameters for small datasets (Van der Auwera et al. 2013). SNPs were 
removed if Quality Depth < 2.0, Fisher Strand > 60.0, Mapping Quality < 40.0, 
HaplotypeScore > 13.0, MappingQualityRankSum < -12.5 and ReadPosRankSum < -
8.0. INDELs were removed if Quality Depth < 2.0, Fisher Strand > 200.00 and 
ReadPosRankSum < -20.0.  
High quality variants that conformed to an autosomal recessive inheritance pattern were 
retained. Concordant variants were annotated with Variant Effect Predictor (VEP) 
provided by Ensembl (McLaren et al. 2010). Known, common SNPs listed in dbSNP 
were removed and remaining functional coding variants were considered for testing in a 
wider study cohort.  
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Identification of regions concordant with recessive inheritance  
The two case (USCF516, USCF519) and 12 control dogs including the PRA clear 
parents (USCF347, USCF524, USCF525) were genotyped at 172,938 SNP markers 
using the CanineHD BeadChip array (Illumina, San Diego, CA) by GeneSeek (Lincoln, 
NE). Markers that were genotyped as homozygous for the minor allele for the cases 
only were regarded as target loci (concordant). Candidate genes and concordant loci 
were charted onto the concordance map (Figure 1).  
Sanger sequencing of candidate genes in associated loci  
USCF516 and USCF519 were screened for putative functional variants in coding exons 
of candidate genes that resided within concordant loci using PCR and Sanger 
sequencing. Primers were designed in Primer3 (Rozen & Skaletsky 2000) to amplify 
RLBP1 and NR2E3 exons (primer sequences, melting temperatures and product sizes 
can be found in Table S2). PCR was carried out using the AmpliTaq Gold 360 Master 
Mix (Applied Biosystems) in a 20 μL reaction volume. Thermocycling conditions were 
carried out as follows: denaturation at 95 oC for 15 min; 35 cycles of 95 oC for 30 sec, 
annealing at melting temperatures (Tm) according to Table S2 for 30 sec, 72 oC for 45 
sec; and lastly a final elongation step at 72 oC for 10 min. PCR products were purified 
by dispensing 7 μL of PCR product into 3 μL of a master mix containing 10x shrimp 
alkaline phosphatase (SAP) buffer, 1U SAP, 1U Exo I and water. The 10 μL reaction 
volume was placed into a thermocycler to allow enzymatic activity for 30 min at 37oC, 
followed by a deactivation period of 15 min at 80oC. Sanger sequencing of purified PCR 
products was carried out by the Australian Genome Research Facility at Westmead in 
accordance with the vendor’s instructions. Sequences were assessed for any variants 
alternative to the reference genome.  
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Figure S1. Pedigree of Hungarian Puli dogs segregating progressive retinal 
atrophy. Two dogs are affected with progressive retinal atrophy (USCF516, 
USCF519). Their parents (USCF347, USCF524, USCF525) and 9 dogs in the 
pedigree have normal vision. Dogs with individual identifiers were used in this study.  
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Table S1. A list of the 53 PRA candidate genes screened. Candidates include PRA 
genes causative or associated with PRA in other purebred dogs and genes that cause 
analogous autosomal recessive disease in humans. 
 
 Gene  CanFam3.1 Position  Reference  
CNGB1  chr2:58574552-58640412  (Winkler et al. 2016)  
DHDDS  chr2:73593302-73608757  (Winkler et al. 2016)  
RLBP1  chr3:52261271-52269489  (Winkler et al. 2016)  
PROM1  chr3:64260671-64360950  (Winkler et al. 2016)  
PDE6B  chr3:91746571-91775372  (Winkler et al. 2016; Downs et al. 2014)  
RGR  chr4:32492211-32495738  (Winkler et al. 2016)  
RBP3  chr4:34972797-34983018  (Winkler et al. 2016)  
PDE6A  chr4:59103965-59163857  (Winkler et al. 2016; Downs et al. 2014)  
AIPL1  chr5:30828619-30834894  (Winkler et al. 2016)  
GUCY2D  chr5:32844033-32859263  (Winkler et al. 2016)  
NPHP4  chr5:59819237-59935037  (Winkler et al. 2016; Downs et al. 2014)  
ABCA4  chr6:55058361-55253309  (Winkler et al. 2016)  
RPE65  chr6:76887399-76911133  (Winkler et al. 2016; Downs et al. 2014)  
CRB1  chr7:5277947-5419381  (Winkler et al. 2016)  
RD3  chr7:9874740-9887791  (Winkler et al. 2016)  
C1ORF36  chr7:9875590-9875862  (Winkler et al. 2016)  
PDC  chr7:19498785-19514226  (Downs et al. 2014)  
NRL  chr8:4086435-4091100  (Winkler et al. 2016)  
RDH12  chr8:41686714-41689770  (Winkler et al. 2016)  
SPATA7  chr8:59658291-59697320  (Winkler et al. 2016)  
TTC8  chr8:60077187-60108376  (Winkler et al. 2016; Downs et al. 2014)  
PDE6G  chr9:527987-528889  (Winkler et al. 2016)  
PRCD  chr9:4185466-4188777  (Winkler et al. 2016; Downs et al. 2014)  
FAM161A  chr10:61812850-61839706  (Winkler et al. 2016; Downs et al. 2014)  
TULP1  chr12:4633093-4639684  (Winkler et al. 2016)  
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EYS  chr12:28547134-28708579  (Winkler et al. 2016)  
C6ORF152  chr12:40445676-40489047  (Winkler et al. 2016)  
CNGA1  chr13:43831161-43864273  (Winkler et al. 2016)  
COL9A2  chr15:2647620-2661552  (Miyadera et al. 2012)  
RPGRIP1  chr15:18331912-18385143  (Winkler et al. 2016; Downs et al. 2014)  
CEP290  chr15:29194929-29281291  (Winkler et al. 2016)  
LRAT  chr15:52401373-52401765  (Winkler et al. 2016)  
SLC4A3  chr16:15117725-15126206  (Winkler et al. 2016; Downs et al. 2014)  
ADAM9  chr16:26413196-26551132  (Winkler et al. 2016; Downs et al. 2014)  
ZNF513  chr17:21332278-21335631  (Winkler et al. 2016)  
C2ORF71  chr17:22899286-22910537  (Winkler et al. 2016; Downs et al. 2014)  
MERTK  chr17:36336858-36445789  (Winkler et al. 2016)  
BEST1  chr18:54468844-54480311  (Vilboux et al. 2008)  
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Table S2. PCR primer sequences. 
CanFam3.1 
Position 
 Forward primer (5’-3’) Reverse Primer (5’-3’) Tm 
(oC) 
Product 
length (bp) 
chr3:52,260,877-
52,278,803 
 
1 TTGGTAGTAAAGCTGAGGTCATTG TGGCCCTATCTCTCCATTTG 60 373 
 2 GGATGGCCCCTAGAATAAGC TTCCCAAAGTGTAGCCCAAG 60 866 
 3 GGATGGCCCCTAGAATAAGC TTCCCAAAGTGTAGCCCAAG 60 866 
 4 CAATCCATGTTTCGGGTAGG GGAAGTGGAGGCTATTGTCG 60 645 
 5 GACCCACACCTCACTTCCAC TGCGTATCCTGCTCAGTCAC 60 460 
 6 AAGGTGTAGGCAGGTTCAAGTC TTTCACCAGTCCCTTATTGTTG 59 744 
 7 CCACACACAAGTCCTAAACCTC CTCCTAGTGGGCTATCCTTTG 58 758 
 8 CCACACACAAGTCCTAAACCTC CTCCTAGTGGGCTATCCTTTG 58 758 
chr30:35,378,421
-35,381,822 
1 CCCAGGCATCTAGGACCAG TAGATGCTGGATTCGTGCTG 60 829 
 2 CCCAGGCATCTAGGACCAG TAGATGCTGGATTCGTGCTG 60 829 
 3 CCCAGGCATCTAGGACCAG TAGATGCTGGATTCGTGCTG 60 829 
 4 CTCACCCACAAAAATCATGC TGGAACTGCTAGGTCACAGG 59 522 
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Table S3. Putative variants identified from screening 53 candidate genes in parent-proband and an affected half 
sibling case. 
Parent 
Genotype1 
Case 
Genotype1 
Gene Position2 Type Consequence3 
G A  G G PDE6A 4:59105480 Intronic Modifier  
G A A A PDE6A 4:59139522 Intronic Modifier  
C T T T RD3 7:9886063 Intronic,  
non-coding transcript 
Modifier  
C T T T PRCD 9:4187887 Intronic Modifier  
G C A A PRCD 9:4188050 Intronic Modifier  
A G G G MERTK 17:36360580 Intronic Modifier  
G A A A MERTK 17:36361700 Intronic Modifier  
C T T T MERTK 17:36371425 Intronic Modifier  
1High quality genotypes were called using Unified Genotyper provided by GATK and recommended hard filtering 
parameters (McKenna et al. 2010; Van der Auwera et al. 2013). 2CanFam 3.1 positions. 3Variant consequences on 
protein function or expression was predicted by Ensembl’s Variant Effect Predictor (McLaren et al. 2010). 
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4.2. Synopsis - A Coding Variant in the Gene Bardet-Biedl Syndrome 4 (BBS4) Is 
Associated with a Novel Form of Canine Progressive Retinal Atrophy  
With the indication that a potentially novel form of progressive retinal atrophy was 
affecting the case Hungarian Puli as identified in section 4.1, in section 4.2, we present 
a published original research article that describes our methods for identifying a putative 
variant for canine progressive retinal atrophy. This method involved genotyping array 
and whole genome sequencing of parent-offspring trio samples. We executed this 
method and identified a highly associated nonsense SNP in BBS4 (c.58.A > T, PCHISQ = 
3.43e14, n = 103). BBS4 is a novel canine progressive atrophy gene. In humans, this 
gene is involved with Bardet-Biedl Syndrome, a ciliopathy that can cause other disease 
phenotypes including obesity and infertility. In this paper, we also provide evidence that 
the identified mutation in canine BBS4 may cause syndromic disease as we observe 
similar phenotypes in the cases. BBS4 is the second Bardet-Biedl Syndrome gene that 
has been linked to canine progressive retinal atrophy.   
INVESTIGATION
A Coding Variant in the Gene Bardet-Biedl
Syndrome 4 (BBS4) Is Associated with a Novel Form
of Canine Progressive Retinal Atrophy
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ABSTRACT Progressive retinal atrophy is a common cause of blindness in the dog and affects .100
breeds. It is characterized by gradual vision loss that occurs due to the degeneration of photoreceptor
cells in the retina. Similar to the human counterpart retinitis pigmentosa, the canine disorder is clinically and
genetically heterogeneous and the underlying cause remains unknown for many cases. We use a positional
candidate gene approach to identify putative variants in the Hungarian Puli breed using genotyping data of
14 family based samples (CanineHD BeadChip array, Illumina) and whole genome sequencing data of two
proband and two parental samples (Illumina HiSeq 2000). A single nonsense SNP in exon 2 of BBS4
(c.58A. T, p.Lys20) was identiﬁed following ﬁltering of high quality variants. This allele is highly associated
(PCHISQ = 3.425e 14, n = 103) and segregates perfectly with progressive retinal atrophy in the Hungarian
Puli. In humans, BBS4 is known to cause Bardet Biedl syndrome which includes a retinitis pigmentosa
phenotype. From the observed coding change we expect that no functional BBS4 can be produced in
the affected dogs. We identiﬁed canine phenotypes comparable with Bbs4 null mice including obesity and
spermatozoa ﬂagella defects. Knockout mice fail to form spermatozoa ﬂagella. In the affected Hungarian
Puli spermatozoa ﬂagella are present, however a large proportion of sperm are morphologically abnormal
and ,5% are motile. This suggests that BBS4 contributes to ﬂagella motility but not formation in the dog.
Our results suggest a promising opportunity for studying Bardet Biedl syndrome in a large animal model.
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Progressive retinal atrophy (PRA) (OMIA #000830 9615) is the most
common cause of hereditary blindness in the domestic dog (Canis lupus
familiaris), affecting.100 pure breeds (Whitley et al. 1995). It is clin
ically and genetically heterogeneous and encompasses several forms of
disease which vary by etiology, rate of progression, and age of onset
(Downs et al. 2014a). The typical characteristics are gradual night,
followed by day vision loss due to the degeneration of rod and cone
photoreceptors, and this degeneration continues until the affected
animal is completely blind (Parry 1953). Ophthalmic features that
become apparent as the retina deteriorates include tapetal hyper
reﬂectivity, vascular attenuation, pigmentary changes, and atrophy
of the optic nerve head (Parry 1953; Clements et al. 1996; Petersen
Jones 1998).
PRAis recognizedas theveterinaryequivalentof retinitispigmentosa
(RP) in humans due to the clinical and genetic similarities between the
disorders (Petersen Jones 1998; Cideciyan et al. 2005; Zangerl et al.
2006; Downs et al. 2011). RP is a common cause of blindness in hu
mans and affects 1 in 4000 people (Hamel 2006). There are very
limited treatment options for both PRA and RP at present (Hamel
2006). For this reason, the dog has become a valuable large animal
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model for retinal degeneration, in particular, for testing the efﬁcacy of
novel therapeutics such as gene therapy (Pearce Kelling et al. 2001;
Acland et al. 2001; Narfström et al. 2003; Cideciyan et al. 2005;
Beltran et al. 2012; Pichard et al. 2016). As of 2016, 256 retinal dis
ease associated genes were identiﬁed for humans (https://sph.uth.edu/
retnet/). Some of these genes cause nonsyndromic RP, while others
contribute to syndromic disorders such as Bardet Biedl syndrome
(BBS) (Hamel 2006).
Currently, retinal dystrophies in 58 domestic dog breeds have been
linked toat least 25mutations in 19differentgenes (Miyadera et al.2012;
Downs et al. 2014b). Canine PRA is typically inherited in an autosomal
recessive pattern, although two forms that are X linked (Vilboux et al.
2008) and one that has dominant inheritance have been reported (Kijas
et al. 2002, 2003). Many of these discoveries in the canine were made
using candidate gene studies, linkage mapping and genome wide asso
ciation studies (GWAS) followed with ﬁne mapping (Acland et al.
1999; Goldstein et al. 2006; Kukekova et al. 2009; Downs et al.
2014b). This success has been facilitated by the unique breeding
structure of dogs. Intense artiﬁcial selection, genetic drift, and
strong founder effects have resulted in stretches of linkage disequi
librium (LD) that can persist for several Mb within breeds, but only
tens of kb across breeds (Lindblad Toh et al. 2005). This species
population structure has allowed for the successful mapping of
Mendelian traits with fewer markers and subjects compared to hu
man gene mapping studies: as few as 10 unrelated cases and 10 con
trols (Karlsson et al. 2007; Frischknecht et al. 2013; Jagannathan
et al. 2013; Willet et al. 2015; Gerber et al. 2015; Wolf et al. 2015).
Such methods are accepted to work extremely well for mapping
monogenic traits that segregate within a single breed.
Despite thisachievement, there are stillmany formsofPRAinseveral
breeds of dog that have yet to be genetically characterized. Traits with
underlyinggeneticheterogeneityanda lateonsetarenotoriouslydifﬁcult
to map using linkage or GWAS methods (Hirschhorn and Daly 2005;
Korte and Farlow 2013). Although PRA is collectively common, in
dividually, speciﬁc forms are relatively rare and it may take many
generations until an adequately sized cohort of unrelated case samples
are collected. The genetic heterogeneity of PRA can complicate the
results of linkage mapping and GWAS, as different causative variants
and genes can be responsible for an identical phenotype. In addition,
both linkage andGWAS rely onmarkers to be in LD and segregate with
the disease gene, making it difﬁcult to detect rare or de novo variants
(Hirschhorn and Daly 2005).
Since the advent of whole genome sequencing (WGS) and whole
exome sequencing technologies, the discovery of causal variants for rare
or genetically heterogeneous diseases has becomemore rapidwith fewer
case samples necessary for success. One study design of note that has
been used in human and more recently in canine studies is the
sequencing of parent proband trios (Zhu et al. 2015; Sayyab et al.
2016). As this method provides the chance for earlier diagnosis than
previously possible, this gives patients the opportunity to access more
personalized treatment options (Farwell et al. 2015; Zhu et al. 2015;
Sawyer et al. 2016).
In a preliminary study, extensive screening of 53 genes associated
with autosomal recessive PRA or RP revealed no putative variants that
could be associated with PRA in the Hungarian Puli breed (Chew et al.
2017). Here, we combine genotyping array data and WGS data of a
parent proband trio with an additional half sibling case to identify a
potentially novel canine PRA gene. We successfully identify a highly
associated mutation in exon 2 of BBS4 (c.58A. T, PCHISQ = 3.425e 14,
n = 103) that segregates perfectly with the disease phenotype. This
mutation encodes a premature stop codon which is expected to result
in complete loss of function of the BBS4 protein. The association of
BBS4 with canine PRA is a novel ﬁnding and presents the ﬁrst de
scription of an associated variant for PRA in the Hungarian Puli.
MATERIALS AND METHODS
Samples
This study involved 255 dogs (C. lupus familiaris) that comprised
103 Hungarian Puli and 152 Hungarian Pumi samples. This sample
cohort included 14 Hungarian Pulis segregating PRA in an autosomal
recessive pattern from a previous study (Chew et al. 2017). Three
affected Hungarian Pulis (USCF516, USCF519, and USCF1311) were
diagnosed with PRA at the age of 2 yr by registered specialists in veter
inary ophthalmology. Diagnosis was based on observed ophthalmologic
changes including vascular attenuation, hyper reﬂectivity, and reduced
myelination in the optic nerve head. The parents (USCF347, USCF524,
and USCF525) were similarly tested and conﬁrmed as PRA clear. The
remaining dogs were.3 yr of age and had normal vision as reported by
their owners or veterinarians. Hungarian Pumis are a very closely related
breed to the Hungarian Pulis and have been considered as a unique
breed only since the 1920s, so were considered as a compatible cohort
for this study.
Biological samples from the 255 dogswere collected either as EDTA
stabilized whole blood or buccal cells using noninvasive swabs (DNA
Genotek) or indicating Whatman FTA Cards (GE Healthcare). Geno
mic DNA was isolated from whole blood using the illustra Nucleon
BACC2 kit (GE Healthcare) or from buccal cells on swabs using the
PerformageneKit. For samples collected on an FTA card, DNAon discs
was puriﬁed according to the manufacturer’s guidelines.
We ensured that recommendations from theAustralianCode for the
Care and Use of Animals for Scientiﬁc Purposes were strictly followed
throughout the study. Animal ethics approval was granted to conduct
this research by the Animal Ethics Committee at the University of
Sydney (approval number N00/9 2009/3/5109, September 24, 2009)
and the State Provincial Ofﬁce of Southern Finland (ESAVI/6054/
04.10.03/2012).
Genotyping array data
Genotyping array data of 14Hungarian Puli andWGS data of a parent
proband trio and one additional half sibling case (USCF347, USCF516,
USCF519, and USCF525) were obtained from the preliminary study
(Chew et al. 2017). Genotyping was performed on the CanineHD
BeadChip array (Illumina, San Diego, CA) by GeneSeek (Lincoln,
NE). WGS was performed as 101 bp, paired end reads on the Illumina
HiSeq 2000 by the Ramaciotti Centre, University of New South Wales,
Kensington. The Illumina TruSeq DNA polymerase chain reaction
(PCR) free kit was used to prepare the libraries. The four samples were
barcoded and sequenced on two lanes of the sequencing machine. For
additional information on sample and data collection, refer to the
supplementary information in Chew et al. (2017). Sample information
for this study can be found in Supplemental Material, File S1.
Candidate gene selection
Comprehensive screening of 53 PRA loci in the Hungarian Puli family
revealed no obvious functional variants for the phenotype of interest
(Chew et al. 2017). To identify novel candidates, regions concordant
with a recessive inheritance pattern were identiﬁed using two case
(USCF516 and USCF519) and 12 control dogs that were genotyped at
172,938 SNPmarkers on the CanineHDarray. The control dogs included
three PRA clear parents (USCF347, USCF524, and USCF525). Only
markers that were genotyped as homozygous for theminor allele in cases,
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heterozygous in the parents, and heterozygous or homozygous for the
reference allele in the remaining nine control dogswere regarded as target
loci (Microsoft Excel 2010).
Candidate genes were selected from the region with the highest
frequency and density of concordant SNPs. LD in purebred dogs can
span several Mb long (Lindblad Toh et al. 2005), thus we considered
markers within 5 Mb to be in a single haplotype block. Using the
corresponding syntenic positional region in the mouse reference ge
nome (mouse genome assembly GRCm38, January 2012 build, the
Genome Reference Consortium), we restricted our analysis to genes
with a known phenotypic connection to vision using the Mouse Ge
nome Browser (http://jbrowse.informatics.jax.org/). Any genes within
the identiﬁed regions that were not already assessed in the preliminary
PRA gene screening study (Chew et al. 2017) were chosen as positional
candidate genes and considered for further analysis.
Whole-genome sequence processing and putative
mutation detection
Next generation sequencing data from two cases (USCF516 and
USCF519) and two parental controls (USCF347 and USCF525) were
aligned to CanFam 3.1 (Hoeppner et al. 2014). Reads were aligned as
pairs using the Burrows Wheeler Alignment tool with default param
eters (Li and Durbin 2009). PCR duplicates were marked using Picard
(http://broadinstitute.github.io/picard/). Local realignment around
insertion deletions (indels) was performed using the Genome Anal
ysis Tool Kit (GATK) (McKenna et al. 2010; DePristo et al. 2011).
Highqualityvariantswerecalled forall four individualssimultaneously
over 12 candidate genes that were selected from the locuswith the highest
density of SNPs concordant with autosomal recessive inheritance. Raw
variants were ﬁrst called using HaplotypeCaller provided by GATK
(Van der Auwera et al. 2013; McKenna et al. 2010). SNPs were then
removed if Quality Depth ,2.0, Fisher Strand .60.0, Mapping
Quality ,40.0, HaplotypeScore .13.0, MappingQualityRankSum
, 12.5, and ReadPosRankSum , 8.0. Indels were removed if
Quality Depth,2.0, Fisher Strand.200.00, and ReadPosRankSum
, 20.0.
The remaining high quality SNPs and indels were annotated using
Variant Effect Predictor provided by Ensembl (McLaren et al. 2010).
Known population variants obtained from publically available data were
not considered as candidates (Lindblad Toh et al. 2005; Vaysse et al. 2011;
Axelsson et al. 2013). Exonic variants were manually evaluated for geno
type quality and conformation to the expected inheritance pattern using
SAMtools tview (Li et al. 2009) and theUCSCGenome Browser. Remain
ing variants which were predicted by SIFT (Sim et al. 2012) to be delete
rious (,0.05) were then considered for genotype validation and
segregation analysis in the wider population by Sanger sequencing.
Variant validation and segregation analysis
The pedigree relationships among the 14 array genotyped individuals
forwhich registered (AustralianNationalKennelCouncil) pedigreedata
were available were tested through identity by descent proportions
calculated using PLINK (Purcell et al. 2007).
To conﬁrm that the identiﬁed mutation was not a sequencing error
and that the variant was concordant with the Mendelian expectation of
thedisorderphenotype,wegenotyped103HungarianPuliand152Hun
garian Pumi for the candidate causative mutation c 58A . T in BBS4
using PCR and Sanger sequencing.
Forward (59 GTTAGCAAGATACATGGTGTTGC 39) and re
verse (59 GACTATTACTGCTTTCCCCAAAA 39) primers were
designed with Primer3 (Rozen and Skaletsky 2000) to amplify a
225 bp product ﬂanking the candidate mutation. PCR was carried out
using the AmpliTaq Gold 360 Master Mix (Applied Biosystems) in a
20 ml reaction volume. Following denaturation at 95 for 15 min, sam
ples underwent ampliﬁcation for 35 cycles at 95 for 30 sec, 55 for
30 sec, 72 for 45 sec, followed by a ﬁnal elongation step at 72 for
10 min. For the puriﬁcation of each sample, 7 ml of PCR product was
dispensed into 3 ml of master mix containing 10· shrimp alkaline
phosphatase (SAP) buffer, 1 U SAP, 1 U Exo I, and water. Enzymatic
activity was enabled for 30 min at 37 and was then deactivated during
15 min at 80. Sanger sequencing of puriﬁed PCR products was carried
out by the Australian Genome Research Facility at Westmead in ac
cordance with the vendor’s instructions.
Figure 1 Positions of SNP array
markers that segregate with the
PRA phenotype and candidate
genes are identiﬁed. Concor
dant markers are indicated in
blue. Color opacity describes the
density of concordant markers
with darker hues corresponding
with higher concordant marker
density. Candidate genes are
depicted in red. The locus
with the highest frequency and
density of markers is chr30:
25,254,123 39,976,525, with
103 markers and 12 candidate
genes residing on the region.
Following this is chr4: 556,510
10,473,708 with 61 markers and
three candidate genes and chr20:
9,562,689 20,226,838 with
60 markers and three candi
date genes.
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with60 concordantmarkers.This is syntenic tomouse chr6, 100.0 110.0Mb.
The mouse phenome browser revealed three candidate genes on each
of the chr4 and chr20 regions. A total of 18 genes were selected as
positional candidates in the current study (Table S1).
WGS and variant detection
Sequencing on the Illumina HiSeq 2000 produced an average of
171 million raw reads per dog. Of these reads, 99.3% were successfully
mapped to the CanFam 3.1 reference genome, resulting in an average
mapped coverage of 6.9· per individual.
In the18selectedcandidategenes,2726highqualitySNPsweredetected,
1918 of which are not currently known population variants (Table 1;
Lindblad Toh et al. 2005; Vaysse et al. 2011; Axelsson et al. 2013). Of
the 44 exonic SNPs, there were 27 synonymous, 16 missense, and one
nonsense SNP. Two of the missense SNPs, one at MEGF11, chr30:
30,251,670 and the other at STRA6, chr30: 37,344,538, followed the
expected inheritance pattern. Both were predicted by SIFT to be tolerated
(P = 1) and therefore were not considered for further analysis. The single
nonsense SNP detected occurred at BBS4, chr30: 36,063,748 and followed
the expected inheritance pattern. This was predicted to be a deleterious
mutation and was considered for validation and segregation analysis.
A total of 912 indels were detected, 900 of which are not currently
known population variants (Table 1). Four of these were exonic, and by
manual inspection none of these followed the expected inheritance
pattern and so were not considered for further analysis.
Validation and segregation of putative nonsense variant
in BBS4
A single, putative functional coding variant that passed all hard ﬁltering
criteria was identiﬁed. The variant results in a stop gained mutation in
BBS4 and is predicted to be deleterious. We manually completed the
annotation of BBS4 in the CanFam 3.1 reference genome as exon 1 was
evidently missing (refer to File S2 for a full description of the methods
used). The complete canine BBS4 protein can be accessed through
Genbank (accession KX290494). In the complete BBS4 gene, the puta
tivemutation results in a premature stop codon (p Lys20) as a result of
a c.58A . T SNP in exon 2 (Figure 2).
The 103 Hungarian Puli included the three affected animals and
14 others with normal vision from the same kennel (Figure 3). Pedigree
relationships for the 14 individuals for which genotyping array data
were available were conﬁrmed through identity by descent estimations
(Table S2). Through Sanger sequencing, we observed that all three
affected dogs (USCF516, USCF519, and USCF1311) were homozygous
for the variant allele (T/T), all three obligate carrier parents were het
erozygous (A/T), and the remaining unaffected Hungarian Puli were
either heterozygous or homozygous for the wild type allele (A/A, Figure
4). All Hungarian Pumi were homozygous for the wild type allele.
Genotypes for each individual in the study can be found in File S1.
An association of PCHISQ= 3.425e 14 between the c.58A.T SNP in
BBS4 to the disease phenotype was found for all validated Hungarian
Puli genotypes (n = 103). When including validated Hungarian Pumi
genotypes, the association is PCHISQ = 3.252e 34 (n = 255). The geno
types are perfectly consistent with an autosomal recessive pattern of
inheritance for the 17 Hungarian Puli individuals with pedigree infor
mation, which supports the expected segregation pattern for PRA in
this breed (Figure 3).
Assessment of Bbs4 / mouse phenotypes in the dog
The intact affected male Hungarian Puli (n = 1) was found to be
subfertile. Semen analysis indicated normal sperm concentration but
Figure 3 Segregation of the BBS4 SNP (c.58A . T, p.Lys20) in the Hungarian Puli family. DNA samples were available for all individuals with an
identiﬁer (n 17). PRA is consistent with an autosomal recessive form in this family. Genotypes conﬁrmed through Sanger sequencing repre
sented by unﬁlled (homozygous wild type A/A), ﬁlled (homozygous mutant T/T), or half ﬁlled (heterozygous A/T) circles (females) or squares
(males) support this mode of inheritance.
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BBS is recognized as a syndromic disease, however in the dog, the
disease may appear as nonsyndromic PRA. Like canine PRA, BBS is
typically inherited in an autosomal recessive manner, except for one
report of triallelic inheritance (Katsanis et al. 2001; Forsythe and Beales
2013). In human BBS type 4, symptoms that are observed in addition to
RP include obesity, hypogenitalism, polydactyly, mental retardation,
renal anomalies, and decreased olfaction (Iannaccone et al. 1999,
2005; Riise et al. 2002; Li et al. 2014; Aksanov et al. 2014). The severity
and frequency of occurrence of each of these symptoms is variable like
for all types of BBS, and clinical diagnosis is based on the presence of
three to four primary and two secondary symptoms (Forsythe and
Beales 2013). The difference in the underlying genetic mutation for
reports of BBS type 4 is likely to contribute to this heterogeneity.
The affected Hungarian Puli in this study were predicted to have no
functional BBS4, so we compared their phenotypes to those observed in
Bbs4 null mice. In these mice, obesity and a complete lack of sperma
tozoa ﬂagella were observed in addition to retinal degeneration
(Mykytyn et al. 2004). In the dog, we observed all of these phenotypes
but found that canine spermatozoa ﬂagella were not as severely affected
as those in the mouse. We observed 22% of sperm with normal mor
phology in the dog; however, a large proportion of abnormal sperm had
defective ﬂagella (74%) and a very small proportion were motile (,5%;
Table 2). This suggests that BBS4 is only of moderate importance to
ﬂagella formation but is necessary for providing motility in the dog.
More canine samples are required to conﬁrm this.
The difﬁculty with differentiating nonsyndromic and syndromic
disease in companion animals such as the dog is that many of the
concurrent symptoms may not be diagnosed or recognized. Obesity
is common with 26 43% of pure and mixed breed dogs classed as
overweight in an Australian survey (McGreevy et al. 2005). As it is
widely recognized as a nutritional disease, many people would un
derestimate the genetic component of this phenotype. Further, in
Australia many companion animals are desexed prior to maturity,
limiting the opportunity to recognize fertility deﬁcits. Other symp
toms such as learning or developmental delay and decreased olfac
tion may be difﬁcult to assess in animals. For these reasons, we
recommend that all human BBS genes might be considered as
potential candidate genes for cases of canine PRA with unknown
genetic causation. Further studies are required to conﬁrm that
BBS4 causes syndromic disease in the dog and this should be mon
itored as it may potentially be a useful large animal model for
human BBS.
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Chapter 5. The Genetics of Severe Haemophilia A in the 
Australian Kelpie 
5.1. Abstract 
Haemophilia A is a bleeding disorder caused by a reduced activity of factor VIII (FVIII) 
that is required in the coagulation cascade to create blood clots. Disease is associated 
with a wide range of mutation types in the FVIII gene that either have X-linked 
inheritance or have occurred sporadically. In this study, we report the occurrence of 
haemophilia A in two purebred Australian Kelpie pups. The affected dogs had a FVIII 
coagulation activity of <1.5 %, which is considered to be severe by the Animal Health 
Diagnostic Centre, Cornell University. To our knowledge, there was no family history of 
this disease in the affected kennel. Using genotyping array data from the CanineHD 
BeadChip array, we inferred haplotypes in the FVIII loci. The apparently healthy 
maternal grandsire contained the same apparent haplotypes as the affected dogs, 
suggesting a putative de novo mutation in the FVIII gene. Using 100 base pair, paired-
end Illumina sequencing reads from one affected and 11 unrelated control dogs, we 
called putative SNP, indel and structural variants in the FVIII gene and 13 other 
bleeding disorder loci using GATK’s haplotype caller, SVtyper and LUMPY.  A total 37 
intronic SNPs unique to the affected dog were identified, but without functional data, 
their effect could not be confirmed. Comprehensive screening of the FVIII gene in whole 
genome sequence data and through Sanger sequencing revealed no candidate exonic 
mutations. The affected dogs were also clear of a commonly reported inversion 
mutation affecting intron 22, which was tested by long range PCR. Low mutation 
detection success rates are common in rare disease research, and this emphasizes the 
need for the development of more statistically powerful and effective methodologies to 
provide sufferers with a rapid diagnosis.   
5.2. Introduction 
Haemophilia A is recognized as one of the most common and severe bleeding disorders 
affecting a range of animals including both dogs (Canis lupus familiaris) and people 
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(Brooks 1999; Graw et al. 2005). It has an X-linked recessive mode of inheritance and 
occurs in ~1 in 10,000 live male births worldwide. Disease occurs when damaging 
mutations in the FVIII gene cause coagulation factor VIII (FVIII) to be dysfunctional, 
limiting an individual’s ability to propagate the intrinsic coagulation pathway that is 
necessary to control bleeding (Tantawy 2010). In addition to excessive bleeding, clinical 
signs include increased risk of haematoma and spontaneous haemorrhaging in joints 
and muscles. The severity of disease may be classified as mild, moderate or severe 
depending on endogenous circulating FVIII levels (< 1%, 2-5% and 5-20% respectively) 
(Brooks 1999; Bolton-Maggs and Pasi 2003). Disease symptoms can be managed by 
the periodic transfusion of plasma-derived of recombinant FVIII and lifestyle changes to 
minimize the risk of bleeding. Due to the short half-lives of the proteins and the 
development of neutralizing antibodies in patients, treatment success is limited and the 
search for better treatment options is ongoing. Dogs with severe disease are often 
euthanized before reaching the age of one year due to recurrent and high risk of fatal 
haemorrhaging.  
The FVIII gene is a large and complex gene that includes 26 exons spanning over 186 
kilobases (kb) of DNA at the end of the long arm of the X chromosome in both humans 
and dogs. It coincides with a mutational hotspot and for 30% of human cases, 
spontaneous disease occurs in individuals with no prior family history of haemophilia A. 
In humans, over 2,015 distinct causative mutations have been identified and each is 
linked to a specific type of clinical severity (http://www.factorviii-db.org/) (Graw et al. 
2005; Repessé et al. 2007; Tantawy 2010). The most commonly occurring mutation 
(~45% of severe human cases) is an inversion causing a breakpoint at intron 22 within 
the FVIII gene. Intra-chromosomal recombination between a 9.5 kb region within intron 
22 (termed int22h1) and two highly homologous regions distal to the FVIII locus and 
towards the telomere on the X chromosome (int22h1 and int22h3) can cause this 
inversion event spontaneously. A wide range of other causal variant types including 
other inversions, insertions, deletions, nonsense and missense mutations have been 
reported.  
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Haemophilia A has been documented in several pure and mixed breed dogs (OMIA 
#000437-9615). There is a breed predisposition for the clinical severity of haemophilia A 
and for the tendency for disease to occur sporadically (Brooks 1999; Brooks et al. 2008; 
Dunning et al. 2009). Unlike human haemophilia A, the genetic characterisation of 
disease is lacking in the veterinary literature and so genetic testing for the detection of 
carrier individuals is not available in many breeds (Mischke et al. 2011). Amongst the 
cases that have been characterised, a mutation that resembles the intron 22 inversion 
in humans was evident in two separate dog colonies. The colony housed at Queen’s 
University established from affected Miniature Schnauzers and obligate carrier 
Schnauzer-Brittany Spaniel females were found with an abnormal FVIII transcript that 
contained a novel sequence element following exons 1-22 (Hough et al. 2002). 
Researchers similarly described an aberrant FVIII transcript in a colony of Irish Setters 
from the University of North Carolina in Chapel Hill (Lozier et al. 2002). Several other 
nonsense and missense mutations in breeds including German Shepherds, Boxers and 
an Old English Sheepdog have been found to associate with severe haemophilia A 
(Mischke et al. 2011; Christopherson et al. 2014; Lozier et al. 2016).  
Mice, pigs and dogs are popular animal models for testing novel therapies for 
haemophilia A (and B, caused by dysfunctional coagulation factor IX) (Yen et al. 2016). 
Besides their use in preclinical trials for FVIII infusion safety testing, dogs are popular 
models for a variety of gene therapy technologies to treat and ultimately cure 
haemophilia in humans because of the high homology of the FVIII gene and immune 
systems between the two species (Yen et al. 2016). In the last 20 years, researchers 
have used adeno-associated viral vectors and are challenged with achieving prolonged, 
high FVIII expression levels, whilst reducing vector toxicity and curbing patient response 
of inhibiting antibodies that block the function of infused FVIII (Ward and Walsh 2017). 
More recently, CRISPR-Cas9 mediated genome editing strategies have been used to 
achieve mutation correction without off target side effects in mice, showing the potential 
for pre-clinical testing in a larger model such as the dog (Ohmori et al. 2017). 
This study reports the first case of HA in the Australian Kelpie breed. Two male 
littermates were diagnosed with severe disease through FVIII coagulation assays 
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conducted by the Animal Health Diagnostic Centre, Cornell University. Here we explore 
the FVIII gene and genetic cause of disease in this family. We utilize CanineHD 
BeadChip genotyping array data from the two affected, male pups and 10 of their 
unaffected relatives to infer haplotypes at the FVIII loci. Whole genome sequencing 
(WGS) data from one affected and 11 unrelated Australian Kelpie dogs obtained from 
the Illumina HiSeq 2000 or 2500 were used to call variants in FVIII and 13 other 
bleeding candidate loci. We also used PCR and Sanger sequencing to confirm that the 
affected dogs were clear of obvious exonic mutations and the alleged intron 22 
inversion. We identified 37 putative intronic SNPs which should be further investigated 
for functional importance. 
5.3. Methods 
5.3.1. Animals 
Two male, Australian Kelpie littermates (USCF305 and USCF311) were brought to the 
University Veterinary Teaching Hospital at the University of Sydney. The pups were 
presenting with symptoms consistent with severe coagulopathy. One individual died and 
the second was subsequently euthanized.  The two affected and 21 control dogs of the 
same breed were selected for this study. The control cohort included 10 samples from 
the same extended pedigree as the affected individuals (refer to the section 5.4.1 for 
pedigree information). The diagnosis of haemophilia A in the affected dogs and nine of 
their unaffected relatives was confirmed by factor VIII and/or factor IX coagulation 
assays carried out by the Animal Health Diagnostic Centre, Cornell University. FIX tests 
are commonly performed with FVIII because reduced activity in this factor is commonly 
seen in haemophilia A patients and it is used to test the affection status of an even rarer 
bleeding disorder, haemophilia B. All other individuals exhibited no disease phenotypes 
or were unrelated, and so were assumed healthy. To the author’s knowledge, 
haemophilia A has not been diagnosed in this family prior. HA has an X-linked recessive 
inheritance pattern which supports the segregation of disease in this family.  
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Genomic DNA was extracted from EDTA stabilized whole blood samples from each 
individual using the illustra Nucleon BACC2 kit using the manufacturer’s recommended 
protocol (GE Healthcare). Recommendations from the Australian Code for the Care and 
Use of Animals for Scientific Purposes were strictly adhered to throughout this study.  
Research was conducted with animal ethics approval, granted by the Animal Ethics 
Committee at the University of Sydney (approval number N00/9–2009/3/5109, 
September 24, 2009).  
5.3.2. Genotyping array and whole genome sequencing data 
Genotyping array data for two affected and 10 unaffected relatives were obtained from 
the CanineHD BeadChip array at 173, 650 SNPs (Illumina, San Diego, CA) by Neogen 
(Lincoln). The unaffected dogs include the dam of the affected animals. The data was 
used to infer FVIII haplotypes by observing sample genotypes its residing region on 
chromosome X (122,897,137 – 123,043,373). Only markers with a minor allele 
frequency (MAF) > 0.1 were considered.  
Next generation sequencing data was performed for one affected Kelpie (USCF305) on 
the Illumina HiSeq 2000 as 100 base pair, paired end reads on a single lane of the 
sequencing platform at the Ramaciotti Centre (University of New South Wales, 
Kensington). The quality and quantity of DNA for the other affected male was 
insufficient for whole genome sequencing.  Whole genome sequencing data similarly 
sequenced on the Illumina HiSeq 2000 or 2500 for 11 Australian Working Kelpies were 
obtained from an unrelated study (Arnott et al. 2015; Pan et al. 2017).  
Raw reads were aligned as pairs to the CanFam 3.1 reference sequence using the 
Burrows-wheeler Alignment (BWA-MEM) tool (version 0.7.15) with default parameters 
(Li and Durbin 2009). PCR duplicates were marked with SAMBLASTER (version 0.1.22) 
(Faust and Hall 2014). Local realignment was performed around insertion-deletions with 
the Genome Analysis Tool Kit (GATK version 3.6.0) (McKenna et al. 2010; DePristo et 
al. 2011). Base quality scores were recalibrated with GATK using known variants that 
were downloaded from Ensembl’s dbSNP database.   
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5.3.3. Screening for putative variants in known bleeding disorder loci 
A reduction in coagulation FVIII can be influenced by proteins other than FVIII including 
FIX and von Willebrand factor. For this reason, we called SNP and small indel variants 
in WGS data in a total of 14 genes known to be associated with a bleeding tendency 
phenotype (Table S1).  GATK’s HaplotypeCaller was used to call these variants 
following best practice recommendations (Van der Auwera et al. 2013). Low quality 
SNPs defined by Quality Depth < 2.0, Fisher Strand > 60.0, Mapping Quality < 40.0, 
HaplotypeScore > 13.0, MappingQualityRankSum < -12.5 or ReadPosRankSum < -8.0 
were removed. Similarly, low quality indels defined by Quality Depth < 2.0, Fisher 
Strand > 200.0 and ReadPosRankSum < -20.0 were removed. We also called structural 
variants by using LUMPY (version 0.2.11) and genotyped these calls with SVtyper 
(version 0.0.2) with the default settings applied (Layer et al. 2014; Chiang et al. 2015). 
Common population variants were not considered as candidates (Lindblad-Toh et al. 
2005; Vaysse et al. 2011; Axelsson et al. 2013). The remaining variants were annotated 
with Ensembl’s Variant Effect Predictor (McLaren et al. 2010). Alleles which segregated 
in an autosomal or X-linked recessive manner, or which were predicted to have a high 
impact by VEP were considered for further validation. 
5.3.4. Screening the FVIII gene 
To ensure that no variants were missed, we manually screened for variants in the 26 
exons of the FVII gene using WGS data of affected individual USCF305 using SAMtools 
tview. For exons with low to no coverage, we performed polymerase chain reaction 
(PCR) and Sanger sequencing for two affected (USCF305 and USCF311) and two 
control dogs (USCF316, USCF1290). Primer 3 (Rozen and Skaletsky 2000) was used 
to design forward and reverse primers that captured both exons 23 and 24 in a 896 bp 
product (5’-ATGTCTGTGCGGATTCTTCC -3’ and 5’-TTGTACCCTGTCTGCACCTG-3’ 
respectively) and  exon 26 in a 844 bp product (5’-GTCACTGCACAGAGGACGTG-3’ 
and 5’-TGGGTTCGACGTGATGAAG-3’, respectively).  
  
126 
PCR was performed using the AmpliTaq Gold 360 Master Mix (Applied Biosystems) in a 
10 µL reaction volume. Solutions underwent PCR cycling conditions using the Veriti 96 
Fast Thermal Cycler (Applied Biosystems) as follows: denaturation at 95oC for 15 min; 
amplification for 35 cycles at 95 oC for 30 sec, 55 oC for 30 sec, 72 oC for 45 secs; a final 
elongation step at 72 oC for 10 min. PCR products were purified in a 10 µL reaction 
volume. This contained 7 µL of PCR product and a 3 µL master mix containing 1 U Exo 
I, 1 U shrimp alkaline phosphatase (SAP) and 10x SAP buffer.  Sanger sequencing was 
performed at the Australian Genome Research Facility (Westmead) according to the 
vendor’s instructions.  
5.3.5. Analysis of a putative inversion mutation at intron 22 of FVIII 
In humans, the most prevalent causative mutation of severe HA is an inversion causing 
a break of the FVIII gene within intron 22, occurring in ~45% of cases. Two independent 
canine studies have alluded to a similar mutational event causing severe HA in their dog 
colonies. We used LUMPY to call structural variants in WGS Kelpies. We also extracted 
improperly paired reads using SAMtools from intron 22 of FVIII.  
To test for a putative inversion with a breakpoint at this location, we designed a long-
range PCR test using Primer 3 to design primers to capture intron 22. We decided to 
capture the entire intron 22 which spans 16,081 bp as the exact location of the putative 
breakpoint is unknown. We designed two separate PCR tests with overlapping 
fragments as we were unable to amply the 16 kb fragment in a single PCR. The test 
was performed for the two cases (USCF305, USCF311) with the SequalPrep Long PCR 
kit with dNTPs (Thermo Fisher Scientific). The first PCR contained forward (5’- 
GTAATGGGTTGGGTGCAAAC-3’) and reverse (5’- AAGGAGCCAATGACAAATGG-3’) 
primers that captured an 11,031 bp fragment. The subsequent PCR contained forward 
(5- TGTCATTGGCTCCTTTATAGCTC-3) and reverse (5’- TCTCCAGCCTCTACGTGTC 
TC-3’) primers that captured a 5,256 bp fragment. Each PCR was performed in a 10 µL 
reaction volume. Solutions underwent PCR cycling conditions using the Veriti 96 Fast 
Thermal Cycler (Applied Biosystems) using the recommended cycling conditions 
provided by the SequalPrep Long PCR kit.  
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5.4. Results 
5.4.1. FVIII assessment in the affected family 
Coagulation activity assays for FVIII and FIX for the samples obtained from the affected 
pedigree are shown in Figure 5.1. Affected individual USCF305 and USCF311 have a 
coagulation FVIII activity of <1.5 % and 1.5% respectively. A FVIII activity of <2% is 
defined by the Animal Health Diagnostic Centre, Cornell University as an individual with 
severe HA. FIX coagulation could not be obtained for USCF311 and four other relatives 
due to poor sample quality. USCF305 had the lowest FIX activity in the family (29%). 
Regional haplotypes at FVIII on chromosome X indicate that the unaffected grandparent 
contains the same haplotype as the affected littermates (Figure 5.1).  
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Figure 5.1 Pedigree of the Australian Kelpie family segregating haemophilia A. 
Individual identifiers are displayed under the individuals that were included in this 
study. Severe disease was diagnosed in USCF305 and USCF311 based on the level 
of coagulation FVIII and FIX activity that were measured by the Animal Health 
Diagnostic Centre, Cornell University. Reference levels for FVIII and FIX coagulation 
are 50 – 200% and 50 – 150% respectively. Haplotypes represented by genotyping 
data obtained from the Canine HD BeadChip array are depicted by the colour of the X 
under each individual.  
5.4.2. Detection of variants in bleeding disorder loci 
Variants were called and annotated in 14 clotting factor loci for the single case 
(USCF305) and 11 unrelated control Australian Kelpie dogs.  Using GATK’s 
HaplotypeCaller, 2,282 and 668 raw SNPs and indels were called respectively. There 
were no structural variants called by LUMPY in any of the candidate genes. After 
filtering for quality and for variants which are not known to be common in the population, 
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1,580 SNPs and 646 indels remained. None of the indels conformed to the expected 
mode of inheritance with at least one control animal containing an identical genotype as 
the case animal at the putative loci. There were 37 SNPs which followed the expected 
inheritance pattern. All SNPs were intronic (Table 5.1).  
Table 5.1. Variants detected in 14 bleeding tendency candidate genes using whole 
genome sequencing data of one case and 11 control Australian Kelpies.  
Each locus was genotyped for each of the 12 animals. Alternative alleles detected were 
only present in affected dog USCF305 and were not found in the control dogs. Positions 
and reference alleles are relative to the CanFam 3.1 reference genome.  
Chromosome Position Gene Intron 
Reference 
Allele 
Alternative 
Allele 
9 9,212,395 GPIIIa 2 C T 
9 9,213,121 GPIIIa 2 A G 
9 9,214,462 GPIIIa 2 C G 
9 9,214,942 GPIIIa 2 G A 
9 9,215,281 GPIIIa 1 C A 
9 9,216,703 GPIIIa 1 G A 
9 9,216,981 GPIIIa 1 C A 
9 9,217,017 GPIIIa 1 G A 
9 9,217,129 GPIIIa 1 C T 
9 9,224,785 GPIIIa 1 A T 
9 9,226,881 GPIIIa 1 G A 
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9 19,053,999 ITGA2B 10 A G 
9 19,054,961 ITGA2B 12 G T 
9 19,058,091 ITGA2B 16 T C 
18 42,783,087 F2 13 G A 
18 42,783,320 F2 12 T C 
18 42,783,362 F2 12 G A 
18 42,783,978 F2 12 A T 
18 42,784,501 F2 12 T C 
18 42,784,518 F2 12 A G 
18 42,785,453 F2 12 T C 
18 42,785,747 F2 12 T C 
18 42,785,748 F2 12 G A 
18 42,785,756 F2 12 G A 
18 42,786,022 F2 12 T A 
18 42,786,584 F2 12 A G 
18 42,788,637 F2 12 A G 
18 42,788,747 F2 12 C A 
18 42,788,894 F2 12 T C 
18 42,791,141 F2 12 C T 
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18 42,791,283 F2 12 A G 
22 60,576,451 F7 2 C T 
22 60,591,358 F10 4 C G 
22 60,591,363 F10 4 G A 
22 60,594,634 F10 6 C A 
X 109,526,498 F9 6 A T 
X 122,916,938 F8 22 G T 
 
5.4.3. Screening the FVIII gene for novel and known mutations 
We performed SNP, indel and structural variant calling in WGS data and Sanger 
sequencing of exons which were not sufficiently covered (exons 23, 24 and 26). In 
addition to the intron variant detected previously (Table 5.1), we found four exonic SNP 
variants in USCF305. This included one missense mutation in exon 14 and three 
synonymous SNPs in exons 1 and 15 (Table S2). These alleles were genotyped as 
homozygous alternative in USCF305 and one or more of the control dogs and so are 
not likely to be causative for haemophilia A. An additional missense SNP (G > T) was 
detected in the WGS of the affected dog in exon 23 (chrX: 122,907,870) but confirmed 
to be homozygous for the reference allele through Sanger sequencing. No structural 
variants were detected in any of the candidate gene loci.  
We manually detected seven improperly paired reads in intron 22 using SAMtools tview 
(Table S3). All reads in intron 22 were in the forward orientation. Five of the reverse 
read mates mapped to a location distal to the FVIII gene, suggesting a possible 
inversion event similar to the prevalent intron 22 inversion seen in humans. Two 
separate, long range PCR tests that were designed to overlapping fragments that 
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together span the entire intron 22 were performed. The expected fragment sizes (~11kb 
and 5kb) were observed for both affected and unaffected Australian Kelpies, confirming 
that the improperly paired reads were caused by an alignment artefact and are not of a 
biological cause. 
5.5. Discussion 
Haemophilia A is considered the most common bleeding disorder loci in both humans 
and dogs.  Although it affects a variety of pure and mixed breeds, the underlying genetic 
cause of disease is unknown for many cases and thus genetic testing is unavailable for 
many breeds. Of the genetic mutations that are known, similarities to the human 
disorder are apparent. In both species, a variety of inherited and spontaneously 
occurring mutations in the FVIII gene can either be associated with mild, moderate or 
severe disease. The most commonly reported mutation in humans involves a large 
fragment of chromosome X at the telomere, which is inverted causing disruption in the 
FVIII gene with a breakpoint occurring in intron 22. A similar event has also been 
observed in dogs with severe haemophilia A. 
Here we report occurrence of severe haemophilia A in purebred Australian Kelpies. The 
two affected dogs (USCF305, USCF311) presented with classic clinical signs of 
haemophilia A, including low FVIII activity (<1.5%) in addition to reduced FIX activity in 
USCF305. Only males were affected in the litter, which conforms to the X-linked 
recessive mode of inheritance of haemophilia A. We screened for mutations in the FVIII 
gene. To ensure that we tested for a comprehensive list of putative loci, 13 other genes 
that have a known association with a bleeding tendency phenotype in humans were 
included in the analysis and hence we also considered the possibility of autosomal 
recessive inheritance. 
Using WGS data of affected Kelpie USCF305 and 11 unrelated control dogs, we 
detected 37 intronic SNP variants in 7 of the selected candidate genes that fit the 
expected mode of inheritance. These were predicted to have a modifier (one with low 
impact in ITGA2B at CanFam 3.1 chr9: 19,058,091) effect on the corresponding 
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proteins and includes one intronic mutation in FVIII (CanFam 3.1, chrX: 122,916,938). 
Whilst intronic mutations have no obvious impact on protein function, several point 
mutations and a deletion in intron 22 have been associated with severe haemophilia A 
in people (http://www.factorviii-db.org/). As we had not collected transcriptome samples 
and the affected dogs were deceased, we were unable to confirm the effect of putative 
variants on protein function. No indel or structural variants that were concordant to the 
expected mode of inheritance were detected.  
As haemophilia A is known to be caused by defects in FVIII, we performed 
comprehensive screening at this locus. Using 173, 650 SNP genotyping array data 
obtained from the CanineHD BeadChip, we inferred FVIII haplotypes in two cases and 
in 10 apparently healthy relatives. This revealed that the maternal grandsire (USCF316) 
had the same apparent haplotype as the affected pups despite being healthy. If FVIII 
was the causal locus, this suggests that the mutation occurred sporadically, either in the 
grandsire’s sperm or mother’s oocyte (USCF1290). Presuming the latter situation, the 
mother would not appear to be a carrier in direct genetic testing and we took this into 
consideration throughout this study. 
The FVIII gene was manually screened at each of the 26 exons and Sanger sequencing 
was performed for exons that were insufficiently covered in WGS data to ensure that all 
coding sequence was assessed. Two non-synonymous SNPs were found in exons 14 
and 23, however were also present in other healthy WGS samples and did not conform 
to the expected mode of inheritance. We made the decision to test for a mutation similar 
to the most prevalent intron 22 inversion observed in humans, especially because a 
similar event in severely affected Miniature Schnauzers and Irish Setters was found 
(Hough et al. 2002; Lozier et al. 2002). Improperly paired reads in intron 22 of USCF305 
provided some evidence for this mutation. The mates of five of these forward reads that 
mapped to intron 22 mapped 387,826 - 387,858 bp telomeric to the FVIII gene (Table 
S3). Interestingly, there is also a SNP variant following the expected mode of 
inheritance in this intron (Table 5.1). Without transcript data, we used long range PCR 
to test for a putative breakpoint within intron 22, however found no evidence for an 
inversion event as fragments of the expected size were amplified in affected dogs. 
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The detection of rare variants that are causative of disease is extremely challenging and 
mutation detection studies are often underpowered due to low case numbers. With 
canine genomes, regions that are highly associated with disease can be identified with 
~10 case and ~10 control samples for simple Mendelian traits (Karlsson et al. 2007). 
Whilst this is easily achieved for common traits, it is often unachievable for rare traits 
without colony creation, a time consuming and expensive task with obvious animal 
welfare implications. The challenge in identifying candidate variants causative for 
diseases is exacerbated by several technical limitations associated with current 
sequencing technologies and resources available. Sequencing depth, raw read 
mappability to the reference genome and completeness of annotation vary across the 
genome (Sims et al. 2014). For example, GC-rich regions which are characteristic at 
transcription start sites of protein coding genes are prone to low sequencing depth and 
hence, are likely to be less represented than other genomic contexts by whole genome 
sequencing data. 
For human medicine, where rapid diagnosis and personalized treatment for people with 
rare diseases is more pertinent, researchers are using WGS and whole exome 
sequencing from parent-offspring trios as a powerful approach to map causative 
variants in these scenarios (Zhu et al. 2015). This approach has more recently been 
applied in two independent canine studies with success (Sayyab et al. 2016; Chew, 
Haase, Bathgate, et al. 2017) and should be considered in the experimental design of 
future rare disease mapping studies. The emergence and reducing costs of next 
generation sequencing technologies have enabled these successes, however, the 
overall the diagnostic rate for rare diseases still remains relatively low at 25 – 50% 
(Yang et al. 2014; Ankala et al. 2015; Taylor et al. 2015; Chong et al. 2015; Cummings 
et al. 2017). For rare diseases where mutations are sporadically occurring, the issue of 
achieving statistical power in mutation detection studies is exacerbated because the 
disease may not appear to have Mendelian inheritance.  
Although each rare disease affects a small percentage of individuals in a population, 
when all types of rare diseases are considered collectively, they are a common 
problem. The challenges presented in this study which are common in rare disease 
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research highlight the need for the development of mapping strategies and the careful 
consideration in the experimental design of future research in this field. 
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Chapter 6. General Discussion and Conclusions 
The accumulation of new spontaneously occurring variation in the genome is known to 
drive evolution and contribute to disease. In this thesis, we explored the role of de novo 
germline mutations in the evolution of and diseases occurring in the domestic dog 
(Canis lupus familiaris). We used next generation sequencing (NGS) technologies to 
interrogate the whole genomes of canine samples to: estimate the de novo mutation 
rate in dogs (chapter 3); identify a putative mutation in a potentially novel canine 
progressive retinal atrophy gene that is associated with blindness in the Hungarian Puli 
(chapter 4); and explore the genetics of spontaneously occurring severe haemophilia A 
in Australian Kelpies (chapter 5). Whilst NGS platforms are extremely powerful in their 
high throughput and in the abundance of data that they can generate, important 
biological gene variants can be missed due to technical limitations of the technology 
and bioinformatics methodology employed to the data. Because of this, we first carried 
out a performance comparison of single nucleotide variant (SNV) detection 
methodologies that was applied to our specific data type to ensure that we utilized 
optimal bioinformatics pipelines in the subsequent chapters (chapter 2). In this chapter, 
we discuss the outcomes and knowledge gained from each experimental chapter 
separately. 
6.1. Conclusions from chapter 2 
A preliminary study prompted us to initiate the study in chapter 2 where we compared 
the performance of 10 SNV calling pipelines using five popular variant callers on the 
data used in this thesis. In the preliminary study, we tested several pipelines to 
determine the optimal bioinformatics methodology that would allow us to achieve an 
accurate estimation of the de novo per base mutation rate in dogs. Achieving a high 
level of accuracy requires extremely high calling specificity so that true de novo 
mutation loci are detected without the inclusion of other variants, including population 
variation, sequencing errors and variants caused by other technical artefacts. Yet, 
increasing specificity is often at the cost of sensitivity, and without sufficient sensitivity, 
de novo variants may not be captured due to the rarity of new mutation events. To 
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obtain an adequate balance between sensitivity, specificity and accuracy, we 
systematically compared 10 SNV calling pipelines in chapter 2. The metrics provided 
can be used to formulate optimal variant calling pipelines tailored for all other types of 
studies that utilize similar datasets, specifically, studies with Illumina NGS sequencing 
data, relatively small sample sizes and average sample coverage (~10X).  
In chapter 2 we compared five popular SNV callers: FreeBayes (Garrison and Marth 
2012); the Genome Analysis Tool-kit’s Haplotype Caller (GATK HC) and Unified 
Genotyper (GATK UG) (McKenna et al. 2010); SAMtools (Li et al. 2009); and VarScan 
(Koboldt et al. 2013). We ran each variant caller without any additional quality filtering 
(raw pipeline), and then applied recommended hard filtering (filtered pipeline) where 
genotypes are considered as ‘not called’ if they do not meet certain quality metric 
criteria (Van der Auwera et al. 2013; Koboldt et al. 2013; Garrison 2015; Willet et al. 
2015). As many other studies have observed (Yu et al. 2013; Cheng et al. 2014; De 
Summa et al. 2015; Willet, Haase, et al. 2015a), we found that the level of minimum 
coverage requirement parameter had a major impact on genotyping accuracy rates, 
estimated sensitivity and estimated specificity of each variant caller. The differences in 
the measured metrics were greatest between the pipelines with no minimum coverage 
requirement. The raw VarScan pipeline outperformed the other nine pipelines at 
minimum coverage requirement levels less than 10X in this study. As the minimum 
coverage requirement increased, the pipelines performed more similarly in accuracy, 
sensitivity and specificity, except for two underperforming pipelines (FreeBayes and 
VarScan with filters applied). There was no clear overall outperforming pipeline at 
minimum coverage requirement levels of over 10X. There is a common agreement that 
genotypes can be called with a sufficient level of confidence at sites with at least 10X 
coverage (Koboldt et al. 2013). 
Applying hard filters that were recommended by other studies (Van der Auwera et al. 
2013; Koboldt et al. 2013; Garrison 2015; Willet et al. 2015) in variant calling pipelines 
generally did not improve genotyping accuracy for the dataset used in this study. The 
genotyping accuracy was greatly affected at loci that had low coverage. As the 
minimum coverage requirements of the algorithm were increased, hard filtering became 
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more effective and the differences between the accuracies of the raw and pipelines 
including hard filters became minimal. However, we observed only two variant callers 
(GATK HC and SAMtools) that had slightly improved genotyping accuracy at higher 
levels of minimum coverage requirement (over 14X).  
We found that achieving higher sensitivity always costs in calling specificity, and vice 
versa. An optimal variant calling pipeline should be unique to each specific project 
depending on the nature of the sample data and the project goals. For example, a 
project with the goals of identifying a causative genetic variant for a phenotype may 
prioritise sensitivity over specificity, within reason, where there is a feasible number of 
putative variants to further investigate. As previously described, we used the results of 
chapter 2 to obtain an optimal pipeline for estimating the canine per generation de novo 
mutation rate, a primary aim of the research conducted in chapter 3. 
The additional benefit of sequencing at higher depths of over 10X for accurate SNV 
calling drastically reduces with increasing depth of coverage. Realistically, achieving 
high levels of per sample coverage requires continued decline in sequencing costs. For 
the same cost, many researchers will still opt to sequence more samples at a reduced 
coverage, as opposed to fewer samples at higher coverage (Le and Durbin 2011; Sims 
et al. 2014; Gilly et al. 2017). The largest sequencing company, Illumina, achieved its 
promise to decrease the cost of sequencing a single human genome for ~$1,000 USD 
at 30X depth of coverage with the release of the HiSeq X Ten platform in 2014. Illumina 
has since promised to reduce this cost to just $100, however, Schwarze et al. has found 
little evidence for this cost reduction in whole exome and genome studies conducted 
from 2013 - 2017 (Schwarze et al. 2018). The deceleration of cost reduction may be an 
intended business choice rather than restriction by technical limitations, as Illumina 
already owns the largest market share in sequencing platforms.  
Despite the ever-increasing affordability of short read NGS, these technologies are still 
limited by their ability to resolve other types of variants accurately. For this reason, we 
were restricted to analysing SNVs in chapter 2 and 3 in this thesis. This limitation 
provides an opportunity for companies such as Pacific Biosciences and Oxford 
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Nanopore that produce longer read platforms to compete in the current market. 
Resolving GC-rich regions, repetitive, insertion-deletion (indel) and copy number 
variants (CNVs) greater than 500 bp are more successful with long read sequencing 
technologies (Chaisson et al. 2014; Reuter et al. 2015; Pollard et al. 2018). In addition, 
de novo assemblies with long reads provide more complete and accurate coverage of 
whole genomes than de novo assemblies using short reads (Pollard et al. 2018). De 
novo assembly methods organise reads without the need for a reference genome. 
Biases and restrictions associated with using a reference genome (see section 1.4.2) 
can thus be avoided. Omitting cost, the current high per base error rates of long read 
(11 – 38.2%) compared to short read (0.11 – 0.28%) sequencing limit the potential for 
long read platforms to completely replace short read platforms (Minoche et al. 2011; 
Pollard et al. 2018).     
In the foreseeable future, more complete interrogation of whole genomes by accurate 
identification of all variant types and sequence contexts will be possible by combining 
short and long read sequencing data. Efficiency needs to be improved for both 
technologies, especially long read sequencing, which is still unobtainable for many 
researchers. With access to both short and long read sequencing data and 
subsequently, more accurate genotyping of all variant types, applications and research 
questions that utilise sequencing technologies can be broadened.  
6.2. Conclusions from chapter 3 
New DNA mutations are the primary source of genetic diversity and enable evolution to 
occur. In only a few hundred years, hundreds of dog breeds that specialise in a variety 
of morphological, physiological and behavioural traits have been created. To improve 
our understanding of canine evolution, we characterised the germline de novo mutation 
rates and variant distributions throughout the canine genome in chapter 3. Through 
direct observation of de novo mutations by whole genome sequencing of parent-
offspring trios, we were able to estimate the per-base, per-generation mutation rate to 
be 3.9 x 10-8 (95% confidence interval 3.5 – 4.4 x 10-8). In the canine genome which is 
2.4 gigabases in size, this is equivalent to 81 – 112 de novo nucleotide changes in each 
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individual genome per meiosis. Transitions outnumber transversions by 2.3 (95% 
confidence interval 1.3 – 3.3), which is similar to the transition to transversion ratio in 
other mammals including humans (2.2), mice (2.1) and chimpanzees (2.2) (Campbell 
and Eichler 2013; Venn et al. 2014; Uchimura et al. 2015; Narasimhan et al. 2017). 
Our estimate of the per base mutation rate in dogs is slightly higher than the reported 
estimates for other species including humans, mice, chimpanzees and birds by 1 – 4 x 
10-9 nucleotide changes per generation (Campbell and Eichler 2013; Venn et al. 2014; 
Uchimura et al. 2015; Smeds et al. 2016; Narasimhan et al. 2017). This elevated rate 
coupled with relatively large litter sizes (5.4 puppies on average for purebred dogs) and 
shorter generation times in comparison to other studied species may have facilitated 
rapid phenotypic diversification of the dog.  
To understand the possible effects of de novo mutations on phenotype in the dog, we 
categorised observed mutations into seven genomic features based on their physical 
position in the annotated reference genome. The categories included protein-coding, 
CpG island, intergenic, intronic, conserved, 3’ untranslated region (UTR) and the 5’ 
UTR. We did not find any significant bias towards mutation in any particular feature, 
except that mutations are significantly less likely in the 3’ UTR compared to intronic and 
intergenic regions (PT-TEST < 0.05). This is unlike other species, who have found that 
CpG dinucleotides are highly hypermutable compared to other genomic contexts (10 – 
30 times, depending on the animal) (Kondrashov 2002; Lynch 2010; Keightley et al. 
2011; Hodgkinson and Eyre-Walker 2011; Kong et al. 2012; Smeds et al. 2016; 
Narasimhan et al. 2017).  
The accuracy in the estimated per base mutation rate for dogs derived in chapter 3 is 
likely to be impacted by technical quirks that are unique to our dataset. Sequencing 
difficulty of GC rich contexts in Illumina NGS data, relatively low sample sequencing 
coverage and strict variant calling filtering criteria resulted in a low observation of GC 
contexts for this study. Due to our limited ability to observe GC rich contexts, there is a 
possible underestimate in the average per base mutation rate in dogs. We expect there 
to be an underestimate because the mutation rate in other animal species in CpG 
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islands is reported to be 10-30 times higher compared with non-CpG sites (Kondrashov 
2002; Lynch 2010; Kong et al. 2012; Narasimhan et al. 2017). To overcome these 
technical limitations, a greater a sequencing depth of over 30X has previously been 
recommended to obtain the high specificity and sensitivity required for accurate SNV 
calling, as well as appropriate representation of all genomic sequence contexts (Cheng 
et al. 2014; Francioli et al. 2017).  With additional utilization of long read sequencing 
technologies, characteristics other types of de novo variants including indels and CNVs 
can be characterised accurately in a range of genomic contexts. As discussed at the 
end of section 6.1, the opportunity for sequencing samples at a higher depth or to obtain 
long read sequencing data is limited by cost. 
6.3. Conclusions from chapter 4 
De novo mutations that are associated with disease are notoriously difficult to detect 
through common mapping methods such as genome wide association analyses (Lee et 
al. 2014). New variants are not in linkage disequilibrium to genetic markers that are 
typically used to identify genetic variants associated with phenotypes. In addition, 
spontaneously occurring diseases caused by new mutations are often rare and limited 
to a very small number of individuals within families. In chapter 4, we studied 
spontaneously occurring progressive retinal atrophy (PRA) in three related Hungarian 
Puli dogs. Although PRA is typically an autosomal recessive disorder in other breeds, 
there was no prior history of PRA in the subject Hungarian Puli family. 
In the first part of this chapter, we performed screening of a comprehensive list of 
reported canine PRA genes using NGS data (Miyadera et al. 2012; Downs, Hitti, et al. 
2014; Winkler et al. 2016). We found no coding variants in 53 candidate loci for the 
phenotype of interest. To ensure that we captured all possible coding variants in likely 
candidate genes, we used Sanger sequencing to sequence the exons that were not 
sufficiently covered in NGS data of any of the 53 genes that were segregating in an 
autosomal recessive pattern.  These genes were identified using genotyping array 
markers that followed the expected inheritance pattern and co-located with candidate 
  
146 
genes. With no potential damaging variants identified and no family history of PRA, we 
considered the possibility that PRA in this family of Hungarian Puli was novel.  
We further assessed positional candidate genes in loci segregating in an autosomal 
recessive pattern and identified a single nonsense SNP in exon 2 of BBS4 that was 
significantly associated with the disorder (c.58.A > T, PCHISQ = 3.43e14, n = 103). 
Dysfunctional BBS4 is known to cause Bardet-Biedl Syndrome in people, a ciliopathy 
which is characterised by many phenotypes including retinitis pigmentosa, obesity and 
infertility (Katsanis et al. 2002; Mykytyn et al. 2004; Wei et al. 2012). We also found 
evidence that the identified nonsense SNP could cause syndromic disease, as affected 
Puli were anecdotally obese, and the sole intact male was confirmed to be infertile 
primarily due to morphologically abnormal flagella. This is the first report of BBS4 and 
its involvement in canine PRA. 
Since the emergence of NGS technologies, researchers have recognised and 
demonstrated the potential for these platforms to identify low frequency, rare and de 
novo variants, particularly through sequencing of parent-offspring samples (Buermans 
and den Dunnen 2014; Zhu et al. 2015; Francioli et al. 2017; Sayyab et al. 2016). We 
applied this technique of parent-offspring whole genome sequencing here to 
successfully identify a rare SNP that is strongly associated with a potentially novel form 
of BBS4, whilst contributing to research in canine PRA.  Fast identification of 
spontaneous disease-causing variants in turn allows for DNA screening protocols to 
commence earlier. Subsequently, the identified BBS4 nonsense SNP associated with 
PRA can be eliminated from Hungarian Puli dogs more rapidly.  
The manuscript presented in section 4.2 is the second report implicating a Bardet-Biedl 
Syndrome gene with canine PRA. Besides BBS4, TTC8 was found to be associated 
with PRA in Golden Retriever Dogs (Downs, Wallin-Håkansson, et al. 2014). Our study 
and Downs et al. were opportunistic and our ability to obtain data was restricted by 
access and need to maintain the welfare of the pet dogs involved. Opportunistic studies 
enable scientists to understand diseases and how they arise in a natural context. 
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Researchers are also able to provide pet owners with a diagnosis and tests to manage 
the disease, which are particularly pertinent to animal breeders.  
Despite the benefits of opportunistic research, they lack a controlled environment and 
perpetual research to further understand the disease and explore treatment possibilities 
is limited by access to the samples. As we experienced, Downs et al. had limited 
opportunities to thoroughly explore other known Bardet-Biedl phenotypes found in 
people with the disease, or observed in BBS knockout gene mouse models (Nishimura 
et al. 2004; Iannaccone et al. 2005; Benzinou et al. 2006; Swiderski et al. 2007; 
Aksanov et al. 2014). Establishing a canine colony for research could confirm whether 
the BBS4 or TTC8 are associated with syndromic diseases, as in humans and mice. 
Colonies could also present as large animal models for the human disease counterpart. 
However, with obvious animal welfare consequences associated with maintaining a 
research colony, the benefit of this research needs to be carefully evaluated. 
6.4. Conclusion to chapter 5 
In chapter 5, we investigated the genetic basis of severe haemophilia A that was 
presented in two Australian Kelpie purebred littermates. Haemophilia A is a rare disease 
that is characterised by uncontrollable bleeding and has been reported in several 
species including dogs and people (Brooks 1999; Graw et al. 2005). In people, over 
2,015 distinct, causative mutations for haemophilia A have been identified in the factor 
VIII gene (Graw et al. 2005; Repessé et al. 2007; Tantawy 2010). The gene encodes for 
coagulation factor VIII (FVIII) and is necessary for the successful operation of the 
coagulation cascade. Disease is generally inherited in an X-linked recessive pattern, 
however, a third of all human haemophilia A cases occur sporadically (Crow 2000; 
Graw et al. 2005).  Sporadic haemophilia A has also been reported in several dog 
breeds (Brooks 1999). The present study is the first to our knowledge to report 
haemophilia A in the Australian Kelpie breed and in a sporadic form, as there was no 
prior family history of bleeding tendencies in the family. 
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As Haldane was first to realise, the mutation rate is higher in male germ cells than in 
female germ cells (Haldane 1935, 1946; Crow 2000; Nachman 2004). He made this 
hypothesis because sporadic haemophilia A was often associated with an apparently 
heterozygous, rather than a homozygous normal mother (Haldane 1935). Through 
genotyping array data of the affected Australian Kelpie family, we also observed this 
pattern (Figure 5.1). The maternal grandfather of the two cases had the apparently 
affected haplotype, despite being in the clinically normal range for coagulation assays 
for FVIII clotting. This suggests that a spontaneously occurring mutation occurred in the 
grandfather’s germ cell. 
In chapter 5, we screened for putative mutations in FVIII as well as 13 other bleeding 
disorder loci in NGS of one case and 11 unrelated Australian Kelpie control samples. 
Whilst we did not detect any damaging variants in the candidate genes selected 
including the FVIII gene, 37 intronic SNP variants in 7 of the candidate genes were 
found.  As we described in the conclusions for chapter 4, research in sporadically 
occurring or rare diseases are challenging. In chapter 5, we were tested with low 
sample numbers and limited access to sample type. As we found in chapter 4, the value 
in creating a canine colony to provide the required samples to sufficiently model the 
haemophilia A in dogs should be evaluated. Although it was not possible to access 
additional case samples, access to cDNA would reveal the functional impact of the 
putative variants identified. Whole genome sequences or transcriptomes of the parents 
and the additional case would greatly enhance the power to detect damaging variants. 
Potential use of NGS technologies in a clinical setting for obtaining a genetic diagnosis 
for spontaneously occurring diseases can also be faced with similar challenges 
described.  
6.5. Final remarks 
In this thesis, we used NGS technologies to assess the contribution of germline de novo 
mutations in canine evolution and disease. We systematically compared popular, 
recommended variant calling pipelines to provide benchmark performance metrics that 
can be used as a guide to develop an optimal pipeline that is tailored to a specific study 
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depending on their priorities for accuracy, sensitivity and specificity. We used these 
results to develop our own pipeline that enabled us to directly observe characteristics of 
de novo mutations and to estimate the per base, per generation germline mutation rate 
in the domestic dog. Finally, we contribute to research in two canine rare diseases that 
were potentially caused by de novo mutations and the outcomes of the research 
highlighted potential applications and challenges with using NGS in clinical diagnosis for 
spontaneously occurring diseases.  
6.6. References 
Aksanov, O., P. Green, and R. Z. Birk, 2014 BBS4 directly affects proliferation and 
differentiation of adipocytes. Cell. Mol. Life Sci. 71: 3381–3392. 
Van der Auwera, G. A., M. O. Carneiro, C. Hartl, R. Poplin, G. del Angel et al., 2013 
From FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best 
Practices Pipeline, Curr. Protoc. Bioinform. 43: 1-33. 
Benzinou, M., A. Walley, S. Lobbens, M.-A. Charles, B. Jouret et al., 2006 Bardet-Biedl 
syndrome gene variants are associated with both childhood and adult common obesity 
in French Caucasians. Diabetes 55: 2876–2882. 
Brooks, M., 1999 A review of canine inherited bleeding disorders: biochemical and 
molecular strategies for disease characterization and carrier detection. J. Hered. 90: 
112–118. 
Buermans, H. P. J., and J. T. den Dunnen, 2014 Next generation sequencing 
technology: Advances and applications. Biochim. Biophys. Acta - Mol. Basis Dis. 1842: 
1932–1941. 
Campbell, C. D., and E. E. Eichler, 2013 Properties and rates of germline mutations in 
humans. Trends Genet. 29: 575–584. 
 
 
  
150 
Chaisson, M. J. P., J. Huddleston, M. Y. Dennis, P. H. Sudmant, M. Malig et al., 2015 
Resolving the complexity of the human genome using single-molecule sequencing. 
Nature 517: 608–611. 
Cheng, A. Y., Y. Y. Teo, and R. T. H. Ong, 2014 Assessing single nucleotide variant 
detection and genotype calling on whole-genome sequenced individuals. Bioinformatics 
30: 1707–1713. 
Crow, J. F., 2000 The origins, patterns and implications of human spontaneous 
mutation. Nat. Rev. Genet. 1: 40–47. 
Downs, L. M., R. Hitti, S. Pregnolato, and C. S. Mellersh, 2014 Genetic screening for 
PRA-associated mutations in multiple dog breeds shows that PRA is heterogeneous 
within and between breeds. Vet. Ophthalmol. 17: 126–130. 
Downs, L. M., B. Wallin-Håkansson, T. Bergström, and C. S. Mellersh, 2014 A novel 
mutation in TTC8 is associated with progressive retinal atrophy in the golden retriever. 
Canine Genet. Epidemiol. 1: 4. 
Francioli, L. C., M. Cretu-Stancu, K. V Garimella, M. Fromer, W. P. Kloosterman et al., 
2017 A framework for the detection of de novo mutations in family-based sequencing 
data. Eur. J. Hum. Genet. 25: 227–233. 
Francioli, L. C., M. Cretu-Stancu, K. V Garimella, M. Fromer, W. P. Kloosterman et al., 
2016 A framework for the detection of de novo mutations in family-based sequencing 
data Genome of the Netherlands Consortium. Eur. J. Hum. Genet. 25147: 227–233. 
Garrison, E., 2015 Freebayes in Depth: Model, Filtering, and Walk-Through. Presented 
at the University of Cambridge, May 2015. Available at:https://wiki.uiowa.edu/download/ 
attachments/145192256/erik%20garrison%20-%20iowa%20talk%202.pdf?api=v2.  
Garrison, E., and G. Marth, 2012 Haplotype-based variant detection from short-read 
sequencing. https://arxiv.org/abs/1207.3907v2.  
  
151 
Graw, J., H. H. Brackmann, J. Oldenburg, R. Schneppenheim, M. Spannagl et al., 2005 
Haemophilia A: from mutation analysis to new therapies. Nat. Rev. Genet. 6: 488–501. 
Haldane, J. B. S., 1935 The rate of spontaneous mutation of a human gene. J. Genet. 
31: 317–326. 
Haldane, J. B. S., 1946 The Mutation Rate of the Gene for Haemophilia, and Its 
Segregation Ratios in Males and Females. Ann. Eugen. 13: 262–271. 
Hodgkinson, A., and A. Eyre-Walker, 2011 Variation in the mutation rate across 
mammalian genomes. Nat. Rev. Genet. 12: 756–766. 
Iannaccone, A., K. Mykytyn, A. M. Persico, C. C. Searby, A. Baldi et al., 2005 Clinical 
evidence of decreased olfaction in Bardet-Biedl syndrome caused by a deletion in the 
BBS4 gene. Am. J. Med. Genet. A 132A: 343–346. 
Katsanis, N., E. R. Eichers, S. J. Ansley, R. A. Lewis, H. Kayserili et al., 2002 BBS4 is a 
minor contributor to Bardet-Biedl syndrome and may also participate in triallelic 
inheritance. Am. J. Hum. Genet. 71: 22–29. 
Keightley, P. D., L. Eöry, D. L. Halligan, and M. Kirkpatrick, 2011 Inference of mutation 
parameters and selective constraint in mammalian coding sequences by approximate 
Bayesian computation. Genetics 187: 1153–1161. 
Koboldt, D. C., D. E. Larson, and R. K. Wilson, 2013 Using VarScan 2 for Germline 
Variant Calling and Somatic Mutation Detection. Curr. Protoc. Bioinforma. 44: 15.4.1-17. 
Kondrashov, A. S., 2002 Direct estimates of human per nucleotide mutation rates at 20 
loci causing mendelian diseases. Hum. Mutat. 21: 12–27. 
Kong, A., M. L. Frigge, G. Masson, S. Besenbacher, P. Sulem et al., 2012 Rate of de 
novo mutations and the importance of father’s age to disease risk. Nature 488: 471–5. 
Lee, S., G. R. Abecasis, M. Boehnke, and X. Lin, 2014 Rare-Variant Association 
Analysis: Study Designs and Statistical Tests. Am. J. Hum. Genet. 95: 5–23. 
  
152 
Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan et al., 2009 The Sequence 
Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079. 
Lynch, M., 2010 Rate, molecular spectrum, and consequences of human mutation. 
Proc. Natl. Acad. Sci. U. S. A. 107: 961–968. 
McKenna, A., M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis et al., 2010 The 
Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA 
sequencing data. Genome Res. 20: 1297–1303. 
Minoche, A. E., J. C. Dohm, and H. Himmelbauer, 2011 Evaluation of genomic high-
throughput sequencing data generated on Illumina HiSeq and Genome Analyzer 
systems. Genome Biol. 12: R112. 
Miyadera, K., G. M. Acland, and G. D. Aguirre, 2012 Genetic and phenotypic variations 
of inherited retinal diseases in dogs: The power of within- and across-breed studies. 
Mamm. Genome 23: 40–61. 
Mykytyn, K., R. F. Mullins, M. Andrews, A. P. Chiang, R. E. Swiderski et al., 2004 
Bardet-Biedl syndrome type 4 (BBS4)-null mice implicate Bbs4 in flagella formation but 
not global cilia assembly. Proc. Natl. Acad. Sci. U. S. A. 101: 8664–8669. 
Nachman, M. W., 2004 Haldane and the first estimates of the human mutation rate. J. 
Genet. 31: 235–244. 
Narasimhan, V. M., R. Rahbari, A. Scally, A. Wuster, D. Mason et al., 2017 Estimating 
the human mutation rate from autozygous segments reveals population differences in 
human mutational processes. Nat. Commun. 8: 303. 
Nishimura, D. Y., M. Fath, R. F. Mullins, C. Searby, M. Andrews et al., 2004 Bbs2-null 
mice have neurosensory deficits, a defect in social dominance, and retinopathy 
associated with mislocalization of rhodopsin. Proc. Natl. Acad. Sci. U. S. A. 101: 16588–
16593. 
 
  
153 
Pollard, M. O., D. Gurdasani, A. J. Mentzer, T. Porter, and M. S. Sandhu, 2018 Long 
reads: their purpose and place. Hum. Mol. Genet. 27: R234–R241. 
Repessé, Y., M. Slaoui, D. Ferrandiz, P. Gautier, C. Costa et al., 2007 Factor VIII (FVIII) 
gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and 
correlation with FVIII inhibitor development. J. Thromb. Haemost. 5: 1469–1476. 
Reuter, J. A., D. V Spacek, and M. P. Snyder, 2015 High-throughput sequencing 
technologies. Mol. Cell 58: 586–597. 
Sayyab, S., A. Viluma, K. Bergvall, E. Brunberg, V. Jagannathan et al., 2016 Whole-
Genome Sequencing of a Canine Family Trio Reveals a FAM83G Variant Associated 
with Hereditary Footpad Hyperkeratosis. G3 (Bethesda) 6: 521-527. 
Schwarze, K., J. Buchanan, J. C. Taylor, and S. Wordsworth, 2018 Are whole-exome 
and whole-genome sequencing approaches cost-effective? A systematic review of the 
literature. Genet. Med. 20: 1122–1130. 
Smeds, L., A. Qvarnström, and H. Ellegren, 2016 Direct estimate of the rate of germline 
mutation in a bird. Genome Res. 26: 1211–1218. 
De Summa, S., G. Malerba, R. Pinto, A. Mori, V. Mijatovic et al., 2015 GATK hard 
filtering: tunable parameters to improve variant calling for next generation sequencing 
targeted gene panel data. BMC Bioinformatics. 18: 119. 
Swiderski, R. E., D. Y. Nishimura, R. F. Mullins, M. a Olvera, J. L. Ross et al., 2007 
Gene expression analysis of photoreceptor cell loss in bbs4-knockout mice reveals an 
early stress gene response and photoreceptor cell damage. Invest. Ophthalmol. Vis. 
Sci. 48: 3329–3340. 
Tantawy, A. a. G., 2010 Molecular genetics of hemophilia A: Clinical perspectives. 
Egypt. J. Med. Hum. Genet. 11: 105–114. 
  
154 
Uchimura, A., M. Higuchi, Y. Minakuchi, M. Ohno, A. Toyoda et al., 2015 Germline 
mutation rates and the long-term phenotypic effects of mutation accumulation in wild-
type laboratory mice and mutator mice. Genome Res. 25: 1–10. 
Venn, O., I. Turner, I. Mathieson, N. de Groot, R. Bontrop et al., 2014 Strong male bias 
drives germline mutation in chimpanzees. Science 344: 1272–1275. 
Wei, Q., Y. Zhang, Y. Li, Q. Zhang, K. Ling et al., 2012 The BBSome controls IFT 
assembly and turnaround in cilia. Nat. Cell Biol. 14: 950–957. 
Willet, C. E., B. Haase, M. A. Charleston, and C. M. Wade, 2015 Simple, rapid and 
accurate genotyping-by-sequencing from aligned whole genomes with ArrayMaker. 
Bioinformatics 31: 599–601. 
Winkler, P. A., J. A. Davis, S. M. Petersen-Jones, P. J. Venta, and J. T. Bartoe, 2016 A 
tool set to allow rapid screening of dog families with PRA for association with candidate 
genes. Vet. Ophthalmol. 20: 372-376. 
Yu, X., S. Sun, F. Collins, L. Brooks, A. Chakravarti et al., 2013 Comparing a few SNP 
calling algorithms using low-coverage sequencing data. BMC Bioinformatics 14: 274. 
Zhu, X., S. Petrovski, P. Xie, E. K. Ruzzo, Y. F. Lu et al., 2015 Whole-exome 
sequencing in undiagnosed genetic diseases: interpreting 119 trios. Genet. Med. 17: 
774–781. 
 
  
Appendices 
Appendix I: Supplementary material for chapter 2 
Table S1. Sample information  
B
re
e
d
 
Id
e
n
ti
fi
e
r 
G
e
n
o
ty
p
in
g
  
a
rr
a
y
 
S
a
m
p
le
 t
y
p
e
 
S
e
q
u
e
n
c
in
g
 
p
la
tf
o
rm
 
L
ib
ra
ry
 
S
e
q
u
e
n
c
in
g
 l
a
n
e
s
 
R
e
a
d
 l
e
n
g
th
 
N
u
m
b
e
r 
o
f 
ra
w
 
re
a
d
s
 
R
e
a
d
s
 m
a
p
p
e
d
 t
o
 
C
a
n
F
a
m
 3
.1
 (
%
) 
R
a
w
 a
v
e
ra
g
e
 
c
o
v
e
ra
g
e
 
Australian 
Cattle Dog 
USCF1292 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2000 
TruSeq 
(PCR-
free) 
1/2 x 2 100 326,493,791 98.4 12.5 
Australian 
Cattle Dog 
USCF1293 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2000 
TruSeq 
(PCR-
free) 
1/2 x 1 101 348,600,508 99.12 13.3 
Australian 
Cattle Dog 
USCF1294 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2000 
TruSeq 
(PCR-
free) 
1/2 x 1 101 381,441,309 99.0 14.5 
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Miniature 
Schnauzer 
USCF138 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2500 
TruSeq 
(PCR-
free) 
1/2 x 2 100 273,023,711 98.8 10.2 
Miniature 
Schnauzer 
USCF301 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2500 
TruSeq 
(PCR-
free) 
1/2 x 2 100 422,811,078 99.0 15.9 
Miniature 
Schnauzer 
USCF134 Illumina 
CanineHD 
BeadChip 
Tissue Illumina 
HiSeq 
2000 
TruSeq 1/2 x 1 101 229,564,555 99.6 8.7 
Miniature 
Schnauzer 
USCF136 Illumina 
CanineHD 
BeadChip 
Tissue Illumina 
HiSeq 
2000 
TruSeq 1/2 x 1 101 192,777,994 99.6 7.2 
Hungarian 
Puli 
USCF525 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2000 
TruSeq 
(PCR-
free) 
1/2 x 1 101 197,791,391 99.3 7.5 
Hungarian 
Puli 
USCF347 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2000 
TruSeq 
(PCR-
free) 
1/2 x 1 101 167,359,624 99.3 6.4 
Hungarian 
Puli 
USCF516 Illumina 
CanineHD 
BeadChip 
Whole 
blood 
Illumina 
HiSeq 
2000 
TruSeq 
(PCR-
free) 
1/2 x 1 101 191,605,356 99.3 7.3 
  
Table S2. Description of filtering parameters used in raw and filtered pipelines for 
five variant calling software 
 
Software Pipeline Filter Description 
FreeBayes Raw No indels  Ignore insertion-deletions 
No mnps  Ignore multi-nucleotide 
polymorphisms 
No-complex  Ignore complex events 
(composites of other classes of 
allele types) 
Report monomorphic Report loci which are non-variant 
to the reference allele 
Filtered  QUAL > 1 Include sites in the output only if 
the reported quality of the site is 
greater than 1. QUAL is the 
Phred-scaled probability that the 
variant reported in the ALT field of 
the VCF file exists in the 
sequencing data 
QUAL/AO > 10 AO is to observation count of the 
alternate allele (depth). Include 
sites if QUAL/AO is greater than 
10.  
SAF > 0 Include sites if the alternate allele 
is present on more than 0 sites on 
the forward sequencing reads 
SAR > 0 Include sites if the alternate allele 
is present on more than 0 sites on 
the reverse sequencing reads 
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RPR > 1 Include sites if the reads placed 
right (number of reads supporting 
the alternate is balanced to the 3’ 
end) is greater than 1 
RPL > 1 Include sites if the reads placed 
left (number of reads supporting 
the alternate is balanced to the 5’ 
end) is greater than 1 
GATK HC Raw emitRefConfidence 
GVCF 
Emit reference confidence scores 
variant_index_type 
LINEAR 
Type of variant indexing to use 
variant_index_parameter 
128000 
Variant to pass to the VCF/BCF 
IndexCreator 
stand_emit_conf 10 Include sites in the output if the 
emission confidence threshold 
(Phred-scaled) that the site is 
possibly variant is greater than 10 
stand_call_conf 30 Include sites if the calling 
confidence (Phred-scaled) is 
greateer than 30 
allSites Report loci which are non-variant 
to the reference allele 
Filtered QD > 2.0 Exclude sites if quality of depth 
(quality score normalized by the 
allele depth, AD) is greater than 
2.0 
FS > 60.0 Exclude sites if the Fisher’s exact 
test (Phred-scaled) is greater than 
60.0 to remove sites with evidence 
of strand bias 
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MQ < 40.0 Exclude sites if mapping quality 
(Phred-scaled) is less than 40.0 
MappingQualityRankSum 
< -12.5 
Exclude sites if the mapping 
qualities of reads supporting the 
reference and alternate is less 
than -12.5. An ideal value is 0, 
which indicates no difference in 
quality between alleles 
ReadPosRankSum < -
8.0 
ReadPosRankSum measures bias 
in the position of the alleles in the 
sequencing reads. Exclude sites 
where ReadPosRankSum is less 
than -8.0  
GATK UG Raw stand_emit_conf 10 Include sites in the output if the 
emission confidence threshold 
(Phred-scaled) that the site is 
possibly variant is greater than 10 
stand_call_conf 30 Include sites if the calling 
confidence (Phred-scaled) is 
greateer than 30 
glm BOTH Perform genotype likelihoods 
calculation for both SNP and indel 
Filtered QD > 2.0 Exclude sites if quality of depth 
(quality score normalized by the 
allele depth, AD) is greater than 
2.0 
FS > 60.0 Exclude sites if the Fisher’s exact 
test (Phred-scaled) is greater than 
60.0 to remove sites with evidence 
of strand bias 
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MQ < 40.0 Exclude sites if mapping quality 
(Phred-scaled) is less than 40.0 
HaplotypeScore > 13.0 HaplotypeScore measures 
evidence of regions with poor 
quality alignments and is based on 
the expectation that the sample is 
diploid. Exclude sites with a 
HaplotypeScore greater than 13.0 
MappingQualityRankSum 
< 12.5 
Exclude sites if the mapping 
qualities of reads supporting the 
reference and alternate is less 
than -12.5. An ideal value is 0, 
which indicates no difference in 
quality between alleles 
ReadPosRankSum < -
8.0 
Exclude sites if the mapping 
qualities of reads supporting the 
reference and alternate is less 
than -12.5. An ideal value is 0, 
which indicates no difference in 
quality between alleles 
SAMtools Raw p 1 p is the probability that the site is 
variant. Include sites if p is less 
than or equal to 1 
c Use Bayesian inference in variant 
calling 
Filtered Q 20 Exclude bases with base quality 
less than 20 
q 20 Exclude reads with mapping 
quality less than 20 
C 50 Recommended by SAMtools if 
mapping quality is overestimated 
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for reads containing excessive 
mismatches 
E Perform extended base alignment 
quality calculation (probability of a 
read being mis-aligned) 
Maximum coverage 2 x 
average sample 
coverage 
Exclude if the maximum coverage 
at the loci is greater than 2 times 
the average coverage in the 
sample 
c Use Bayesian inference in variant 
calling 
VarScan Raw B Disable base alignment quality 
calculation 
p 1 p is the probability that the site is 
variant. Include sites if p is less 
than or equal to 1 
c Use Bayesian inference in variant 
calling 
Filtered q 10 Exclude reads with mapping 
quality less than 10 
B Disable base alignment quality 
calculation 
min-avg-qual 15 Include base if quality (Phred-
scaled) is greater than 15 
min-reads2 1 Include if minimum number of 
reads supporting the variant allele 
is greater than 1 
min-var-freq 0.20 Include variants if the variant allele 
frequency is greater than 0.20 of 
the total reads present at the site 
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p-value 0.10 Set p-value threshold of 0.10 
(Fisher’s exact test) which a 
variant call is deemed significant 
min-freq-for-hom 0.75 Minimum variant allele frequency 
above which a variant will be 
called homozygous in a given 
sample 
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Table S3. Genotyping rates (n = 10) across 11 minimum coverage requirement 
levels obtained from raw and filtered pipelines using five different variant callers 
(FreeBayes, GATK HC, GATK UG, SAMtools and VarScan) compared against 
genotypes obtained using the CanineHD BeadChip array. 
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FreeBayes Raw 0 1,715,475 1,245 99.927 
FreeBayes Raw 2 1,701,023 15,697 99.086 
FreeBayes Raw 4 1,629,333 87,387 94.910 
FreeBayes Raw 6 1,457,691 259,029 84.911 
FreeBayes Raw 8 1,202,033 514,687 70.019 
FreeBayes Raw 10 924,196 792,524 53.835 
FreeBayes Raw 12 672,794 1,043,926 39.191 
FreeBayes Raw 14 470,366 1,246,354 27.399 
FreeBayes Raw 16 316,495 1,400,225 18.436 
FreeBayes Raw 18 203,059 1,513,661 11.828 
FreeBayes Raw 20 123,641 1,593,079 7.2021 
FreeBayes Filtered 0 1,697,474 19,246 98.879 
FreeBayes Filtered 2 1,683,039 33,681 98.038 
FreeBayes Filtered 4 1,612,095 104,625 93.906 
FreeBayes Filtered 6 1,442,670 274,050 84.036 
FreeBayes Filtered 8 1,190,351 526,369 69.339 
FreeBayes Filtered 10 916,316 800,404 53.376 
FreeBayes Filtered 12 668,160 1,048,560 38.921 
FreeBayes Filtered 14 467,913 1,248,807 27.256 
FreeBayes Filtered 16 315,338 1,401,382 18.369 
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FreeBayes Filtered 18 202,584 1,514,136 11.801 
FreeBayes Filtered 20 123,451 1,593,269 7.191 
GATK HC Raw 0 1,715,726 994 99.942 
GATK HC Raw 2 1,700,986 15,734 99.083 
GATK HC Raw 4 1,629,061 87,659 94.894 
GATK HC Raw 6 1,457,226 259,494 84.884 
GATK HC Raw 8 1,201,509 515,211 69.989 
GATK HC Raw 10 923,690 793,030 53.806 
GATK HC Raw 12 672,373 1,044,347 39.166 
GATK HC Raw 14 470,047 1,246,673 27.381 
GATK HC Raw 16 316,261 1,400,459 18.422 
GATK HC Raw 18 202,908 1,513,812 11.820 
GATK HC Raw 20 123,542 1,593,178 7.196 
GATK HC Filtered 0 1,706,809 9,911 99.423 
GATK HC Filtered 2 1,696,622 20,098 98.829 
GATK HC Filtered 4 1,625,493 91,227 94.686 
GATK HC Filtered 6 1,454,488 262,232 84.725 
GATK HC Filtered 8 1,199,534 517,186 69.874 
GATK HC Filtered 10 922,396 794,324 53.730 
GATK HC Filtered 12 671,639 1,045,081 39.123 
GATK HC Filtered 14 469,676 1,247,044 27.359 
GATK HC Filtered 16 316,055 1,400,665 18.410 
GATK HC Filtered 18 202,795 1,513,925 11.812 
GATK HC Filtered 20 123,462 1,593,258 7.192 
GATK UG Raw 0 1,710,535 6,185 99.640 
GATK UG Raw 2 1,700,394 16,326 99.049 
GATK UG Raw 4 1,628,997 87,723 94.890 
GATK UG Raw 6 1,457,458 259,262 84.898 
GATK UG Raw 8 1,201,866 514,854 70.009 
GATK UG Raw 10 924,084 792,636 53.828 
GATK UG Raw 12 672,719 1,044,001 39.186 
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GATK UG Raw 14 470,324 1,246,396 27.397 
GATK UG Raw 16 316,462 1,400,258 18.434 
GATK UG Raw 18 203,040 1,513,680 11.827 
GATK UG Raw 20 123,628 1,593,092 7.201 
GATK UG Filtered 0 1,707,817 8,903 99.481 
GATK UG Filtered 2 1,697,822 18,898 98.899 
GATK UG Filtered 4 1,626,644 90,076 94.753 
GATK UG Filtered 6 1,455,494 261,226 84.783 
GATK UG Filtered 8 1,200,413 516,307 69.925 
GATK UG Filtered 10 923,232 793,488 53.779 
GATK UG Filtered 12 672,280 1,044,440 39.161 
GATK UG Filtered 14 470,086 1,246,634 27.383 
GATK UG Filtered 16 316,304 1,400,416 18.425 
GATK UG Filtered 18 202,935 1,513,785 11.821 
GATK UG Filtered 20 123,541 1,593,179 7.196 
SAMtools Raw 0 1,716,385 335 99.980 
SAMtools Raw 2 1,701,837 14,883 99.133 
SAMtools Raw 4 1,629,904 86,816 94.943 
SAMtools Raw 6 1,458,027 258,693 84.931 
SAMtools Raw 8 1,202,210 514,510 70.029 
SAMtools Raw 10 924,265 792,455 53.839 
SAMtools Raw 12 672,825 1,043,895 39.192 
SAMtools Raw 14 470,374 1,246,346 27.400 
SAMtools Raw 16 316,483 1,400,237 18.435 
SAMtools Raw 18 203,038 1,513,682 11.827 
SAMtools Raw 20 123,612 1,593,108 7.200 
SAMtools Filtered 0 1,703,114 13,606 99.207 
SAMtools Filtered 2 1,693,281 23,439 98.635 
SAMtools Filtered 4 1,622,273 94,447 94.498 
SAMtools Filtered 6 1,451,191 265,529 84.533 
SAMtools Filtered 8 1,196,001 520,719 69.668 
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SAMtools Filtered 10 918,599 798,121 53.509 
SAMtools Filtered 12 667,564 1,049,156 38.886 
SAMtools Filtered 14 465,388 1,251,332 27.109 
SAMtools Filtered 16 311,959 1,404,761 18.172 
SAMtools Filtered 18 199,040 1,517,680 11.594 
SAMtools Filtered 20 120,764 1,595,956 7.035 
VarScan Raw 0 1,715,452 1,268 99.926 
VarScan Raw 2 1,701,004 15,716 99.085 
VarScan Raw 4 1,629,313 87,407 94.908 
VarScan Raw 6 1,457,667 259,053 84.910 
VarScan Raw 8 1,202,002 514,718 70.017 
VarScan Raw 10 924,160 792,560 53.833 
VarScan Raw 12 672,760 1,043,960 39.189 
VarScan Raw 14 470,339 1,246,381 27.398 
VarScan Raw 16 316,460 1,400,260 18.434 
VarScan Raw 18 203,018 1,513,702 11.826 
VarScan Raw 20 123,595 1,593,125 7.199 
VarScan Filtered 0 1,678,687 38,033 97.785 
VarScan Filtered 2 1,675,183 41,537 97.580 
VarScan Filtered 4 1,624,844 91,876 94.648 
VarScan Filtered 6 1,456,627 260,093 84.849 
VarScan Filtered 8 1,201,446 515,274 69.985 
VarScan Filtered 10 923,780 792,940 53.811 
VarScan Filtered 12 672,508 1,044,212 39.174 
VarScan Filtered 14 470,180 1,246,540 27.388 
VarScan Filtered 16 316,362 1,400,358 18.428 
VarScan Filtered 18 202,987 1,513,733 11.824 
VarScan Filtered 20 123,596 1,593,124 7.200 
 



  
Appendix II: Supplementary material for chapter 3 
Table S1.  Sample and pedigree information for the parent-offspring trios used in the study 
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USCF1292 Cattle Dog USCF1294 Father Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 100 
USCF1293 Cattle Dog USCF1294 Mother Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 101 
USCF1294 Cattle Dog USCF1294 Child Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 101 
USCF1225 Labrador 
USCF1119; 
USCF1014 Father Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 101 
USCF1224 Labrador USCF1119 Mother Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 100 
USCF1222 Labrador USCF1014 Mother Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 100 
  
171 
USCF1119 Labrador USCF1119 Child Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 101 
USCF1014 Labrador USCF1014 Child Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
550bp insert 101 
USCF138 
Miniature 
Schnauzer 
USCF136; 
USCF134 Father Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
350bp insert  100 
USCF301 
Miniature 
Schnauzer 
USCF136; 
USCF134 Mother Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
350bp insert  100 
USCF136 
Miniature 
Schnauzer USCF136 Child Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
350bp insert  101 
USCF134 
Miniature 
Schnauzer USCF134 Child Ramaciotti 
Illumina HiSeq 
2000 
PCR-free TruSeq 
350bp insert  101 
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Table S2. Average coverage in parent-offspring trio samples 
Child 
identifier 
Father 
identifier 
Mother 
identifier 
Raw average 
coverage 
(Child) 
Raw average 
coverage 
(Father) 
Raw average 
coverage 
(Mother) 
Raw average 
coverage in 
trio 
USCF1294 USCF1292 USCF1293 14.5 12.5 13.3 13.4 
USCF1119 USCF1225 USCF1224 7.5 11.0 6.6 8.4 
USCF1014 USCF1225 USCF1222 11.7 11.0 17.9 13.5 
USCF136 USCF138 USCF301 7.2 10.2 15.9 11.1 
USCF134 USCF138 USCF301 8.7 10.2 15.9 11.6 
  
Table S3.  Observed sites per parent-offspring trio, per chromosome 
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1 122,678,785 USCF134 25,430,142 0 0 0 0 0 0 0 
2 85,426,708 USCF134 16,165,018 0 0 0 0 0 0 0 
3 91,889,043 USCF134 20,019,354 0 0 0 0 0 0 0 
4 88,276,631 USCF134 19,528,607 1 1 0 0 0 0 0 
5 88,915,250 USCF134 14,645,917 0 0 0 0 0 0 0 
6 77,573,801 USCF134 14,642,397 0 0 0 0 0 0 0 
7 80,974,532 USCF134 17,849,351 0 0 0 0 0 0 0 
8 74,330,416 USCF134 16,469,421 3 0 1 2 0 0 0 
9 61,074,082 USCF134 9,013,245 0 0 0 0 0 0 0 
10 69,331,447 USCF134 13,681,867 0 0 0 0 0 0 0 
11 74,389,097 USCF134 16,093,419 1 0 1 0 0 0 0 
12 72,498,081 USCF134 17,542,020 0 0 0 0 0 0 0 
13 63,241,923 USCF134 14,309,623 1 1 0 0 0 0 0 
14 60,966,679 USCF134 15,416,789 1 0 0 0 1 0 0 
15 64,190,966 USCF134 14,592,372 1 0 0 1 0 0 0 
16 59,632,846 USCF134 12,063,722 0 0 0 0 0 0 0 
17 64,289,059 USCF134 13,030,745 2 0 0 0 0 0 2 
  
174 
18 55,844,845 USCF134 10,017,989 2 0 2 0 0 0 0 
19 53,741,614 USCF134 12,722,779 0 0 0 0 0 0 0 
20 58,134,056 USCF134 10,101,522 0 0 0 0 0 0 0 
21 50,858,623 USCF134 10,929,873 0 0 0 0 0 0 0 
22 61,439,934 USCF134 15,367,588 1 1 0 0 0 0 0 
23 52,294,480 USCF134 12,190,912 1 1 0 0 0 0 0 
24 47,698,779 USCF134 7,772,509 0 0 0 0 0 0 0 
25 51,628,933 USCF134 10,939,621 0 0 0 0 0 0 0 
26 38,964,690 USCF134 5,051,270 1 0 0 1 0 0 0 
27 45,876,710 USCF134 10,410,574 1 0 1 0 0 0 0 
28 41,182,112 USCF134 7,502,532 0 0 0 0 0 0 0 
29 41,845,238 USCF134 10,364,260 0 0 0 0 0 0 0 
30 40,214,260 USCF134 8,816,006 0 0 0 0 0 0 0 
31 39,895,921 USCF134 8,839,281 0 0 0 0 0 0 0 
32 38,810,281 USCF134 10,639,933 0 0 0 0 0 0 0 
33 31,377,067 USCF134 7,771,882 2 2 0 0 0 0 0 
34 42,124,431 USCF134 9,013,408 0 0 0 0 0 0 0 
35 26,524,999 USCF134 5,301,285 1 0 1 0 0 0 0 
36 30,810,995 USCF134 7,804,227 1 0 0 0 1 0 0 
37 30,902,991 USCF134 7,113,522 0 0 0 0 0 0 0 
38 23,914,537 USCF134 4,832,706 0 0 0 0 0 0 0 
1 122,678,785 USCF136 13,865,057 0 0 0 0 0 0 0 
2 85,426,708 USCF136 8,414,400 0 0 0 0 0 0 0 
3 91,889,043 USCF136 11,446,442 0 0 0 0 0 0 0 
4 88,276,631 USCF136 11,040,943 0 0 0 0 0 0 0 
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5 88,915,250 USCF136 7,771,766 0 0 0 0 0 0 0 
6 77,573,801 USCF136 7,976,768 1 0 1 0 0 0 0 
7 80,974,532 USCF136 9,724,290 0 0 0 0 0 0 0 
8 74,330,416 USCF136 9,248,297 1 0 0 0 0 1 0 
9 61,074,082 USCF136 4,513,086 0 0 0 0 0 0 0 
10 69,331,447 USCF136 7,229,263 0 0 0 0 0 0 0 
11 74,389,097 USCF136 9,050,430 1 0 0 0 0 0 1 
12 72,498,081 USCF136 10,157,185 0 0 0 0 0 0 0 
13 63,241,923 USCF136 8,287,198 0 0 0 0 0 0 0 
14 60,966,679 USCF136 8,556,469 1 1 0 0 0 0 0 
15 64,190,966 USCF136 8,209,955 0 0 0 0 0 0 0 
16 59,632,846 USCF136 6,900,144 0 0 0 0 0 0 0 
17 64,289,059 USCF136 7,160,794 0 0 0 0 0 0 0 
18 55,844,845 USCF136 5,777,671 1 0 1 0 0 0 0 
19 53,741,614 USCF136 7,707,702 0 0 0 0 0 0 0 
20 58,134,056 USCF136 5,304,180 0 0 0 0 0 0 0 
21 50,858,623 USCF136 6,428,309 0 0 0 0 0 0 0 
22 61,439,934 USCF136 9,329,742 0 0 0 0 0 0 0 
23 52,294,480 USCF136 6,646,976 0 0 0 0 0 0 0 
24 47,698,779 USCF136 4,040,944 0 0 0 0 0 0 0 
25 51,628,933 USCF136 6,020,721 0 0 0 0 0 0 0 
26 38,964,690 USCF136 2,711,785 0 0 0 0 0 0 0 
27 45,876,710 USCF136 5,726,948 1 0 1 0 0 0 0 
28 41,182,112 USCF136 3,927,984 0 0 0 0 0 0 0 
29 41,845,238 USCF136 6,104,239 1 0 1 0 0 0 0 
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30 40,214,260 USCF136 4,704,568 0 0 0 0 0 0 0 
31 39,895,921 USCF136 5,416,406 2 0 1 0 1 0 0 
32 38,810,281 USCF136 6,240,165 0 0 0 0 0 0 0 
33 31,377,067 USCF136 4,251,515 1 0 0 0 1 0 0 
34 42,124,431 USCF136 5,183,011 0 0 0 0 0 0 0 
35 26,524,999 USCF136 2,818,856 0 0 0 0 0 0 0 
36 30,810,995 USCF136 4,351,416 0 0 0 0 0 0 0 
37 30,902,991 USCF136 3,964,706 0 0 0 0 0 0 0 
38 23,914,537 USCF136 2,831,219 0 0 0 0 0 0 0 
1 122,678,785 USCF1014 46,730,472 2 2 0 0 0 0 0 
2 85,426,708 USCF1014 28,656,218 0 0 0 0 0 0 0 
3 91,889,043 USCF1014 37,970,148 0 0 0 0 0 0 0 
4 88,276,631 USCF1014 36,191,043 1 1 0 0 0 0 0 
5 88,915,250 USCF1014 27,094,983 3 1 2 0 0 0 0 
6 77,573,801 USCF1014 27,289,875 2 1 1 0 0 0 0 
7 80,974,532 USCF1014 32,077,117 2 0 1 1 0 0 0 
8 74,330,416 USCF1014 30,048,531 1 0 1 0 0 0 0 
9 61,074,082 USCF1014 15,941,552 0 0 0 0 0 0 0 
10 69,331,447 USCF1014 24,742,921 1 1 0 0 0 0 0 
11 74,389,097 USCF1014 29,758,111 0 0 0 0 0 0 0 
12 72,498,081 USCF1014 32,700,207 1 0 1 0 0 0 0 
13 63,241,923 USCF1014 26,974,267 0 0 0 0 0 0 0 
14 60,966,679 USCF1014 27,814,599 0 0 0 0 0 0 0 
15 64,190,966 USCF1014 26,889,028 1 0 0 0 0 0 1 
16 59,632,846 USCF1014 23,169,967 1 0 1 0 0 0 0 
  
177 
17 64,289,059 USCF1014 23,627,586 1 0 1 0 0 0 0 
18 55,844,845 USCF1014 19,467,098 0 0 0 0 0 0 0 
19 53,741,614 USCF1014 24,765,288 1 1 0 0 0 0 0 
20 58,134,056 USCF1014 18,276,715 1 0 1 0 0 0 0 
21 50,858,623 USCF1014 20,571,130 0 0 0 0 0 0 0 
22 61,439,934 USCF1014 29,814,498 0 0 0 0 0 0 0 
23 52,294,480 USCF1014 21,958,424 2 1 1 0 0 0 0 
24 47,698,779 USCF1014 14,257,328 1 0 0 0 1 0 0 
25 51,628,933 USCF1014 19,940,398 0 0 0 0 0 0 0 
26 38,964,690 USCF1014 9,902,023 0 0 0 0 0 0 0 
27 45,876,710 USCF1014 18,822,187 0 0 0 0 0 0 0 
28 41,182,112 USCF1014 13,678,576 0 0 0 0 0 0 0 
29 41,845,238 USCF1014 19,747,443 1 0 0 0 0 0 1 
30 40,214,260 USCF1014 15,467,753 0 0 0 0 0 0 0 
31 39,895,921 USCF1014 17,438,733 0 0 0 0 0 0 0 
32 38,810,281 USCF1014 19,629,246 0 0 0 0 0 0 0 
33 31,377,067 USCF1014 14,102,693 0 0 0 0 0 0 0 
34 42,124,431 USCF1014 17,378,887 1 1 0 0 0 0 0 
35 26,524,999 USCF1014 9,633,840 2 0 0 0 1 0 1 
36 30,810,995 USCF1014 14,524,417 2 1 0 0 0 0 1 
37 30,902,991 USCF1014 13,076,859 2 0 2 0 0 0 0 
38 23,914,537 USCF1014 9,369,603 0 0 0 0 0 0 0 
1 122,678,785 USCF1119 3,305,006 0 0 0 0 0 0 0 
2 85,426,708 USCF1119 1,882,224 0 0 0 0 0 0 0 
3 91,889,043 USCF1119 2,908,986 0 0 0 0 0 0 0 
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4 88,276,631 USCF1119 2,763,173 0 0 0 0 0 0 0 
5 88,915,250 USCF1119 1,613,746 0 0 0 0 0 0 0 
6 77,573,801 USCF1119 1,903,218 0 0 0 0 0 0 0 
7 80,974,532 USCF1119 2,340,767 0 0 0 0 0 0 0 
8 74,330,416 USCF1119 2,305,060 0 0 0 0 0 0 0 
9 61,074,082 USCF1119 925,742 0 0 0 0 0 0 0 
10 69,331,447 USCF1119 1,698,459 0 0 0 0 0 0 0 
11 74,389,097 USCF1119 2,225,884 0 0 0 0 0 0 0 
12 72,498,081 USCF1119 2,730,763 0 0 0 0 0 0 0 
13 63,241,923 USCF1119 2,165,272 0 0 0 0 0 0 0 
14 60,966,679 USCF1119 2,264,187 0 0 0 0 0 0 0 
15 64,190,966 USCF1119 2,105,469 0 0 0 0 0 0 0 
16 59,632,846 USCF1119 1,720,829 1 1 0 0 0 0 0 
17 64,289,059 USCF1119 1,636,973 0 0 0 0 0 0 0 
18 55,844,845 USCF1119 1,401,134 0 0 0 0 0 0 0 
19 53,741,614 USCF1119 2,054,344 1 1 0 0 0 0 0 
20 58,134,056 USCF1119 1,179,438 0 0 0 0 0 0 0 
21 50,858,623 USCF1119 1,572,824 0 0 0 0 0 0 0 
22 61,439,934 USCF1119 2,654,496 1 0 1 0 0 0 0 
23 52,294,480 USCF1119 1,663,253 0 0 0 0 0 0 0 
24 47,698,779 USCF1119 834,802 0 0 0 0 0 0 0 
25 51,628,933 USCF1119 1,479,466 0 0 0 0 0 0 0 
26 38,964,690 USCF1119 508,932 0 0 0 0 0 0 0 
27 45,876,710 USCF1119 1,448,255 0 0 0 0 0 0 0 
28 41,182,112 USCF1119 867,561 0 0 0 0 0 0 0 
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29 41,845,238 USCF1119 1,663,548 0 0 0 0 0 0 0 
30 40,214,260 USCF1119 1,134,303 0 0 0 0 0 0 0 
31 39,895,921 USCF1119 1,566,164 0 0 0 0 0 0 0 
32 38,810,281 USCF1119 1,765,144 0 0 0 0 0 0 0 
33 31,377,067 USCF1119 1,152,217 0 0 0 0 0 0 0 
34 42,124,431 USCF1119 1,332,050 0 0 0 0 0 0 0 
35 26,524,999 USCF1119 631,670 0 0 0 0 0 0 0 
36 30,810,995 USCF1119 1,189,373 0 0 0 0 0 0 0 
37 30,902,991 USCF1119 1,035,278 0 0 0 0 0 0 0 
38 23,914,537 USCF1119 767,365 0 0 0 0 0 0 0 
1 122,678,785 USCF1294 55,273,848 1 1 0 0 0 0 0 
2 85,426,708 USCF1294 33,962,454 0 0 0 0 0 0 0 
3 91,889,043 USCF1294 44,808,613 0 0 0 0 0 0 0 
4 88,276,631 USCF1294 42,405,666 3 1 1 0 0 0 1 
5 88,915,250 USCF1294 31,540,124 2 0 1 0 1 0 0 
6 77,573,801 USCF1294 31,510,673 2 0 1 1 0 0 0 
7 80,974,532 USCF1294 37,673,467 1 0 1 0 0 0 0 
8 74,330,416 USCF1294 35,374,163 1 1 0 0 0 0 0 
9 61,074,082 USCF1294 18,425,316 4 2 1 1 0 0 0 
10 69,331,447 USCF1294 29,111,937 0 0 0 0 0 0 0 
11 74,389,097 USCF1294 34,929,857 0 0 0 0 0 0 0 
12 72,498,081 USCF1294 38,591,544 2 2 0 0 0 0 0 
13 63,241,923 USCF1294 31,436,333 0 0 0 0 0 0 0 
14 60,966,679 USCF1294 32,686,722 2 0 2 0 0 0 0 
15 64,190,966 USCF1294 31,934,038 2 1 1 0 0 0 0 
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16 59,632,846 USCF1294 27,445,376 0 0 0 0 0 0 0 
17 64,289,059 USCF1294 27,828,461 0 0 0 0 0 0 0 
18 55,844,845 USCF1294 22,735,961 1 0 0 1 0 0 0 
19 53,741,614 USCF1294 29,306,186 1 0 0 0 1 0 0 
20 58,134,056 USCF1294 21,537,088 3 1 2 0 0 0 0 
21 50,858,623 USCF1294 24,198,736 0 0 0 0 0 0 0 
22 61,439,934 USCF1294 34,847,974 1 0 0 1 0 0 0 
23 52,294,480 USCF1294 26,112,421 0 0 0 0 0 0 0 
24 47,698,779 USCF1294 16,567,521 0 0 0 0 0 0 0 
25 51,628,933 USCF1294 23,480,203 1 0 0 0 1 0 0 
26 38,964,690 USCF1294 11,670,827 0 0 0 0 0 0 0 
27 45,876,710 USCF1294 22,444,721 0 0 0 0 0 0 0 
28 41,182,112 USCF1294 15,860,271 0 0 0 0 0 0 0 
29 41,845,238 USCF1294 23,393,326 1 0 1 0 0 0 0 
30 40,214,260 USCF1294 18,288,054 0 0 0 0 0 0 0 
31 39,895,921 USCF1294 20,339,076 3 1 1 0 0 0 1 
32 38,810,281 USCF1294 23,068,897 0 0 0 0 0 0 0 
33 31,377,067 USCF1294 16,566,263 1 1 0 0 0 0 0 
34 42,124,431 USCF1294 20,477,674 2 1 1 0 0 0 0 
35 26,524,999 USCF1294 11,616,663 0 0 0 0 0 0 0 
36 30,810,995 USCF1294 17,128,788 1 1 0 0 0 0 0 
37 30,902,991 USCF1294 15,402,868 0 0 0 0 0 0 0 
38 23,914,537 USCF1294 10,884,299 0 0 0 0 0 0 0 
  
Table S4.  Physical position on CanFam 3.1 and genotypes for de novo mutations 
observed in parent-offspring trios 
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1 3,779,247 G G G G A G USCF1294 
1 121,739,924 G G G G A G USCF1014 
1 121,739,926 A A A A G A USCF1014 
4 8,941,678 C C C C T C USCF1294 
4 20,422,856 G G G G T G USCF1294 
4 24,592,772 G G G G A G USCF134 
4 49,638,228 G G G G A G USCF1294 
4 70,281,398 G G G G A G USCF1014 
5 21,562,488 T T T T C T USCF1014 
5 22,537,046 T T T T A T USCF1294 
5 22,998,572 C C C C T C USCF1014 
5 46,644,004 A A A A G A USCF1014 
5 85,195,818 T T T T C T USCF1294 
6 9,814,311 A A A A G A USCF1014 
6 28,518,209 C C C C T C USCF136 
6 32,980,209 C C C C T C USCF1014 
6 40,729,015 C C C C T C USCF1294 
6 45,422,851 A A A A C A USCF1294 
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7 8,365,994 T T T T C T USCF1294 
7 16,247,159 C C C C T C USCF1014 
7 33,746,227 A A A A C A USCF1014 
8 20,425,502 G G G G C G USCF136 
8 22,350,581 C C C C T C USCF1014 
8 55,853,926 A A A A G A USCF1294 
8 73,607,623 C C C C A C USCF134 
8 73,719,433 C C C C T C USCF134 
8 73,765,592 A A A A C A USCF134 
9 7,983,435 C C C C A C USCF1294 
9 9,424,569 G G G G A G USCF1294 
9 26,817,438 G G G G A G USCF1294 
9 28,733,303 T T T T C T USCF1294 
10 37,953,116 A A A A G A USCF1014 
11 33,950,398 T T T T C T USCF134 
11 35,963,522 G G G G T G USCF136 
12 26,613,923 A A A A G A USCF1294 
12 44,019,294 A A A A G A USCF1294 
12 55,060,734 T T T T C T USCF1014 
13 21,462,229 G G G G A G USCF134 
14 25,558,020 G G G G A G USCF136 
14 26,858,614 A A A A T A USCF134 
14 58,324,036 C C C C T C USCF1294 
14 59,269,467 T T T T C T USCF1294 
  
183 
15 26,825,863 C C C C A C USCF134 
15 32,458,744 T T T T C T USCF1294 
15 51,809,687 A A A A G A USCF1294 
15 51,904,204 G G G G T G USCF1014 
16 25,737,306 A A A A G A USCF1119 
16 54,487,862 C C C C T C USCF1014 
17 9,819,454 T T T T G T USCF134 
17 32,261,540 T T T T C T USCF1014 
17 41,353,018 T T T T G T USCF134 
18 28,418,247 T T T T C T USCF134 
18 28,418,247 T T T T C T USCF136 
18 29,365,717 C C C C T C USCF134 
18 55,700,372 A A A A C A USCF1294 
19 16,343,711 T T T T A T USCF1294 
19 20,163,470 G G G G A G USCF1014 
19 37,757,686 G G G G A G USCF1119 
20 3,790,590 T T T T C T USCF1294 
20 5,526,459 T T T T C T USCF1294 
20 41,440,801 C C C C T C USCF1014 
20 57,437,942 G G G G A G USCF1294 
22 13,103,933 G G G G A G USCF134 
22 37,991,629 C C C C A C USCF1294 
22 41,906,946 T T T T C T USCF1119 
23 6,329,495 T T T T C T USCF1014 
  
184 
23 9,749,895 A A A A G A USCF134 
23 49,416,247 G G G G A G USCF1014 
24 843,131 A A A A T A USCF1014 
25 32,245,185 A A A A T A USCF1294 
26 36,568,797 A A A A C A USCF134 
27 14,937,023 C C C C T C USCF134 
27 17,145,045 T T T T C T USCF136 
29 1,948,843 C C C C T C USCF1294 
29 6,803,696 T T T T G T USCF1014 
29 35,609,029 C C C C T C USCF136 
31 8,781,152 A A A A T A USCF136 
31 12,579,393 G G G G A G USCF1294 
31 13,978,308 C C C C T C USCF136 
31 16,302,436 T T T T C T USCF1294 
31 20,782,899 T T T T G T USCF1294 
33 6,036,956 G G G G A G USCF1294 
33 8,560,784 A A A A T A USCF136 
33 10,917,719 A A A A G A USCF134 
33 10,917,725 G G G G A G USCF134 
34 9,822,177 G G G G A G USCF1294 
34 37,099,031 T T T T C T USCF1294 
34 39,504,460 A A A A G A USCF1014 
35 4,004,809 A A A A T A USCF1014 
35 5,316,122 T T T T G T USCF1014 
  
185 
35 10,820,922 C C C C T C USCF134 
36 4,491,107 T T T T A T USCF134 
36 17,100,470 G G G G A G USCF1014 
36 28,660,864 G G G G T G USCF1014 
36 30,792,870 G G G G A G USCF1294 
37 14,223,810 T T T T C T USCF1014 
37 20,717,756 T T T T C T USCF1014 
 
  
Table S5. Number of sites passing quality filters for each parent-offspring trio in seven genomic features 
observed including coding sequence (cds), CpG island (cpg), intergenic, intronic, conserved (phastCons33), 3’ 
untranslated region (utr3) and 5’ untranslated region (utr5) 
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1 cds 197,848 0 100,598 0 455,176 0 23,760 0 503,783 0 1,281,165 0 
1 cpg 5,122 0 972 0 190,546 2 3,862 0 137,304 0 337,806 2 
1 intergenic 11,444,649 0 6,531,414 0 21,810,056 0 1,612,715 0 25,754,093 0 67,152,927 0 
1 intron 10,877,576 0 5,730,122 0 19,267,383 0 1,343,739 0 22,799,433 0 60,018,253 0 
1 phastCons33 1,131,539 0 560,633 0 2,098,615 0 146,136 0 2,423,006 0 6,359,929 0 
1 utr3 198,801 0 100,840 0 366,218 0 25,827 0 414,975 0 1,106,661 0 
1 utr5 53,841 0 26,162 0 112,444 0 7,024 0 131,434 0 330,905 0 
2 cds 145,788 0 62,765 0 300,131 0 16,132 0 349,901 0 874,717 0 
2 cpg 3,603 0 567 0 179,587 0 3,410 0 102,474 0 289,641 0 
2 intergenic 6,788,105 0 3,675,063 0 12,385,484 0 796,244 0 14,728,973 1 38,373,869 1 
2 intron 7,336,713 0 3,751,349 0 12,681,210 0 864,921 0 14,995,021 0 39,629,214 0 
2 phastCons33 850,004 0 388,148 0 1,498,100 0 98,265 0 1,737,769 0 4,572,286 0 
2 utr3 151,047 0 68,075 0 253,156 0 17,850 0 283,790 0 773,918 0 
  
187 
2 utr5 46,826 0 20,751 0 87,837 0 5,134 0 105,186 0 265,734 0 
3 cds 127,029 0 59,633 0 261,991 0 14,128 0 297,804 0 760,585 0 
3 cpg 2,426 0 667 0 105,083 0 2,269 0 65,481 0 175,926 0 
3 intergenic 11,189,427 0 6,738,147 0 21,877,611 0 1,748,341 0 25,899,472 0 67,452,998 0 
3 intron 7,236,481 0 3,857,468 0 13,075,545 0 943,555 0 15,393,182 0 40,506,231 0 
3 phastCons33 996,189 0 514,823 0 1,846,133 0 141,841 0 2,149,834 0 5,648,820 0 
3 utr3 124,712 0 58,890 0 223,334 0 16,577 0 256,405 0 679,918 0 
3 utr5 33,611 0 14,635 0 63,814 0 3,187 0 73,773 0 189,020 0 
4 cds 136,704 0 61,552 0 276,120 0 14,305 0 325,558 0 814,239 0 
4 cpg 2,690 0 287 0 87,079 0 1,241 0 56,534 0 147,831 0 
4 intergenic 9,792,679 0 5,901,086 0 18,807,740 0 1,522,316 0 22,026,302 2 58,050,123 2 
4 intron 7,570,701 1 3,980,926 0 13,421,841 1 955,756 0 15,747,985 1 41,677,209 3 
4 phastCons33 1,011,362 0 516,511 0 1,848,738 0 138,914 0 2,158,043 0 5,673,568 0 
4 utr3 147,689 0 66,596 0 240,524 0 16,077 0 278,425 0 749,311 0 
4 utr5 38,853 0 18,512 0 71,664 0 4,420 0 88,539 0 221,988 0 
5 cds 125,882 0 57,861 0 301,801 0 12,677 0 321,400 0 819,621 0 
5 cpg 4,060 0 222 0 122,450 0 1,962 0 76,587 0 205,281 0 
5 intergenic 5,667,754 0 3,216,298 0 10,967,760 2 674,613 0 12,795,729 2 33,322,154 4 
5 intron 6,757,305 0 3,423,377 0 12,068,108 1 691,638 0 13,988,847 0 36,929,275 1 
5 phastCons33 818,482 0 392,855 0 1,574,054 0 94,426 0 1,777,430 0 4,657,247 0 
5 utr3 127,985 0 54,847 0 225,141 0 13,271 0 245,087 0 666,331 0 
5 utr5 30,149 0 12,588 0 65,469 0 2,557 0 70,575 0 181,338 0 
6 cds 141,102 0 65,967 0 302,112 0 16,933 0 329,856 1 855,970 1 
6 cpg 2,703 0 333 0 109,396 0 1,752 0 79,570 0 193,754 0 
6 intergenic 5,997,716 0 3,466,145 1 11,592,417 1 836,422 0 13,323,945 0 35,216,645 2 
6 intron 6,616,754 0 3,490,542 0 12,084,920 1 831,436 0 13,939,348 1 36,963,000 2 
6 phastCons33 866,628 0 445,639 0 1,633,563 0 116,738 0 1,859,393 1 4,921,961 1 
6 utr3 132,890 0 57,705 0 220,958 0 14,907 0 246,798 0 673,258 0 
6 utr5 42,631 0 17,506 0 80,915 0 4,952 0 93,598 1 239,602 1 
7 cds 171,518 0 79,939 0 341,704 0 18,532 0 394,493 0 1,006,186 0 
  
188 
7 cpg 1,824 0 181 0 69,493 0 1,301 0 48,175 0 120,974 0 
7 intergenic 7,481,137 0 4,266,470 0 13,865,276 0 1,031,148 0 16,287,797 0 42,931,828 0 
7 intron 8,410,292 0 4,463,906 0 14,676,044 2 1,066,290 0 17,280,255 0 45,896,787 2 
7 phastCons33 898,134 0 448,314 0 1,638,392 0 115,722 0 1,891,642 0 4,992,204 0 
7 utr3 162,820 0 73,703 0 270,602 0 18,316 0 317,107 0 842,548 0 
7 utr5 48,174 0 20,383 0 87,436 0 6,254 0 103,373 0 265,620 0 
8 cds 144,180 0 65,907 0 288,692 0 16,420 0 334,336 0 849,535 0 
8 cpg 3,179 0 712 0 92,810 0 1,490 0 65,359 0 163,550 0 
8 intergenic 7,525,206 3 4,502,240 1 14,415,114 1 1,150,146 0 16,922,554 1 44,515,260 6 
8 intron 6,850,652 0 3,648,936 0 11,955,113 0 898,543 0 14,087,747 0 37,440,991 0 
8 phastCons33 994,126 0 500,787 0 1,803,507 0 139,007 0 2,087,607 0 5,525,034 0 
8 utr3 139,504 0 63,206 0 234,954 0 18,860 0 258,005 0 714,529 0 
8 utr5 38,098 0 16,053 0 71,232 0 4,721 0 85,587 0 215,691 0 
9 cds 123,563 0 51,805 0 288,888 0 10,005 0 303,863 0 778,124 0 
9 cpg 3,158 0 197 0 114,339 0 2,011 0 79,177 0 198,882 0 
9 intergenic 2,365,854 0 1,245,066 0 4,363,431 0 281,295 0 4,899,877 2 13,155,523 2 
9 intron 5,107,705 0 2,531,592 0 8,844,827 0 504,605 0 10,379,862 1 27,368,591 1 
9 phastCons33 631,281 0 287,317 0 1,150,265 0 64,420 0 1,275,367 0 3,408,650 0 
9 utr3 133,485 0 52,020 0 225,195 0 11,765 0 241,639 0 664,104 0 
9 utr5 37,478 0 15,411 0 73,129 0 2,888 0 85,458 0 214,364 0 
10 cds 128,488 0 58,026 0 255,914 0 14,044 0 287,700 0 744,172 0 
10 cpg 2,273 0 866 0 148,882 0 2,049 0 85,900 0 239,970 0 
10 intergenic 6,018,300 0 3,366,069 0 11,365,889 1 810,125 0 13,449,014 0 35,009,397 1 
10 intron 5,858,500 0 2,955,658 0 10,081,845 0 680,145 0 11,832,780 0 31,408,928 0 
10 phastCons33 805,628 0 388,736 0 1,446,202 0 102,593 0 1,685,531 0 4,428,690 0 
10 utr3 132,201 0 56,532 0 208,252 0 13,318 0 242,495 0 652,798 0 
10 utr5 35,749 0 14,170 0 65,446 0 3,504 0 76,651 0 195,520 0 
11 cds 119,282 0 53,810 0 241,935 0 13,236 0 284,308 0 712,571 0 
11 cpg 2,326 0 417 0 84,266 0 1,506 0 57,208 0 145,723 0 
11 intergenic 8,171,150 0 4,849,145 0 15,621,971 0 1,222,391 0 18,320,203 0 48,184,860 0 
  
189 
11 intron 5,993,690 1 3,176,116 1 10,671,211 0 751,324 0 12,551,484 0 33,143,825 2 
11 phastCons33 903,110 1 452,612 1 1,659,683 0 115,254 0 1,924,991 0 5,055,650 2 
11 utr3 126,967 0 57,238 0 208,002 0 15,614 0 238,901 0 646,722 0 
11 utr5 32,683 0 14,489 0 59,582 0 3,934 0 71,419 0 182,107 0 
12 cds 136,178 0 63,496 0 271,672 1 14,672 0 325,639 0 811,657 1 
12 cpg 2,494 0 470 0 60,024 0 1,401 0 51,926 0 116,315 0 
12 intergenic 8,181,131 0 4,995,700 0 15,923,292 0 1,347,288 0 18,752,559 1 49,199,970 1 
12 intron 7,152,297 0 3,972,398 0 12,763,068 0 1,076,169 0 15,064,486 1 40,028,418 1 
12 phastCons33 878,308 0 457,486 0 1,604,856 1 127,798 0 1,885,561 0 4,954,009 1 
12 utr3 134,464 0 61,670 0 223,364 0 18,304 0 250,399 0 688,201 0 
12 utr5 30,960 0 11,991 0 59,250 0 3,327 0 69,943 0 175,471 0 
13 cds 100,035 0 47,753 0 203,981 0 12,705 0 238,049 0 602,523 0 
13 cpg 1,417 0 405 0 79,574 0 1,199 0 45,564 0 128,159 0 
13 intergenic 7,570,508 0 4,610,487 0 14,696,817 0 1,182,296 0 17,226,474 0 45,286,582 0 
13 intron 5,486,050 0 3,005,644 0 9,977,425 0 811,284 0 11,542,150 0 30,822,553 0 
13 phastCons33 640,471 1 331,696 0 1,178,224 0 92,809 0 1,360,719 0 3,603,919 1 
13 utr3 94,223 0 46,543 0 163,554 0 14,063 0 184,561 0 502,944 0 
13 utr5 26,213 0 11,117 0 46,068 0 3,863 0 53,925 0 141,186 0 
14 cds 103,787 0 49,897 0 207,563 0 13,389 0 240,521 0 615,157 0 
14 cpg 787 0 113 0 58,613 0 1,272 0 41,477 0 102,262 0 
14 intergenic 6,397,078 1 3,693,019 1 11,801,137 0 983,933 0 13,934,829 1 36,809,996 3 
14 intron 6,733,905 0 3,615,825 0 11,896,289 0 951,691 0 13,970,333 1 37,168,043 1 
14 phastCons33 919,772 0 467,423 0 1,609,169 0 127,420 0 1,878,266 0 5,002,050 0 
14 utr3 112,618 0 55,529 0 190,582 0 17,362 0 220,309 0 596,400 0 
14 utr5 30,313 0 14,236 0 58,390 0 4,414 0 67,223 0 174,576 0 
15 cds 136,343 0 63,287 0 268,688 0 18,069 0 311,975 0 798,362 0 
15 cpg 1,464 0 302 0 83,854 1 1,577 0 50,086 0 137,283 1 
15 intergenic 6,279,628 1 3,642,650 0 11,886,997 1 935,982 0 14,208,755 1 36,954,012 3 
15 intron 6,578,733 0 3,600,178 0 11,754,704 0 929,296 0 13,899,632 1 36,762,543 1 
15 phastCons33 762,228 0 383,478 0 1,394,823 0 103,875 0 1,606,644 0 4,251,048 0 
  
190 
15 utr3 111,631 0 51,379 0 189,047 0 14,212 0 212,021 0 578,290 0 
15 utr5 38,111 0 18,136 0 74,725 0 4,834 0 85,822 0 221,628 0 
16 cds 82,795 0 38,208 0 179,080 0 9,982 0 208,089 0 518,154 0 
16 cpg 2,306 0 1,644 0 139,129 0 9,629 0 102,493 0 255,201 0 
16 intergenic 5,920,776 0 3,553,494 0 11,750,531 1 893,059 0 13,959,944 0 36,077,804 1 
16 intron 4,636,724 0 2,556,022 0 8,636,017 0 628,958 0 10,189,555 0 26,647,276 0 
16 phastCons33 446,205 0 229,812 0 848,592 0 61,162 0 983,198 0 2,568,969 0 
16 utr3 78,920 0 35,563 0 136,253 0 9,388 0 158,366 0 418,490 0 
16 utr5 23,539 0 10,923 0 46,795 0 3,385 0 54,261 0 138,903 0 
17 cds 130,700 0 58,431 0 249,434 0 13,611 0 286,343 0 738,519 0 
17 cpg 4,587 0 1,526 0 134,234 0 2,410 0 80,016 0 222,773 0 
17 intergenic 6,361,515 2 3,760,497 0 12,201,272 1 885,981 0 14,323,472 0 37,532,737 3 
17 intron 4,976,985 0 2,526,673 0 8,430,026 0 554,739 0 9,961,034 0 26,449,457 0 
17 phastCons33 607,390 0 299,221 0 1,108,081 0 74,281 0 1,268,414 0 3,357,387 0 
17 utr3 123,551 0 53,160 0 196,645 0 12,403 0 227,887 0 613,646 0 
17 utr5 28,759 0 12,543 0 54,163 0 2,709 0 63,009 0 161,183 0 
18 cds 80,253 0 38,679 0 197,265 0 9,135 0 217,073 0 542,405 0 
18 cpg 2,395 0 603 0 106,505 0 1,922 0 67,205 0 178,630 0 
18 intergenic 4,605,710 1 2,814,365 0 9,142,304 0 689,559 0 10,744,776 1 27,996,714 2 
18 intron 4,132,886 1 2,289,807 1 7,869,023 0 561,217 0 9,136,594 0 23,989,527 2 
18 phastCons33 432,564 0 213,989 0 835,848 0 55,064 0 944,109 0 2,481,574 0 
18 utr3 72,385 0 32,224 0 129,239 0 7,569 0 141,404 0 382,821 0 
18 utr5 17,901 0 9,038 0 40,656 0 2,032 0 46,964 0 116,591 0 
19 cds 67,448 0 31,624 0 138,263 0 9,494 0 163,025 0 409,854 0 
19 cpg 689 0 230 0 43,215 0 892 0 34,053 0 79,079 0 
19 intergenic 7,446,859 0 4,740,407 0 14,971,762 1 1,264,666 0 17,713,137 1 46,136,831 2 
19 intron 4,403,756 0 2,502,353 0 8,188,131 0 664,251 1 9,680,549 0 25,439,040 1 
19 phastCons33 651,553 0 343,989 0 1,197,364 0 98,301 0 1,406,716 0 3,697,923 0 
19 utr3 65,568 0 32,036 0 111,852 0 9,196 0 126,690 0 345,342 0 
19 utr5 14,390 0 7,470 0 27,406 0 2,274 0 33,220 0 84,760 0 
  
191 
20 cds 74,998 0 34,689 0 216,490 0 7,317 0 213,416 0 546,910 0 
20 cpg 5,037 0 194 0 137,933 0 1,500 0 88,087 0 232,751 0 
20 intergenic 3,210,072 0 1,801,041 0 5,939,636 0 425,461 0 7,009,288 2 18,385,498 2 
20 intron 5,439,258 0 2,768,029 0 9,638,693 1 599,580 0 11,322,703 0 29,768,263 1 
20 phastCons33 513,560 0 248,302 0 970,889 0 65,091 0 1,097,045 0 2,894,887 0 
20 utr3 74,001 0 29,658 0 138,222 0 8,498 0 153,973 0 404,352 0 
20 utr5 22,278 0 9,782 0 54,486 0 2,339 0 63,409 0 152,294 0 
21 cds 85,205 0 41,572 0 189,619 0 10,456 0 218,169 0 545,021 0 
21 cpg 832 0 24 0 36,468 0 826 0 27,740 0 65,890 0 
21 intergenic 4,639,674 0 2,885,278 0 9,183,913 0 712,456 0 10,868,425 0 28,289,746 0 
21 intron 5,003,056 0 2,809,303 0 8,959,902 0 677,173 0 10,518,677 0 27,968,111 0 
21 phastCons33 496,806 0 249,576 0 911,039 0 67,905 0 1,046,565 0 2,771,891 0 
21 utr3 76,748 0 35,803 0 131,373 0 9,303 0 152,401 0 405,628 0 
21 utr5 19,522 0 8,606 0 37,730 0 2,413 0 45,545 0 113,816 0 
22 cds 74,476 0 30,970 0 143,958 0 8,742 0 168,698 0 426,844 0 
22 cpg 623 0 118 0 40,988 0 1,006 0 29,707 0 72,442 0 
22 intergenic 9,604,922 1 6,177,364 0 19,434,867 0 1,800,167 1 22,630,406 1 59,647,726 3 
22 intron 4,435,098 0 2,411,279 0 7,920,224 0 655,257 0 9,327,909 0 24,749,767 0 
22 phastCons33 779,164 0 425,916 0 1,426,537 0 126,259 0 1,646,435 0 4,404,311 0 
22 utr3 67,646 0 33,549 0 115,331 0 10,337 0 136,581 0 363,444 0 
22 utr5 16,380 0 6,477 0 30,239 0 2,192 0 36,487 0 91,775 0 
23 cds 98,759 0 44,760 0 196,320 0 12,198 0 226,403 0 578,440 0 
23 cpg 1,195 0 425 0 45,932 0 1,072 0 34,294 0 82,918 0 
23 intergenic 5,294,224 0 3,028,471 0 9,967,023 0 769,859 0 11,917,179 0 30,976,756 0 
23 intron 5,238,814 1 2,771,599 0 9,131,389 1 681,472 0 10,789,657 0 28,612,931 2 
23 phastCons33 574,203 0 282,831 0 1,018,793 0 77,066 0 1,192,249 0 3,145,142 0 
23 utr3 88,719 0 40,084 0 147,917 0 10,653 0 167,503 0 454,876 0 
23 utr5 29,825 0 11,532 0 53,289 0 3,697 0 63,960 0 162,303 0 
24 cds 57,917 0 25,491 0 135,712 0 5,714 0 141,261 0 366,095 0 
24 cpg 2,575 0 478 0 146,167 0 1,864 0 70,097 0 221,181 0 
  
192 
24 intergenic 3,412,169 0 1,826,564 0 6,344,424 1 372,521 0 7,401,564 0 19,357,242 1 
24 intron 3,454,047 0 1,763,376 0 6,233,232 0 368,565 0 7,216,476 0 19,035,696 0 
24 phastCons33 419,142 0 198,876 0 788,684 0 45,929 0 893,733 0 2,346,364 0 
24 utr3 62,165 0 27,648 0 110,632 0 5,135 0 120,999 0 326,579 0 
24 utr5 20,009 0 8,181 0 39,746 0 1,844 0 44,816 0 114,596 0 
25 cds 92,005 0 44,841 0 191,702 0 10,784 0 219,454 0 558,786 0 
25 cpg 3,468 0 892 0 136,602 0 2,083 0 69,715 0 212,760 0 
25 intergenic 4,677,041 0 2,639,526 0 8,625,822 0 640,532 0 10,189,888 0 26,772,809 0 
25 intron 4,827,030 0 2,585,563 0 8,618,827 0 641,179 0 10,126,664 1 26,799,263 1 
25 phastCons33 396,676 0 200,535 0 730,279 0 54,769 0 852,236 0 2,234,495 0 
25 utr3 81,519 0 41,177 0 144,733 0 11,212 0 166,568 0 445,209 0 
25 utr5 26,306 0 10,766 0 46,379 0 2,683 0 54,496 0 140,630 0 
26 cds 47,405 0 21,450 0 121,114 0 3,751 0 131,858 0 325,578 0 
26 cpg 1,691 0 408 0 72,919 0 1,047 0 48,036 0 124,101 0 
26 intergenic 1,674,416 0 960,596 0 3,408,188 0 180,304 0 3,993,492 0 10,216,996 0 
26 intron 2,756,964 1 1,456,235 0 5,310,029 0 276,365 0 6,275,415 0 16,075,008 1 
26 phastCons33 208,746 0 94,332 0 413,615 0 18,989 0 464,646 0 1,200,328 0 
26 utr3 47,431 0 17,837 0 89,520 0 4,310 0 97,223 0 256,321 0 
26 utr5 17,195 0 6,210 0 34,768 0 1,710 0 39,575 0 99,458 0 
27 cds 104,743 0 51,541 0 216,236 0 13,802 0 245,319 0 631,641 0 
27 cpg 884 0 40 0 36,192 0 641 0 27,451 0 65,208 0 
27 intergenic 3,594,595 1 2,057,998 1 6,683,512 0 516,881 0 8,058,533 0 20,911,519 2 
27 intron 5,082,339 0 2,713,616 0 8,900,953 0 692,652 0 10,538,466 0 27,928,026 0 
27 phastCons33 489,054 0 241,677 0 887,966 0 67,109 0 1,028,208 0 2,714,014 0 
27 utr3 96,524 0 48,253 0 165,878 0 12,364 0 189,032 0 512,051 0 
27 utr5 27,694 0 12,899 0 53,530 0 2,839 0 64,039 0 161,001 0 
28 cds 88,603 0 37,919 0 171,640 0 9,380 0 193,164 0 500,706 0 
28 cpg 2,633 0 1,107 0 156,933 0 3,106 0 74,504 0 238,283 0 
28 intergenic 2,926,808 0 1,604,399 0 5,504,230 0 339,657 0 6,398,155 0 16,773,249 0 
28 intron 3,543,947 0 1,799,613 0 6,240,420 0 409,251 0 7,244,241 0 19,237,472 0 
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28 phastCons33 462,166 0 217,212 0 832,012 0 55,776 0 958,354 0 2,525,520 0 
28 utr3 93,310 0 39,760 0 147,534 0 10,945 0 173,653 0 465,202 0 
28 utr5 22,007 0 10,819 0 40,129 0 2,846 0 48,658 0 124,459 0 
29 cds 66,074 0 32,083 0 127,957 0 9,454 0 155,707 0 391,275 0 
29 cpg 1,210 0 221 0 40,503 0 870 0 33,559 0 76,363 0 
29 intergenic 5,151,337 0 3,154,182 1 10,069,205 0 859,800 0 11,894,535 1 31,129,059 2 
29 intron 3,933,683 0 2,231,433 0 7,238,504 1 599,880 0 8,628,838 0 22,632,338 1 
29 phastCons33 534,676 0 281,618 0 977,597 0 83,287 0 1,146,770 0 3,023,948 0 
29 utr3 81,632 0 40,541 0 132,680 0 12,714 0 153,601 0 421,168 0 
29 utr5 23,743 0 11,671 0 42,400 0 3,038 0 51,781 0 132,633 0 
30 cds 111,046 0 54,091 0 227,513 0 12,685 0 263,305 0 668,640 0 
30 cpg 1,422 0 92 0 53,643 0 802 0 31,463 0 87,422 0 
30 intergenic 3,115,653 0 1,694,752 0 5,512,469 0 400,129 0 6,558,665 0 17,281,668 0 
30 intron 4,535,122 0 2,420,275 0 7,921,179 0 594,846 0 9,342,342 0 24,813,764 0 
30 phastCons33 572,215 0 281,053 0 1,021,863 0 75,130 0 1,174,888 0 3,125,149 0 
30 utr3 113,935 0 52,884 0 184,783 0 14,947 0 208,505 0 575,054 0 
30 utr5 23,947 0 10,265 0 43,026 0 2,421 0 51,617 0 131,276 0 
31 cds 38,379 0 17,718 0 86,626 0 5,058 0 94,459 0 242,240 0 
31 cpg 2,152 0 483 0 120,525 0 2,009 0 49,964 0 175,133 0 
31 intergenic 5,029,894 0 3,200,386 2 10,071,602 0 931,905 0 11,856,994 2 31,090,781 4 
31 intron 2,590,491 0 1,461,203 0 4,916,019 0 407,140 0 5,690,242 1 15,065,095 1 
31 phastCons33 363,633 0 200,251 0 678,816 0 60,891 0 786,909 0 2,090,500 0 
31 utr3 40,740 0 21,429 0 75,757 0 6,793 0 82,207 0 226,926 0 
31 utr5 12,046 0 4,502 0 23,809 0 1,726 0 26,551 0 68,634 0 
32 cds 81,143 0 37,527 0 152,978 0 10,473 0 183,567 0 465,688 0 
32 cpg 525 0 81 0 13,828 0 159 0 15,005 0 29,598 0 
32 intergenic 4,669,845 0 2,854,235 0 8,914,212 0 798,405 0 10,443,948 0 27,680,645 0 
32 intron 4,644,106 0 2,607,193 0 8,214,541 0 743,762 0 9,684,619 0 25,894,221 0 
32 phastCons33 430,284 0 225,167 0 783,583 0 68,751 0 924,277 0 2,432,062 0 
32 utr3 75,514 0 38,604 0 129,427 0 10,810 0 151,053 0 405,408 0 
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32 utr5 17,978 0 8,381 0 30,714 0 2,652 0 37,634 0 97,359 0 
33 cds 66,721 0 32,105 0 133,724 0 7,746 0 155,705 0 396,001 0 
33 cpg 994 0 83 0 38,780 0 572 0 25,316 0 65,745 0 
33 intergenic 3,357,287 0 1,915,663 0 6,372,765 0 542,551 0 7,454,645 1 19,642,911 1 
33 intron 3,432,577 2 1,841,226 1 5,991,840 0 481,952 0 7,096,521 0 18,844,116 3 
33 phastCons33 398,232 0 197,674 0 712,990 0 54,912 0 828,252 0 2,192,060 0 
33 utr3 74,160 0 32,782 0 118,774 0 9,204 0 140,063 0 374,983 0 
33 utr5 18,993 0 8,868 0 33,438 0 2,729 0 37,178 0 101,206 0 
34 cds 59,693 0 26,374 0 116,018 0 6,413 0 131,174 0 339,672 0 
34 cpg 736 0 255 0 48,101 0 952 0 37,128 0 87,172 0 
34 intergenic 4,577,400 0 2,797,611 0 9,222,780 0 725,903 0 10,874,537 1 28,198,231 1 
34 intron 3,597,219 0 1,939,811 0 6,541,589 1 492,889 0 7,722,784 1 20,294,292 2 
34 phastCons33 432,829 0 221,168 0 795,476 0 59,965 0 929,798 0 2,439,236 0 
34 utr3 64,800 0 31,478 0 114,308 0 9,768 0 130,115 0 350,469 0 
34 utr5 19,824 0 8,670 0 35,826 0 2,256 0 41,782 0 108,358 0 
35 cds 27,571 0 11,916 0 60,652 0 2,473 0 71,061 0 173,673 0 
35 cpg 2,495 0 228 0 44,828 0 936 0 36,256 0 84,743 0 
35 intergenic 2,420,964 1 1,358,419 0 4,523,574 1 309,160 0 5,440,479 0 14,052,596 2 
35 intron 2,042,159 0 1,027,644 0 3,582,332 0 226,855 0 4,320,255 0 11,199,245 0 
35 phastCons33 223,168 0 111,399 0 411,958 0 25,896 0 491,294 0 1,263,715 0 
35 utr3 32,955 0 14,538 0 54,689 0 3,308 0 66,658 0 172,148 0 
35 utr5 9,816 0 3,933 0 18,424 0 781 0 21,928 0 54,882 0 
36 cds 91,359 0 41,096 0 182,396 0 11,922 0 209,672 0 536,445 0 
36 cpg 1,722 0 280 0 37,837 0 881 0 27,128 0 67,848 0 
36 intergenic 3,188,358 0 1,883,942 0 6,235,004 1 508,086 0 7,396,467 0 19,211,857 1 
36 intron 3,538,940 1 1,892,407 0 6,281,275 1 525,559 0 7,374,475 0 19,612,656 2 
36 phastCons33 568,641 0 284,881 0 1,029,813 0 82,334 0 1,192,674 0 3,158,343 0 
36 utr3 74,169 0 36,548 0 124,806 0 10,959 0 143,307 0 389,789 0 
36 utr5 22,015 0 9,811 0 37,906 0 2,902 0 43,601 0 116,235 0 
37 cds 70,238 0 32,317 0 134,874 0 8,481 0 157,271 0 403,181 0 
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37 cpg 499 0 134 0 48,009 0 1,042 0 28,395 0 78,079 0 
37 intergenic 3,053,606 0 1,772,628 0 5,852,293 1 451,489 0 6,919,735 0 18,049,751 1 
37 intron 3,214,021 0 1,749,093 0 5,746,647 1 472,958 0 6,742,146 0 17,924,865 1 
37 phastCons33 450,543 0 227,304 0 814,670 0 61,938 0 946,382 0 2,500,837 0 
37 utr3 70,540 0 34,766 0 115,211 0 8,915 0 126,627 0 356,059 0 
37 utr5 17,557 0 7,536 0 30,961 0 1,610 0 36,091 0 93,755 0 
38 cds 26,608 0 12,143 0 62,849 0 3,701 0 69,040 0 174,341 0 
38 cpg 574 0 160 0 38,633 0 546 0 16,559 0 56,472 0 
38 intergenic 2,799,463 0 1,737,281 0 5,608,742 0 487,020 0 6,539,296 0 17,171,802 0 
38 intron 1,507,363 0 814,638 0 2,757,038 0 209,537 0 3,178,244 0 8,466,820 0 
38 phastCons33 210,709 0 106,568 0 407,038 0 32,520 0 467,350 0 1,224,185 0 
38 utr3 30,081 0 12,865 0 50,415 0 3,660 0 58,872 0 155,893 0 
38 utr5 9,971 0 4,495 0 19,317 0 1,548 0 22,142 0 57,473 0 
All cds 3,761,866 0 1,739,841 0 7,898,788 1 431,779 0 8,972,419 1 22,804,693 2 
All cpg 80,770 0 16,417 0 3,303,900 3 65,069 0 2,096,993 0 5,563,149 3 
All intergenic 211,602,910 11 124,918,098 7 407,000,000 13 31,640,806 1 479,000,000 21 1,254,201,072 53 
All intron 195,533,939 8 104,142,428 3 348,000,000 11 25,466,429 1 410,000,000 9 1,083,211,110 32 
All phastCons33 23,769,421 2 11,919,809 1 43,587,827 1 3,198,543 0 50,372,305 1 132,847,905 5 
All utr3 3,718,050 0 1,707,960 0 6,308,862 0 458,714 0 7,164,205 0 19,357,791 0 
All utr5 1,025,385 0 449,518 0 1,952,538 0 119,639 0 2,291,250 1 5,838,330 1 
  
Appendix III: Supplementary material for chapter 4 
Appendix for chapter 4.2 
File S1. Sample information including data availability and genotypes at BBS4 c.58A > T 
BREED ID GENOTYPING 
ARRAY 
ACCESSION WHOLE 
GENOME 
SEQUENCING 
PLATFORM 
LIBRARY ACCESSION BBS4 c.58A > 
T 
GENOTYPES 
(BY SANGER 
SEQUENCING) 
Hungarian 
Puli 
USCF347 Illumina 
CanineHD 
BeadChip 
GSE87642 Illumina HiSeq 
2000 
TruSeq, 
PCR-free 
PRJNA344694 A T 
Hungarian 
Puli 
USCF350 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
Hungarian 
Puli 
USCF516 Illumina 
CanineHD 
BeadChip 
GSE87642 Illumina HiSeq 
2000 
TruSeq, 
PCR-free 
PRJNA344694 T T 
Hungarian 
Puli 
USCF517 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
Hungarian 
Puli 
USCF518 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
Hungarian 
Puli 
USCF519 Illumina 
CanineHD 
BeadChip 
GSE87642 Illumina HiSeq 
2000 
TruSeq, 
PCR-free 
PRJNA344694 T T 
Hungarian 
Puli 
USCF520 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
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Hungarian 
Puli 
USCF521 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
Hungarian 
Puli 
USCF522 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A A 
Hungarian 
Puli 
USCF523 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A A 
Hungarian 
Puli 
USCF524 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
Hungarian 
Puli 
USCF525 Illumina 
CanineHD 
BeadChip 
GSE87642 Illumina HiSeq 
2000 
TruSeq, 
PCR-free 
PRJNA344694 A T 
Hungarian 
Puli 
USCF526 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
Hungarian 
Puli 
USCF532 Illumina 
CanineHD 
BeadChip 
GSE87642 N/A N/A N/A A T 
Hungarian 
Puli 
USCF1194 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1195 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1197 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1198 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1263 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1264 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1265 N/A N/A N/A N/A N/A A A 
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Hungarian 
Puli 
USCF1266 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1267 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1268 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1269 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1270 N/A N/A N/A N/A N/A A T 
Hungarian 
Puli 
USCF1271 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1272 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1273 N/A N/A N/A N/A N/A A T 
Hungarian 
Puli 
USCF1274 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1275 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1276 N/A N/A N/A N/A N/A A T 
Hungarian 
Puli 
USCF1277 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1278 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1279 N/A N/A N/A N/A N/A A T 
Hungarian 
Puli 
USCF1280 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1281 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1282 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1283 N/A N/A N/A N/A N/A A A 
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Hungarian 
Puli 
USCF1284 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1285 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1286 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1287 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1289 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
USCF1311 N/A N/A N/A N/A N/A T T 
Hungarian 
Puli 
PUL001 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL002 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL003 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL004 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL005 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL006 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL007 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL008 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL009 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL010 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL011 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL012 N/A N/A N/A N/A N/A A A 
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Hungarian 
Puli 
PUL013 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL014 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL015 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL016 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL017 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL018 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL019 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL020 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL021 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL022 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL023 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL024 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL025 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL026 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL027 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL028 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL029 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL030 N/A N/A N/A N/A N/A A A 
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Hungarian 
Puli 
PUL031 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL032 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL033 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL034 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL035 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL036 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL037 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL038 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL039 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL040 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL041 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL042 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL043 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL044 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL045 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL046 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL047 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL048 N/A N/A N/A N/A N/A A A 
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Hungarian 
Puli 
PUL049 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL051 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL052 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL053 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL054 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL055 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL056 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL057 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL058 N/A N/A N/A N/A N/A A A 
Hungarian 
Puli 
PUL059 N/A N/A N/A N/A N/A A A 
 
All Hungarian Pumi used in this study (n = 152) had the ‘A A’ genotype at BBS4 c.58A > T, determined by Sanger sequencing.  
  
File S2. Completion of the current BBS4 annotation in CanFam3.1 reference 
genome 
Introduction 
Exon 1 of BBS4 is not annotated in the most current reference sequence (CanFam3.1). 
Its absence is evident by a lack of an initiation codon. When observing a multiple 
sequence alignment of BBS4 protein sequences from a variety of vertebate species 
including human, orangutan, mouse, rat, cow, cat and elephant it is clear that the dog is 
lacking the first part of the transcript. We hypothesized that exon 1 resided in a 
reference genome assembly gap ~9.7 Kb upstream to the current BBS4 annotation and 
adjacent to a region of high guanine-cytosine density.  
Methods 
Using the popular de novo aligner Velvet version 1.2.10 (Zerbino and Birney 2008), we 
attempted to resolve this gap by assembling unmapped reads and reads that partially 
mapped to the vicinity of the gap in chromosome 30 from four Hungarian Puli dogs. The 
initial attempt at assembly was unsuccessful in building a contig that completely 
resolved the gap. Alternatively, we performed a manual alignment using sequences 
from unmapped mates of reads that had aligned adjacent to the gap. A multiple 
sequence alignment with the assembled contig and exon 1 of human (NR_033028.4), 
mouse (NM_175325.3) and cat (XM_011282956.1) was performed using Clustal 
Omega (Sievers et al. 2011). The assembled contig was translated into an amino acid 
sequence using ExPASy’s translate tool (Gasteiger et al. 2003). We similarly aligned 
the predicted canine BBS4 protein corresponding to exon 1 to human (NP_149017.2), 
mouse (NP_780534.1) and cat (XP_011281258.1) BBS4 proteins. 
Results and Conclusions 
Multiple sequence alignment of the contig produced from manual assembly revealed 
that putative exon 1 of BBS4 in the dog is identical to that of the domestic cat (Felis 
catus) and differs from the human sequence by two nucleotides (Figure S1). Thus, the 
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complete BBS4 protein in dogs consists of 520 amino acids encoded by 1,560 base 
pairs of mRNA organised into 16 exons on chromosome 30 of CanFam 3.1. Protein 
sequences corresponding to exon 1 of BBS4 are identical for dog and cat but differ to 
human and mouse by one and five amino acids respectively (Figure S2).  
 
Figure S1. Multiple sequence alignment of a manually assembled canine contig with 
exon 1 of BBS4 of human (Homo sapiens), mouse (Mus musculus) and domestic cat 
(Felis catus) nucleotide sequences. The canine contig was assembled using reads from 
four Hungarian Puli dogs. Reads include unmapped mates of pairs that aligned adjacent 
to a reference genome gap on chromosome 30, putative to the location of BBS4 exon 1. 
An asterisk denotes full identity of the nucleotide across species.  
 
Figure S2. Multiple amino acid sequence alignment of partial canine BBS4 protein with 
domestic cat (Felis catus), human (Homo sapien) and mouse (Mus musculus) homologs 
corresponding to exon 1 and 2 only. The canine protein sequence corresponding to 
exon 1 (highlighted in grey) and exon 2 was obtained from translation of genomic 
sequence of a contig produced by manual de novo assembly of canine Illumina HiSeq 
2000 reads. 
The complete mRNA and amino acid sequences for canine BBS4 have been deposited 
in Genbank (KX290494).  
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Table S1. Candidate genes for progressive retinal atrophy in the Hungarian Puli 
dog breed. Candidates were selected from the region with the highest density of SNP 
markers (chromosome 30, 25.3 – 40.0 Mb on CanFam 3.1) that were concordant to a 
recessive pattern of inheritance. All genes have a phenotypic connection to vision as 
indicated by the Mouse Genome Browser.  
Gene CanFam 3.1 Position Ensembl Transcript ID 
CPLX3 chr30: 37,888,801-37,892,561 ENSCAFT00000028507 
CSK chr30: 37,866,652-37,869,289 ENSCAFT00000028485 
STRA6 chr30: 37,332,568-37,346,312 ENSCAFT00000048873 
BBS4 chr30: 36,063,713-36,109,202 ENSCAFT00000028102 
HEXA chr30: 35,838,158-35,843,722 ENSCAFT00000028088 
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GLCE chr30: 33,142,327-33,208,130 ENSCAFT00000046216 
CLN6 chr30: 32,246,411-32,264,240 ENSCAFT00000027690 
SMAD3 chr30: 31,246,313-31,360,098 ENSCAFT00000027577 
MAP2K1 chr30: 30,683,192-30,760,479 ENSCAFT00000043934 
MEGF11 chr30: 30,234,191-30,446,063 ENSCAFT00000027347 
SLC24A1 chr30: 29,967,634-29,996,958 ENSCAFT00000027314 
RAB8B chr30: 27,784,338-27,845,901 ENSCAFT00000026890 
*NR2E3 (chr30: 35,378,421-35,381,822) was excluded as it is a known canine PRA 
gene. A preliminary study (Chew et al., 2017 [Animal Genetics in press]) confirms that 
no putative variants are present in this gene. 
Literature Cited 
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progressive retinal atrophy genes for blindness in the Hungarian Puli. Anim. Genet. 48: 
500–501. 
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Table S2. Relationships between 14 Hungarian Puli individuals from the same pedigree 
estimated through proportion of identity by descent (IBD) calculations performed using 
PLINK (Purcell et al. 2007). Relationships were obtained from pedigree records 
(Australian National Kennel Council). 
Individual 1 Individual 2 Relationship  Proportion IBD 
USCF532 USCF347 OT 0 
USCF532 USCF350 PO 0.5 
USCF532 USCF516 OT 0 
USCF532 USCF517 PO 0.5 
USCF532 USCF518 HS 0.244 
USCF532 USCF519 HS 0.1755 
USCF532 USCF520 FS 0.3737 
USCF532 USCF522 PO 0.5 
USCF532 USCF523 HS 0.2037 
USCF532 USCF524 PO 0.5 
USCF532 USCF525 OT 0.1626 
USCF532 USCF526 PO 0.5 
USCF532 USCF521 OT 0.2215 
USCF347 USCF350 OT 0 
USCF347 USCF516 PO 0.5 
USCF347 USCF517 OT 0.0551 
USCF347 USCF518 OT 0 
USCF347 USCF519 OT 0.0577 
USCF347 USCF520 OT 0 
USCF347 USCF522 OT 0 
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USCF347 USCF523 OT 0.1117 
USCF347 USCF524 HS 0.2835 
USCF347 USCF525 OT 0 
USCF347 USCF526 OT 0 
USCF347 USCF521 OT 0 
USCF350 USCF516 OT 0.0656 
USCF350 USCF517 OT 0.3262 
USCF350 USCF518 PO 0.5 
USCF350 USCF519 OT 0.1257 
USCF350 USCF520 OT 0.3004 
USCF350 USCF522 FS 0.4293 
USCF350 USCF523 OT 0.2823 
USCF350 USCF524 OT 0.393 
USCF350 USCF525 OT 0.2628 
USCF350 USCF526 HS 0.2777 
USCF350 USCF521 OT 0.2286 
USCF516 USCF517 OT 0.183 
USCF516 USCF518 OT 0.1856 
USCF516 USCF519 HS 0.3014 
USCF516 USCF520 OT 0.1565 
USCF516 USCF522 OT 0 
USCF516 USCF523 OT 0.1211 
USCF516 USCF524 OT 0.2613 
USCF516 USCF525 PO 0.5 
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USCF516 USCF526 OT 0.1235 
USCF516 USCF521 OT 0.2273 
USCF517 USCF518 OT 0.5 
USCF517 USCF519 OT 0.2414 
USCF517 USCF520 PO 0.5037 
USCF517 USCF522 OT 0.3605 
USCF517 USCF523 OT 0.2289 
USCF517 USCF524 HS 0.3298 
USCF517 USCF525 OT 0.3651 
USCF517 USCF526 OT 0.3112 
USCF517 USCF521 OT 0.3831 
USCF518 USCF519 OT 0.2845 
USCF518 USCF520 PO 0.5 
USCF518 USCF522 PO 0.5 
USCF518 USCF523 HS 0.374 
USCF518 USCF524 OT 0.5 
USCF518 USCF525 OT 0.3875 
USCF518 USCF526 OT 0.3268 
USCF518 USCF521 FS 0.5548 
USCF519 USCF520 HS 0.3208 
USCF519 USCF522 OT 0 
USCF519 USCF523 HS 0.2537 
USCF519 USCF524 PO 0.5 
USCF519 USCF525 PO 0.5 
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USCF519 USCF526 OT 0.1335 
USCF519 USCF521 HS 0.3223 
USCF520 USCF522 OT 0.3634 
USCF520 USCF523 HS 0.2515 
USCF520 USCF524 PO 0.5049 
USCF520 USCF525 PO 0.5 
USCF520 USCF526 OT 0.403 
USCF520 USCF521 PO 0.5 
USCF522 USCF523 OT 0.2233 
USCF522 USCF524 OT 0.3924 
USCF522 USCF525 OT 0.2033 
USCF522 USCF526 HS 0.2459 
USCF522 USCF521 OT 0.2668 
USCF523 USCF524 PO 0.5 
USCF523 USCF525 OT 0.2419 
USCF523 USCF526 OT 0.1263 
USCF523 USCF521 HS 0.3722 
USCF524 USCF525 OT 0.3249 
USCF524 USCF526 OT 0.3451 
USCF524 USCF521 OT 0.5 
USCF525 USCF526 OT 0.2616 
USCF525 USCF521 FS 0.4689 
USCF526 USCF521 PO 0.5 
Samples were genotyped on the CanineHD BeadChip array. Relationships provided by 
pedigree records are consistent with proportion of IBD estimations that were expected 
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depending on the type of relationship. Parent-offspring (PO) relationships have an 
expected IBD = 0.5; full-sibling (FS) relationships have an expected IBD = 0.5; half-
sibling relationships have an expected IBD = 0.25. OT indicates ‘other’ relationships.  
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Appendix IV: Supplementary material for chapter 5 
Table S1. Candidate genes screened in canine individual USCF305 presenting with severe haemophilia A. Genes 
associated with a bleeding tendency phenotype in humans were selected as candidates. 
Gene CanFam 3.1 Position Ensembl Transcript ID Reference 
F2 chr18:42,782,384 - 42,799,459 ENSCAFG00000009122 Archarya et al 2003 
F7 chr22:60,572,511 - 60,582,729 ENSCAFG00000006257 Archarya et al 2003 
F8 chrX:122,897,137 - 123,043,373 ENSCAFG00000019631 Archarya et al 2003 
F9 chrX:109,501,341 - 109,533,798 ENSCAFG00000018998 Archarya et al 2003 
F10 chr22:60,585,600 - 60,596,983 ENSCAFG00000006258 Archarya et al 2003 
F11 chr11:44,466,300 - 44,487,120 ENSCAFG00000007348 Archarya et al 2003 
F13A1 chr35:6,185,898 - 6,347,853 ENSCAFG00000009509 Archarya et al 2003 
F13B chr7:5,674,454 - 5,702,366 ENSCAFG00000011416 Archarya et al 2003 
FGA chr15:52,238,946 - 52,246,920 ENSCAFG00000023178 Acharya and Dimichele, 2008 
FGB chr15:52,220,662 - 52,229,692 ENSCAFG00000008424 Acharya and Dimichele, 2008 
FGG chr15:52,261,220 - 52,270,169 ENSCAFG00000008440 Acharya and Dimichele, 2008 
GPIIIa chr9:9,182,562 - 9,231,046 ENSCAFG00000013735 Nurden, 2006 
ITGA2B chr9:19,050,132 - 19,063,992 ENSCAFG00000014145 Nurden, 2006 
vWF chr27:38,834,909 - 38,972,738 ENSCAFG00000015228 Archarya et al 2003 
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Table S2. SNPs detected in the F8 gene in whole genome sequencing data of one Australian Kelpie with 
haemophilia A (USCF305) and in 11 unrelated controls of the same breed. SNPs were genotyped as homozygous 
alternative in affected dog USCF305 and one or more of the 11 control dogs in whole genome sequencing data. Positions 
are relative to the CanFam 3.1 reference genome. Two missense and three synonymous SNPs were identified and have 
been previously reported in dbSNP.  
Chromosome 
CanFam 3.1 
Position Exon 
Reference 
Allele 
Alternative 
Allele Consequence 
Amino  
acid 
Reference 
SNP cluster 
ID 
X 122,938,611 15 G A synonymous N rs852651766 
X 122,956,540 14 G A missense P/L rs852844707 
X 122,957,205 14 C T synonymous E rs851733901 
X 123,043,038 1 G A synonymous D rs852021679 
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Table S3. Improperly paired reads of USCF305 aligning to CanFam 3.1 in intron 22 in FVIII  
Read ID 
Forward read 
mapping 
position 
Reverse read 
mapping 
position Forward read sequence Reverse read sequence 
HWI-ST1213:110: 
C0MHBACXX:7:2215: 
19129:75378 
122,916,994 123,304,842 TNAGCAACGGGGAAG 
CAGTCAGTAGGTAAGA 
AAATACAAAAGAGGCC 
CATCTGACACAGACTC 
CGCCACCAGTCCTGCG 
CACTCACGTGGCTGCC 
TGGAAG  
ATGTAGGCCTGGGCAG 
CTTTCTTACTGTCTTAT 
GACAAGAATGCTTAGG 
AGTTACGGAATGTGACT 
GGTGATAGTATTTGGGT 
TTGGGTTTAAGAAAAAG 
C  
HWI-ST1213:110: 
C0MHBACXX:7:1210: 
13147:51601 
122,917,100 122,917,100 TTCGGAGCCCTAAAAG 
CCTAGTCTAACTTATTG 
CAACAGTGTTAGGGTGT 
ATCCTCCTTTGTAACTTA 
GCTTTTTCTGGTACAAT 
CTTCTCAACCGGAAAT 
GATTCTGTTCATTTATAT 
CTCTAGAGAAATCCAAT 
GCTGCTCATATACCTAA 
CACCAGGGTTTTTGGTA 
ACCTCTCTATATCATCA 
ATGCAAGGAGTTAGA 
  
HWI-ST1213:110: 
C0MHBACXX:7:1210: 
2901:13903 
122,917,016 123,304,874 TAGGTAAGAAAATACA 
AAAGAGGCCCATCTGA 
CACAGACTCCGCCACC 
AGTCCTGCGCACTCA 
CGTGGCTGCCTGGAA 
GGGTCTTTCGGAGCC 
CTAAAAGC 
TTACTGTCTTATGACAA 
GAATGCTTAGGAGTTAC 
GGAATGTGACTGGTGA 
TAGTATTTGGGTTTGG 
GTTTAAGAAAAAGCCTC 
CTTAGGCCTCTGGTCT 
NA  
HWI-ST1213:110: 
C0MHBACXX:7:2215: 
19102:8424 
122,917,020 123,304,874 TAAGAAAATACAAAA 
GAGGCCCATCTGACA 
CAGACTCCGCCACC 
AGTCCTGCGCACTCAC 
GTGGCTGCCTGGAAGG 
GTCTTTCGGAGCCCTA 
AAAGCCTAG  
ACTGTCTTATGACAAG 
AATGCTTAGGAGTTACG 
GAATGTGACTGGTGATA 
GTATTTGGGTTTGGGTT 
TAAGAAAAAGCCTCCTT 
AGGCCTCTGGTCTAANT 
HWI-ST1213:110: 
C0MHBACXX:7:1311: 
3150:27769 
122,917,037 123,304,863 GGCCCATCTGACACA 
GACTCCGCCACCAGT 
CCTGCGCACTCACGT 
TCTTACTGTCTTATGAC 
AAGAATGCTTAGGAGT 
TACGGAATGTGACTGG 
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GGCTGCCTGGAAGGGT 
CTTTCGGAGCCCTAAA 
AGCCTAGTCTAACTTAT 
TGCAACA 
TGATAGTATTTGGGTTT 
GGGTTTAAGAAAAAGC 
CTCCTTAGGCCTCTGG 
TCT  
HWI-ST1213:110: 
C0MHBACXX:7:2109: 
10573:9641 
122,917,058 123,304,942 GCCACCAGTCCTGCG 
CACTCACGTGGCTGC 
CTGGAAGGGTCTTTCG 
GAGCCCTAAAAGCCT 
AGTCTAACTTATTGCA 
ACAGTGTTAGGGTGTA 
TCCTCCTT 
AAGAAAAAGCCTCCTT 
AGGCCTCTGGTCTAAC 
TCCTTGCATTGATGATA 
TAGAGAGGTTACCAAA 
AACCCTGGTGTTAGGT 
ATATGAGCAGCATTGG 
ATTT  
HWI-ST1213:110: 
C0MHBACXX:7:1208: 
6051:65684 
122,917,105 122,917,105 TCATTTATATCTCTAGA 
GAAATCCAATGCTGCT 
CATATACCTAACACCA 
GGGTTTTTGGTAACCT 
CTCTATATCATCAATG 
CAAGGAGTTAGACCA 
GAGGC 
AGCCCTAAAAGCCTA 
GTCTAACTTATTGCAA 
CAGTGTTAGGGTGTAT 
CCTCCTTTGTAACTTA 
GCTTTTTCTGGTACAA 
TCTTCTCAACCGGAAA 
TGTAGG 
 
